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         CHAPTER I 
 
INTRODUCTION 
 
“In biology, nothing is clear, everything is too complicated, everything is a mess, 
and just when you think you understand something, you peel off a layer 
and find deeper complications beneath. Nature is anything but simple.” 
Richard Preston, The Hot Zone: The Terrifying True Story of the Origins of the Ebola Virus 
 
Thesis overview 
 
This document is the culmination of my work on characterizing the human antibody 
response to Marburg and Ebola virus infections. It is divided into five chapters; chapter I 
provides necessary background information about filoviruses, the structure and function of 
filovirus glycoprotein, and filovirus entry into the host cell. This chapter also explores the 
human humoral response against filovirus infections and provides detailed analysis about 
what we know about the antibodies that target filovirus glycoprotein. 
The beginning of my research starts in chapter II. This part of my research focuses on 
studying the human antibody response to Marburg virus (MARV). I describe a panel of fifty-
one human antibodies against MARV proteins that was isolated using peripheral blood B 
cells from an individual who survived MARV infection several. I use antibodies from the 
MARV survivor to define the mechanism of MARV neutralization, and provide the evidence 
that MARV neutralizing antibodies recognize the receptor-binding site of MARV GP. 
Chapter III focuses on the nature of cross-reactive antibody response in human 
survivors of Ebolavirus infections. I describe a panel of ninety human monoclonal antibodies 
to Ebolavirus glycoprotein isolated from survivors of Bundibugyo virus outbreak. I present 
structural and functional information about human antibodies that neutralize multiple 
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Ebolavirus species and a cross-reactive antibody that completely protect guinea pigs from 
the lethal challenge with Ebola virus. In Chapter IV I describe three naturally-occurring 
human cross-reactive mAbs that target a new antigenic site in the canonical heptad repeat 2 
(HR2) region near the membrane proximal region of EBOV GP. I highlight the structural 
features formed by conserved residues in the protective site that could be used to develop 
an epitope-based vaccine against infection caused by diverse Ebolavirus species. 
In Chapter V I summarize my findings and propose future directions for this work. I 
believe that understanding the principles underlying molecular recognition of viral protein by 
potent neutralizing antibodies will have a broad impact on the rational design of therapeutic 
antibodies and development of vaccines against filoviruses and other emerging viruses. 
 
Epidemiology of Marburg virus infection 
 
Filoviruses are enveloped, negative-sense RNA viruses appearing with a characteristic 
filamentous shape. The family Filoviridae (order Mononegavirales) can be divided into two 
major genera: Marburgvirus and Ebolavirus (Kuhn et al., 2013). The genus Marburgvirus 
includes a single species, Marburg marburgvirus and two divergent viruses: Ravn virus and 
Marburg virus (MARV).  
MARV was discovered in August 1967, when laboratory workers in Marburg and 
Frankfurt (Germany) and Belgrade (former Yugoslavia, now Serbia) were infected with 
unknown infectious agent. It was determined that African green monkeys that had been 
imported from Uganda for the purpose of poliovirus vaccine research were the source of 
infection.  The virus was isolated and characterized by multiple groups and named Marburg 
virus after the city with the most cases (Kissling et al., 1968; Kunz et al., 1968; Siegert et al., 
1968). From 31 infected individuals, seven patients died from complications of the disease 
(23% mortality rate). 
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In the following years from 1967 though 1998, only sporadic outbreaks of MARV 
occurred on the African continent affecting small number of individuals (Brauburger et al., 
2012) (Figure 1). In 1987, an isolated case of Marburg disease was identified in Kenya. The 
virus was isolated and characterized as a new virus in Marburgvirus genus, named Ravn 
virus (Johnson et al., 1996). The first large outbreak of MARV occurred in 1998-2000 in a 
gold-mining village of Durba in the northeastern Democratic Republic of Congo (DRC) 
affecting 154 individuals and killing 83% (Bausch et al., 2006). The outbreak ceased 
abruptly with the closure of the mine, suggesting that the reservoir of the MARV inhabits 
mines or caves (Bausch et al., 2006). The largest outbreak of MARV occurred in Angola in 
2004-2005 causing 252 cases and 227 deaths (90% mortality) (Towner et al., 2006). In 
2007 a small MARV outbreak occurred in western Uganda among miners working in Kitaka 
Cave.  Based on the detection of MARV RNA in bats, virus-specific antibodies in sera, and 
isolation of MARV virus from bat tissue, the cave-dwelling Egyptian fruit bats (Rousettus 
aegyptiacus) was identified as a natural host of MARV (Towner et al., 2009). The genome 
sequences of isolated from miners working in Kitaka Cave and bats from the same cave 
closely matched (99% identity) (Towner et al., 2009). 
While MARV disease remains rare, MARV poses a risk for travelers to Africa. In 2008 
two cases of MARV disease were documented in Dutch and American tourists who 
presumably got infected during a visit to Python Cave in Queen Elizabeth National Park, 
Uganda. While the Dutch tourist died from MARV disease, the American tourist survived the 
infection ((CDC), 2009; Timen et al., 2009). In 2012, as I started my thesis studies in the 
Crowe Lab, I received peripheral blood sample from the American survivor. Using the 
survivor’s peripheral blood mononuclear cells, I isolated a panel of human neutralizing 
antibodies against MARV that revealed the mechanism of MARV inhibition (further 
described in Chapter II). In addition to naturally occurring infections, several cases of 
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laboratory-acquired MARV infection have been reported in Soviet Union (now Russia) of 
which one had a fatal outcome (Brauburger et al., 2012; Nikiforov et al., 1994). 
Including the recent outbreak in Uganda where 4 individuals died from MARV infection 
(Albarino et al., 2013), to date there have been in total 467 cases and 372 documented 
deaths due to the MARV infection. The disease burden of MARV infection in Africa is small 
when compared to other infections diseases such as HIV  (1.3 million deaths caused by HIV 
in 2009 in sub-Saharan Africa alone, (Brauburger et al., 2012)) and malnutrition. However, 
there are some studies suggesting that the number of MARV infections is underestimated. 
During the investigation of a 1998-2000 MARV outbreak in a gold-mining village of Durba in 
the DRC, medical personal reported that the disease was recognized locally as “syndrome 
hémorragique de Durba”, occurring as far back as 1980s (Bausch et al., 2006). 
	
 
Figure 1. Marburg virus outbreaks in Africa. Outbreaks are indicated with 
corresponding year and color-coded according to virus species. From (Leroy et 
al., 2011) 
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Epidemiology of Ebola virus infection 
 
In the Ebolavirus genus, there are five virus species, four of which are known to cause 
severe disease in humans: Ebola virus, Bundibugyo virus, Sudan virus and Taï Forest virus. 
An additional virus, Reston virus (RESTV) was isolated in 1989 from cynomolgus monkeys 
imported from Philippines and housed in a quarantine facility in Reston, Virginia, USA. While 
monkeys developed hemorrhagic disease with high lethality, the small number of confirmed 
human infections did not result in clinical illness despite the presence of RESTV-specific 
antibodies in some of the workers handling monkeys (Miranda and Miranda, 2011; Miranda 
et al., 1991). 
Ebola virus first appeared in 1976 when similar cases of hemorrhagic fever emerged in 
two neighboring locations: first in southern Sudan and then in northern Zaire (now 
Democratic Republic of the Congo, DRC) (WHO, 1978a, b) (Figure 2). The virus was 
isolated from patients in both outbreaks and named Ebola virus after a small river in 
northwestern DRC. In the follow up study it was determined that these two outbreaks were 
caused by two different viruses, Sudan virus (SUDV) and Ebola virus (EBOV) (Cox et al., 
1983). The SUDV outbreak resulted in 284 cases with a fatality rate of 53% while EBOV 
outbreak was responsible for 318 cases with a fatality rate of 89%. It is generally recognized 
now that within the Ebolavirus genus EBOV infection has the highest fatality rates (60-90%), 
followed by SUDV infections (40-60%) (Feldmann and Geisbert, 2011). 
A large outbreak of EBOV occurred in 1995 in the Kikwit town, south of DRC affecting 
315 individuals and killing 254 patients (81% fatality rate) (Khan et al., 1999). The Kikwit 
outbreak has provided much of our current knowledge about EBOV and outbreak 
management. During the outbreak, 80 (25%) of 315 infected individuals were healthcare 
personal (Khan et al., 1999). 
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A large outbreak of SUDV occurred in Uganda in 2000, affecting 425 individuals and 
killing 173 patients (53% fatality rate) (Lamunu et al., 2004). Between 2001 and 2005 there 
were five EBOV outbreaks in the Republic of Congo and Gabon resulting in a total of 311 
cases and 261 fatalities (84% fatality rate) (Formenty et al., 2006; Leroy et al., 2004; Leroy 
et al., 2002). The last species of the Ebolavirus genus, Bundibugyo virus (BDBV), was 
discovered in 2007 in Uganda causing 149 cases and 37 deaths (Towner et al., 2008). The 
Crowe lab obtained de-identified peripheral blood mononuclear cells from 30 survivors of the 
2007 BDBV outbreak of Uganda from a repository at Makerere University (Kampala, 
	
 
Figure 2. Ebola virus outbreaks in Africa. Outbreaks are indicated with corresponding 
year and color-coded according to virus species. Modified from (Leroy et al., 2011) 	
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Uganda), which is part of the Walter Reed Army Institute of Research. Antibodies isolated 
from BDBV survivors are described in Chapter III of this document.  
The only case of Taï Forest virus infection occurred in 1995, when a group of scientists 
was studying a viral hemorrhagic fever epizootic among western chimpanzees (Pan 
troglodytes versus) in Taï National Park in Ivory Coast (Formenty et al., 1999; Le Guenno et 
al., 1995). One of the scientists got infected with the virus when she performed necropsies 
on chimpanzees found dead in the Taï national park. The individual was transported to 
Switzerland for treatment and later recovered from infection. This was the first case of Ebola 
hemorrhagic fever reported in West Africa. Until 2013, the Taï Forest virus infection 
remained the only case of Ebola hemorrhagic fever reported in West Africa. 
 
2013-2015 Ebola outbreak in West Africa 
 
The 2013-2015 Ebola outbreak in West Africa was caused by EBOV Makona variant 
(Kuhn et al., 2014). The outbreak began in the forested region of southeastern Guinea in 
December 2013 and then spread into Liberia in March, Sierra Leone in May, and Nigeria in 
late July 2014. This is the first EBOV outbreak to reach epidemic proportions and the largest 
EBOV outbreak on record (Briand et al., 2014). The Ebola epidemic has caused more than 
28,000 cases and more than 11,000 deaths (WHO Ebola situation report). According to the 
initial epidemiologic investigation, the suspected first case of the outbreak occurred in 
Meliandou in Guéckédou prefecture in Guinea where a 2-year old was infected with virus 
and died on December 6, 2013 (Baize et al., 2014). After a single introduction into the 
human population, the outbreak was then sustained exclusively by human-to-human 
transmission (Baize et al., 2014; Gire et al., 2014). 
In 2014 a total of 10 individuals with EBOV disease were treated in U.S. hospitals; of 
these patients, 8 survived (Epstein et al., 2015) (Lyon et al., 2014). The airlifting of infected 
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individuals for treatment in selected U.S. hospitals has caused an unprecedented level of 
media attention to EBOV disease, which likely played a role in increasing public concern 
(SteelFisher et al., 2015). 
High-throughput EBOV genome sequencing has played a major role in understanding 
EBOV evolution and transmission and also informed public health efforts (Baize et al., 2014; 
Carroll et al., 2015; Gire et al., 2014; Ladner et al., 2015; Park et al., 2015; Simon-Loriere et 
al., 2015; Tong et al., 2015). Based on the rate of nonsynonymous to synonymous 
mutations, it was determined that purifying selection becomes increasingly effective over 
time, removing deleterious mutants from the viral population (Park et al., 2015). Hotspots for 
non-synonymous divergence have likely resulted from a lower level of constraint on 
encoded viral proteins (Ladner et al., 2015), as peaks in non-synonymous divergence 
largely corresponded to intrinsically disordered regions of proteins (for example the region of 
the glycoprotein gene encoding mucin-lilke domain) (Olabode et al., 2015). Little evidence 
was found for EBOV adaptation to the human host suggesting that the frequency of 
interactions between humans and reservoir hosts may be the dominant factor in controlling 
the frequency of spillover events (Ladner et al., 2015). 
Among survivors of EBOV, chronic health problems, including myalgia, arthralgia, and 
ocular findings have been considered to be a rheumatologic entity called the post-Ebola 
syndrome. Recently, the persistence of EBOV in ocular fluid for 9 weeks after the clearance 
of viremia was reported in EBOV survivor (Varkey et al., 2015). In line with previous reports 
that EBOV can be cultured from semen samples (Bausch et al., 2007), a recent study has 
found the first molecular evidence of sexual transmission of EBOV 6 months after patient 
recovery (Mate et al., 2015), which is more than four times as long as the WHO-defined 
waiting period for declaring country to be free of EBOV disease. 
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Filovirus genes and proteins 
 
The family Filoviridae belongs to the order of Mononegavirales, which contains viruses 
characterized by a linear, non-segmented, single negative strand of RNA as a genetic 
material. The EBOV and MARV genomes are about 19 kb in length and they encode seven 
structural proteins: nucleoprotein (NP), virion protein 35 (VP35), virion protein 40 (VP40), 
glycoprotein (GP), virion protein 30 (VP30), virion protein 24 (VP24) and RNA-dependent 
RNA polymerase (L) (Figure 3). EBOV but not MARV also encodes one non-structural 
protein, secreted glycoprotein (sGP). RNA molecule-NP complex is linked to the RNA-
depended RNA polymerase and inner matrix proteins VP30 and VP35 to form a 
ribonucleoprotein complex, which is engaged in replication and transcription (Volchkov et 
al., 2001). Both VP24 and VP40 link the nucleoprotein complex with the lipid bilayer of the 
viral envelope and they are also involved in the formation of nucleocapsid, assembly and 
budding of viral particles (Leroy et al., 2011).  Two matrix proteins, VP35 and VP24 play role 
in the pathogenicity of filovirus infection as they inhibit host antiviral responses (Leroy et al., 
2011). 
 
 
		
Figure	3.	Structure of the filovirus virion particle.	The	exact	position	of	VP24	in	filovirus	virions	is	unclear.	From	(Kuhn,	2008)		
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The structure of filovirus glycoprotein 
 
The filovirus glycoprotein (GP) is the only protein on the viral surface. The filovirus GP 
is a trimer composed of three heavily glycosylated GP1-GP2 heterodimers, which result 
from furin-like enzyme cleavage of the precursor protein. GP1 and GP2 subunits are linked 
by a disulphide bond (Volchkov et al., 1998) and mediate all functions necessary for virus to 
enter the host cell. The GP1 subunit mediates the virus attachment to the cell membrane 
and receptor recognition. The GP2 subunit anchors the GP spike to the viral membrane and 
mediates the fusion of viral and host membranes during the viral entry into the host cell. 
Crystal structures are available for prefusion GPs of EBOV (Lee et al., 2008a), SUDV 
(Bale et al., 2012; Dias et al., 2011a), and MARV (Hashiguchi et al., 2015). The crystal 
structure of EBOV GP in complex with human neutralizing antibody Fab KZ52, illuminated 
the overall structure of Ebolavirus surface protein (Lee et al., 2008a) (Figure 4). The EBOV 
GP trimer adopts a chalice-like shape, in which GP1 subunits form a bowl encircled by 
helices of GP2 subunits (Lee et al., 2008a). When the virus is internalized inside the 
endosome, GP2 unwinds from the GP1 subunit and undergoes a series of conformational 
rearrangements finally collapsing into a six-helix bundle conformation that initiates the fusion 
of viral and host membranes (Saphire, 2013). Several structures of post-fusion 
conformations of the GP2 subunit indicate that pre- and post-fusion structures of GP2 differ 
significantly (Koellhoffer et al., 2012; Malashkevich et al., 1999; Weissenhorn et al., 1998). 
The GP1 subunit can be further divided into several subdomains termed base, head, 
glycan cap, and mucin-like domain (Saphire, 2013) (Figure 4). The GP1 base forms a 
hydrophobic concave surface that clamps GP2 subunits (Lee and Saphire, 2009). The GP1 
head contains a receptor-binding site topped by a glycan cap and highly glycosylated mucin-
like domain (Lee et al., 2008a). The glycan cap and contains four predicted N-linked 
glycosylation sites and the mucin-like domain has seven N-linked glycosylation sites and 15-
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20 O-linked glycosylation sites. The highly-glycosylated mucin-like domain was excised from 
GP for crystallization, but a recent study has indicated the relative position of this subdomain 
using small-angle X-ray scattering (SAXS) in solution (Hashiguchi et al., 2015). The EBOV 
mucin-like domains extend outwards from the GP core (Hashiguchi et al., 2015) (Figure 5). 
Once inside the endosome, GP is cleaved by host proteases that remove approximately 
80% of the mass of the GP1 subunit, including the mucin-like domain and glycan cap and 
exposing the receptor binding site (Chandran et al., 2005; Dube et al., 2009). Both glycan 
cap and mucin-like domains are dispensable for pseudovirus attachment or entry in cell 
culture (Yang et al., 2000). It has been suggested the dense clustering of glycans on the 
glycan cap and mucin-like domain likely shield much of the surface of EBOV GP from 
humoral immune surveillance, leaving only a few sites on the EBOV GP protein where 
neutralizing antibodies could bind without interference by glycans (Cook and Lee, 2013). 
		
Figure	4.	The	structure	of	Ebola	virus	glycoprotein.	(A)	Domain	schematic	of	EBOV	GP.	White	regions	indicate	crystallographically	disordered	domains	and	hash-marked	regions	indicate	construct-deleted	regions.	GP1	base	is	green	(I),	GP1	head	-	blue	(II),	GP1	glycan	cap	-	cyan	(III),	N	terminus	of	GP2	–	red,	GP2	internal	fusion	loop	–	orange,	GP2	HR1	–	yellow.	Red	Y-shaped	symbols	indicate	predicated	N-linked	glycosylation	sites.	Y-symbols	marked	with	an	asterisk	were	mutated.	(B)	Molecular	surface	of	EBOV	GP	viewed	on	its	side	(left)	and	top	(right).	Monomer	A	is	colored	according	to	the	scheme	in	A.	(C)	Molecular	surface	of	EBOV	GP	chalice	and	cradle.	From	(Lee	et	al.,	2008a)	
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GP2 mediates the fusion of viral and host cell membranes and contains the internal 
fusion loop and heptad repeat regions (HR1 and HR2) (Lee et al., 2008a). The crystal 
structures of post-fusion GP2 subunit have indicated that HR1 and HR2 form antiparallel α-
helices (Malashkevich et al., 1999; Weissenhorn et al., 1998). 
Recently, a crystal structure of Marburg virus GP in complex with a neutralizing 
antibody MR78 isolated from a human survivor of Marburg infection has been reported 
(Hashiguchi et al., 2015). SAXS data collected for full-length EBOV and MARV GPs 
indicated that while mucin-like domain of EBOV projects more upward, mucin-like domain of 
MARV is less upward, potentially covering the sides of the GP trimer (Figure 5). While the 
glycan cap and mucin-like domain shield the EBOV receptor-binding sites from humoral 
immune surveillance (Lee et al., 2008a), new SAXS data suggested that the receptor 
binding site on MARV GP surface might be accessible for antibody binding (Hashiguchi et 
al., 2015). 
 
		
Figure 5. Molecular envelopes of full-length filovirus glycoproteins. Envelopes of mucin-like domain-
containing MARV GP (A) and EBOV GP (B) ectodomains determined by Small-Angle X-ray Scattering in 
solution. Rendered Gaussian distributions of molecular envelopes are shown in gray, crystal structures of 
cleaved MARV GP (that lacks the glycan cap and mucin-like domain, colored in purple and grey) and 
EBOV GPΔMuc (that lacks the mucin-like domain, colored in blue and grey) are shown as ribbon models. 
From (Hashiguchi et al., 2015) 
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Entry of filoviruses 
 
During viral entry, the mucin-like domain and glycan cap that contain N-linked and O-
linked glycans mediate binding to host attachment factors present on the cell membrane, 
including C-type lectins (DC-SIGN, L-SIGN and mannose-binding lectin) (Alvarez et al., 
2002; Lin et al., 2003; Marzi et al., 2004; Marzi et al., 2007). New attachment factors that 
bind to phosphatidylserine present in the EBOV and MARV viral envelope were identified 
(Kondratowicz et al., 2011). These phosphatidylserine receptors include members of the T-
cell immunoglobulin and mucin domain protein (TIM) family and TAM family of receptor 
tyrosine kinase (Tyro3/Axl/Mer) (Kondratowicz et al., 2011; Moller-Tank and Maury, 2014; 
Shimojima et al., 2006). Additional study determined that TIM family receptors can bind to  
phosphatidylethanolamine, which is also present in the virions of filoviruses (Richard et al., 
2015) (Figure 6). 
Following attachment, filovirus virions are internalized predominantly through 
macropinocytosis (Nanbo et al., 2010; Saeed et al., 2010). This process is characterized by 
the actin-mediated membrane ruffling and blebbing followed by the formation of 
macropinosomes (Mercer and Helenius, 2009). Internalized virions first distribute into early 
endosomes and then traffic to the late endosomes/lysosomes in a Rab5/Rab7 GTPase-
dependent manner (Saeed et al., 2010). Inside the endosome, GP is cleaved by cysteine 
proteases cathepsin B (CatB) and cathepsin L (CatL) at or around residue 190 (Dube et al., 
2009). The cleavage event removes approximately 80% of the mass of the GP1 subunit, 
including the mucin-like domain and glycan cap (Chandran et al., 2005; Dube et al., 2009).  
After cleavage of GP in the endosome, the receptor-binding sites on 19-kDa GP 
become exposed (Chandran et al., 2005), and the GP1 head then is able to bind to its 
receptor, Niemann-Pick C1 (NPC1) protein (Carette et al., 2011; Côté et al., 2011) (Figure 
6). NPC1 is a large thirteen-pass membrane protein that is expressed inside late 
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endosomes/lysosomes in all cells and functions as a cholesterol transporter (Carstea et al., 
1997). Mutations in NPC1 gene in humans cause a Niemann-Pick type C disease, a rare but 
fatal neurovisceral disorder, characterized by accumulation of cholesterol inside late 
endosomes-lysosomes (Carstea et al., 1997). Fibroblasts obtained from patients with 
Niemann-Pick disease are resistant to EBOV infection (Carette et al., 2011). Chinese 
hamster ovary-derived cells deficient in NPC1 were completely resistant to viral infection 
(Carette et al., 2011; Cote et al., 2011). In mouse models of MARV and EBOV infections, 
heterozygosity for NPC1 protects animals from lethal filovirus infection (Carette et al., 2011). 
A single mutation in NPC1 gene was found in straw-colored fruit bats that are resistant to 
EBOV infection (Ng et al., 2015). The reported amino acid change decreased the affinity of 
NPC1 protein to EBOV GP revealing host adaptation to reduce filovirus replication (Ng et 
al., 2015). Filovirus entry does not require the full-length NPC1 protein, as a single luminal 
domain C of NPC1 mediates the filovirus entry into the host cell, and NPC1 domain C linked 
to synthetic membrane protein constituted a receptor for filovirus infection (Miller et al., 
2012). 
But what is the function of NPC1 in filovirus entry into the host cell? Several models 
have been proposed to explain the role of NPC1 during the filovirus entry into the host cell 
(White and Schornberg, 2012). Initial studies proposed that NPC1 triggers the fusion activity 
of primed GP (Cote et al., 2011; Miller et al., 2012). However, NPC1 binding is not sufficient 
to trigger the conformational rearrangement, and the additional factors required for fusion 
remains to be identified (Miller and Chandran, 2012; White and Schornberg, 2012). 
Recently, endosomal calcium channels called two-pore channels were identified as an 
additional entry factor for filoviruses and were proposed to trigger the conformational 
rearrangement in NPC1-negative endosomes (Falzarano and Feldmann, 2015; Sakurai et 
al., 2015). However, a recent study challenged this idea by showing that glycoprotein fusion 
events occur in NPC1+ endolysosomes (Mingo et al., 2015). 
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Filovirus membrane fusion events are initiated by conformational changes in GP and 
are though to be similar to the fusion processes described for other viral GPs (White et al., 
2008). Triggering expose and reposition the heptad repeat I sequence in GP2 subunit, 
projecting the hydrophobic GP2 fusion loop into the endosomal membrane (Gregory et al., 
		
Figure 6. Model of filovirus entry pathway, from (Miller and Chandran, 2012) 
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2011). This extended GP2 conformation then unwinds and refolds into six-helix bundle, in 
which HR1 and HR2 are packed together, and fusion loop and GP transmembrane domain 
meet (Malashkevich et al., 1999; Weissenhorn et al., 1998). The GP2 conformation 
rearrangement drives viral and cellular membrane mixing and fusion pore formation, 
releasing the ribonucleoprotein complex into the cytoplasm (Harrison, 2008) (Figure 6). 
 
Human humoral response to filovirus infection 
 
The adaptive immune system contributes to protection against filovirus infections in 
nonhuman primates and small animal models (reviewed in (Wong et al., 2014)). In 
accordance with evidence observed in animal models, early upregulation of filovirus-specific 
antibody responses followed by activation of cytotoxic T cells is associated successful 
recovery from EBOV infection. In contrast, fatal outcome is associated with impaired 
antibody responses and early activation of T cells unable to control viral replication (Baize et 
al., 1999). A follow-study identified asymptomatic infections of EBOV in individuals having 
direct contact with symptomatic patients. Eleven of 24 asymptomatic individuals developed 
antibody responses to EBOV antigens, including nucleoprotein and VP40 (Leroy et al., 
2000).  A large serological survey of rural populations in Gabon found EBOV-specific 
antibodies in 15% of analyzed individuals (Becquart et al., 2010). 
Antigen-specific antibodies persist in humans. Survivors from the 1995 Kikwit outbreak 
contained EBOV-specific antibodies 2 years after disease onset (Ksiazek et al., 1999a). In 
another study, antibody responses persisted for 10 years in two survivors of 1976 Yambuku 
outbreak (Ksiazek et al., 1999b). Survivors from 2000 Gulu outbreak contained SUDV GP-
specific antibodies as well as serum-neutralizing activity 12 years after infection (Sobarzo et 
al., 2013b). Analysis of serum samples collected from SUDV survivors demonstrated the 
highest number of samples with neutralizing activity 6 months after recovery, with 
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neutralizing antibodies persisting for prolonged time, even 10 years after infection (Sobarzo 
et al., 2013a). 
A study of immune responses of four survivors of EBOV who received treatment at 
Emory University Hospital found an extensive T- and B-cell activation in all four patients 
(McElroy et al., 2015). The frequencies of activated T and B cells were comparable to other 
acute viral infections, with virus-specific plasmablasts present in the blood even 2 months 
after disease onset (McElroy et al., 2015). 
 
Ebola virus-specific antibodies 
 
Several dozens of EBOV-specific monoclonal antibodies (mAbs) have been described 
in the literature, including nearly 20 murine mAbs (Holtsberg et al., 2015; Qiu et al., 2012c; 
Shedlock et al., 2010; Takada et al., 2003; Wilson et al., 2000), 7 macaque mAbs (Keck et 
al., 2015; Shedlock et al., 2010), and a single neutralizing human antibody KZ52, which was 
isolated from a phage-display library constructed from survivors of 1995 EBOV Kikwit 
outbreak (Maruyama et al., 1999). Additionally, several mAbs have been described for 
related SUDV, including a single neutralizing antibody that was generated in mice (Dias et 
al., 2011b) and several synthetic mAbs isolated from a focused phage library (Chen et al., 
2014). 
Most of our knowledge about humoral response against filovirus infections has come 
from studies of murine mAbs that recognize EBOV GP (Figure 7, Table 1). Several groups 
isolated EBOV-specific antibodies by infecting mice with replicon systems in which the 
native surface protein was replaced genetically with EBOV GP (Qiu et al., 2011; Takada et 
al., 2003; Wilson et al., 2000). After immunization, spleen cells were harvested from mice 
and fused with myeloma cells followed by hybridoma passaging and antibody purification. 
Purified mAbs were initially screened in neutralization assays (Qiu et al., 2012c; Shedlock et 
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al., 2010; Takada et al., 2003; Wilson et al., 2000), and the functional activity for many of 
them was measured in vivo using mouse (Qiu et al., 2012c; Takada et al., 2007; Wilson et 
al., 2000; Zeitlin et al., 2011), guinea pig (Qiu et al., 2012c; Qiu et al., 2014; Takada et al., 
2007) and non-human primate models of EBOV infection (Marzi et al., 2012; Olinger et al., 
2012a; Pettitt et al., 2013; Qiu et al., 2012b; Qiu et al., 2014; Qiu et al., 2013) (Table 1). In 
parallel, antigenic sites for several EBOV GP-specific antibodies were determined using X-
ray crystallography (Bale et al., 2012; Dias et al., 2011a; Lee et al., 2008a; Olal et al., 2012), 
negative stain single-particle electron microscopy (Murin et al., 2014), alanine-scanning 
mutagenesis (Davidson et al., 2015), or linear peptide dot blots (Qiu et al., 2011; Wilson et 
al., 2000) (Table 1). Results from those studies revealed that the highly-glycosylated mucin-
like domains shield the EBOV receptor-binding sites from humoral immune surveillance. As 
a result, mouse antibodies were found to target thee major antigenic regions on the surface 
of EBOV GP: the mucin-like domain, the glycan cap, and the GP base (Davidson et al., 
2015; Murin et al., 2014) (Figure 7). 
		
Figure 7. Sites of vulnerability on EBOV GP for protective mAbs. MAbs target the main three 
sites on GP surface: mucin-like domain, glycan cap and GP base near GP1/GP2 interface. A 
monomer of GPΔMuc(PDB ID code is 3CSY) is fit into the core GP of the c13C6:c4G7 complex. 
MPER – membrane proximal external region. From (Murin et al., 2014) 
	 19 
 
1. Antibodies to the mucin-like domain 
Several mouse antibodies were identified that bind to linear polypeptide sequences 
between glycans in EBOV mucin-like domains (MLD), including mAbs 6D8, 13F6 and 14G7 
(Lee et al., 2008c; Olal et al., 2012; Wilson et al., 2000) (Table 1). Those mAbs protect mice 
from lethal EBOV infection but fail to neutralize EBOV in vitro (Olal et al., 2012; Shedlock et 
al., 2010), likely because mucin-like domains, as well as mAbs attached to them, are 
removed by host cathepsins inside the endosome (Chandran et al., 2005). It has been 
proposed that the protective effect of the MLD-specific antibodies likely results from the 
ability of antibodies to recruit immunological effector function rather than preventing binding 
of virus to the target cell membrane (Olal et al., 2012). Despite the good performance of 
mAbs specific for the MLD in a mouse model of EBOV infection, both 6D8 and 13F6 failed 
to protect guinea pigs and non-human primates from lethal EBOV infection when tested 
individually (Qiu et al., 2014) (Table 1). 
 
2. Antibodies to the glycan cap 
MAb 13C6 (the key component of MB-003 and ZMapp cocktails) and 1H3 (the key 
component of ZMab cocktail) were initially isolated in mice (Qiu et al., 2011; Wilson et al., 
2000) and later shown by negative-stain single-particle EM and alanine-scanning 
mutagenesis to target a second antigenic region – the glycan cap (Davidson et al., 2015; 
Murin et al., 2014). Both 1H3 and 13C6 weakly neutralize EBOV (IC50 > 1.0 µg/mL) (Qiu et 
al., 2012c; Qiu et al., 2014; Wilson et al., 2000) and protected mice against EBOV (Qiu et 
al., 2012c; Wilson et al., 2000). Despite the high protective efficiency of glycan-cap specific 
mAbs in mice, 1H3 failed to protect guinea pigs from lethal challenge (all 5 animal died)
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Table 1. Protective mAbs against Ebolavirus glycoprotein 
MAb Isolated from 
Neutra-
lizing? 
Specificity Protective efficacy References 
Ebolavirus 
speciesa 
GP 
formsb 
Antigenic 
regions 
In 
micec 
In 
guinea 
pigs 
In 
NHPs MAb isolation 
Epitope 
information Protective studies 
KZ52 Human Yes Z GP Base  4/5 0/4 (Maruyama et al., 1999) 
(Davidson et 
al., 2015; Lee 
et al., 2008a) 
(Oswald et al., 2007; 
Parren et al., 2002) 
1H3 Mouse Yes  GP, sGP 
Glycan 
cap 6/15 0/5  
(Qiu et al., 
2011)  
(Davidson et 
al., 2015; 
Murin et al., 
2014) 
(Qiu et al., 2012c) 
13C6 Mouse Yes Z, S GP, sGP 
Glycan 
cap 10/10 1/6 1/3 
(Wilson et al., 
2000) 
(Davidson et 
al., 2015; 
Murin et al., 
2014) 
(Qiu et al., 2014; 
Wilson et al., 2000) 
2G4 Mouse Yes Z GP Base 9/15 3/5  (Qiu et al., 2011) 
(Davidson et 
al., 2015; 
Murin et al., 
2014) 
(Qiu et al., 2012c) 
4G7 Mouse Yes Z GP Base 11/15 3/5  (Qiu et al., 2011) 
(Davidson et 
al., 2015; 
Murin et al., 
2014) 
(Qiu et al., 2012c) 
13F6 Mouse No Z GP Mucin-like domain 10/10 1/6 0/3 
(Wilson et al., 
2000) 
(Davidson et 
al., 2015; Lee 
et al., 2008c) 
(Qiu et al., 2014; 
Wilson et al., 2000) 
6D8 Mouse Yes/No Z GP Mucin-like domain 10/10 0/6 0/3 
(Wilson et al., 
2000) 
(Davidson et 
al., 2015) 
(Qiu et al., 2014; 
Wilson et al., 2000) 
133 Mouse Yes Z GP Base 7/8 1/3  (Takada et al., 2003)  (Takada et al., 2007) 
226 Mouse Yes Z GP, sGP GP1 7/8 1/3  
(Takada et al., 
2003)  (Takada et al., 2007) 
16F6 Mouse Yes S GP Base 0%
 d / 
90% e   
(Dias et al., 
2011a) 
(Dias et al., 
2011a) 
(Chen et al., 2014; 
Dias et al., 2011a) 
 
a Specificity to various Ebolavirus species: Z - Ebola virus, S - Sudan virus,  
b Specificity to various forms of GP: GP - full length GP, sGP - secreted GP, MLD - mucin-like domain 
c Number of BALB/c mice surviving challenge of EBOV when 100 µg of mAb is administered on day 1  
d Percent of SCID mice surviving challenge of SUDV when 100 µg of mAb is administered on days 5, 10, 15 and 20 
e Percent of Type 1 IFN α/β R-/- mice surviving challenge of SUDV when 500 µg of mAb is administered on days -1, 1 and 4 
	 21 
(Qiu et al., 2012c) and 13C6 provided very marginal protection in guinea pigs (1 of 6 
animals survived) or non-human primates (1 of 3 animals survived) (Qiu et al., 2014) (Table 
1). Similar to the mucin-like domain-specific mAbs, it was suggested that the lower in vitro 
neutralization activity of glycan cap-specific antibodies might be due to the removal of the 
glycan cap by host proteases (Chandran et al., 2005; Cote et al., 2011; Misasi et al., 2012) 
inside the endosome before GP engagement with the Niemann-Pick C1 receptor (Carette et 
al., 2011; Cote et al., 2011). 
Murine antibody 226 neutralizes EBOV and protects mice from lethal infection one day 
before or two days after virus challenge (Takada et al., 2007; Takada et al., 2003). Three 
neutralization escape mutants with polymorphisms at residues 134, 194 and 199 of GP1 
were obtained for mAb 226, suggesting that 226 binds the disordered loop on the surface of 
GP1, which has been confirmed to be the site of cathepsin cleavage (Lee and Saphire, 
2009). MAb 226/8.2 might block cathepsin cleavage, preventing the engagement of GP core 
with NPC1 receptor. 
 
3. Antibodies to the base region 
KZ52 is the only human monoclonal antibody known to bind EBOV GP and represents 
the group of antibodies that target GP1/GP2 interface at the GP base (Table 1).  This 
antibody was isolated from a phage display library that was constructed from bone marrow 
RNA obtained from a survivor (Maruyama et al., 1999). KZ52 neutralized EBOV in vitro 
(Maruyama et al., 1999), protected guinea pigs from lethal challenge (Parren et al., 2002), 
but failed to protect non-human primates from EBOV infection (Oswald et al., 2007). KZ52 
mAb is specific for the three discontinuous regions of GP1 and GP2, including the internal 
fusion loop (Lee et al., 2008c). KZ52 neutralizes EBOV most likely by inhibiting the 
conformational changes required for fusion of viral and endosomal membranes (Lee et al., 
2008a). 
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Several murine Abs have also been reported to bind to the base region of EBOV GPs 
(Dias et al., 2011a; Murin et al., 2014).  The ZMapp cocktail is composed of three EBOV 
glycoprotein (GP)-specific mAbs (designated c13C6, c2G4 and c4G7) that were isolated 
initially from mice (Qiu et al., 2011; Wilson et al., 2000), chimerized with human antibody 
constant regions, and then produced in Nicotiana benthamiana plants (Qiu et al., 2014). 
Single-particle EM reconstructions of these mAbs in complex with EBOV surface protein 
have revealed key sites of vulnerability on the EBOV GP (Murin et al., 2014) (Figure 7). 
One such site lies within the GP base at the GP1/GP2 interface; two of three mAbs from the 
ZMapp cocktail (c2G4 and c4G7) bind to overlapping epitopes located in this region.  
 
Marburg virus-specific antibodies 
 
Most of our knowledge about humoral response against filovirus infections has come 
from studies of mAbs that recognize EBOV GP. As the result, there is little information 
available about human or mouse antibodies to other filoviruses, such as MARV. Two murine 
Abs that bind the mucin-like domain of MARV GP reduce MARV budding from infected cells 
in culture, but fail to neutralize virus directly (Kajihara et al., 2012). Polyclonal MARV-specific 
mAbs protect non-human primates when administrated passively after challenge (Dye et al., 
2012). The epitopes recognized by such polyclonal neutralizing mAbs, and the mechanism 
of neutralization by which these Abs act, are unknown.  
Recently, a diverse panel of ten mouse mAbs against MARV has been described 
(Fusco et al., 2015). Four of ten antibodies bind MARV-specific “wing” epitope on GP2 
subunit. The wing region is present only on the surface of MARV GP and is a portion of the 
mucin-like domain attached to GP2 subunit. GP2-specific mAbs provide 60%-100% 
protection in mice challenged with MARV (Fusco et al., 2015). 
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Successful treatment with cocktails of antibodies 
 
While there is no FDA-approved treatment for filovirus infections, several experimental 
therapeutics against EBOV are being investigated, including small interfering RNAs 
(Geisbert et al., 2010; Thi et al., 2015), antisense oligonucleotides (Warren et al., 2010; 
Warren et al., 2015), a nucleoside analog (Warren et al., 2014), therapeutic vaccines 
(Feldmann et al., 2007; Geisbert et al., 2008), and monoclonal antibody (mAb) cocktails 
(Olinger et al., 2012a; Qiu et al., 2012b; Qiu et al., 2014). Of these, preliminary treatment 
studies suggest that the effect of the antibody cocktails exceeded the efficacy and treatment 
window of other experimental therapeutics described so far (Marzi et al., 2012; Pettitt et al., 
2013; Qiu et al., 2012a; Qiu et al., 2014; Zeitlin et al., 2011) (Table 2). 
The ZMapp cocktail is composed of three EBOV glycoprotein (GP)-specific mAbs 
(designated c13C6, c2G4 and c4G7) that were isolated initially from mice (Qiu et al., 2011; 
Wilson et al., 2000), chimerized with human antibody constant regions, and then produced 
in Nicotiana benthamiana (Qiu et al., 2014).  
 
 
Table 2. Efficacy of combined mAb treatment in non-human primates  
Cocktail Components Dose, mg/kg and time of treatment 
No. 
survivors/total References 
ZMapp c13C6+c2G4+c4G7 50, 5dpi 6/6 (Qiu et al., 2014) 
ZMab c1H3+c2G4+c4G7 25, 1-3dpi 4/4 (Qiu et al., 2012a) 
MB-003 c13C6+h13F6+c6D8 50, 1dpi 1/3 (Qiu et al., 2014) 
Two mAb cocktail 133+266 50, -1,1,3 dpi 1/3 (Marzi et al., 2012) 
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CHAPTER II 
 
MECHANISM OF HUMAN ANTIBODY-MEDIATED NEUTRALIZATION  
OF MARBURG VIRUS 
 
“…the  operators offered a side trip, an option, to a place called the Maramagambo Forest, 
where the chief attraction was a peculiar site that everyone knew as Python Cave. 
African rock pythons lived there, languid and content, grown large and fat on a diet of bats.” 
David Quammen, Spillover: Animal Infections and the Next Human Pandemic 
 
Introduction 
 
Most of our knowledge about humoral response against filovirus infections has come 
from studies of murine Abs that recognize EBOV GP. From those studies, we learned that 
mouse nAbs preferentially target peptides exposed in upper, heavily glycosylated domains 
or lower areas (the GP1 base) where rearrangements occur that drive fusion of viral and 
host membranes (Saphire, 2013). Abs have not been identified that target protein features 
of the GP1 head subdomain, where the receptor-binding site to NPC1 protein is located. Ab 
KZ52, the only reported human EBOV GP-specific mAb, was obtained from a phage display 
library that was constructed from bone marrow RNA obtained from a survivor (Maruyama et 
al., 1999). KZ52 binds a site at the base of the GP and neutralizes EBOV, most likely by 
inhibiting the conformational changes required for fusion of viral and endosomal membranes 
(Lee et al., 2008).  
In contrast, very little is known about the mechanisms by which Abs neutralize MARV. 
Two murine Abs that bound the mucin-like domain of MARV GP reduced MARV budding 
from infected cells in culture, but failed to neutralize virus directly (Kajihara et al., 2012). 
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Polyclonal MARV-specific Abs were shown to protect non-human primates when 
administrated passively after challenge (Dye et al., 2012). The epitopes recognized by such 
polyclonal nAbs, and the mechanism of neutralization by which these Abs act, are unknown.  
In this chapter, I describe the isolation of a large panel of human nAbs from B cells of 
an individual who contracted MARV infection in 2008 following exposure to fruit bats in the 
Python Cave in Queen Elizabeth National Park, Uganda. I used Abs isolated from the 
human survivor to define the molecular basis of MARV neutralization by Abs. The results 
show that MARV nAbs recognize the NPC1 receptor-binding site of MARV GP, and in some 
cases also recognize conserved structural features in the equivalent receptor-binding site on 
EBOV GP. 
I acknowledge Alexander Bukreyev’s group for performing neutralization, protection 
experiments as well as providing help with escape mutants generation, Andrew Ward’s 
group for studying MARV-specific mAbs by negative-stain single-particle EM, and Erica 
Saphire’s group for providing MARV GPs. 
 
Isolation of human monoclonal antibodies against Marburg virus 
 
The success of this project depended on the ability to generate large panels of 
filovirus-specific neutralizing antibodies. The hybridoma generation technique was used 
successfully in the Crowe lab in the past to generate hundreds of virus-specific cell lines for 
dengue and influenza viruses (Krause et al., 2011; Smith et al., 2013). From those studies, it 
was determined that the frequency of antigen-specific memory B cells in a PBMC sample, 
the initial transformation efficiency, as well as sensitivity and specificity of the screening 
assays could impact the total number and functional characteristics of the isolated 
antibodies.  
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As the hybridoma generation technique has never been used in the past to obtain 
filovirus-specific human monoclonal antibodies, I decided to test the overall performance of 
the method by using PBMCs samples obtained from an individual who survived MARV 
infection several years earlier. To determine whether the individual was able to mount a 
successful humoral response, I performed an enzyme-linked immunosorbent assay (ELISA) 
where antibodies form the subject’s serum were tested for binding to MARV proteins. Strong 
signal was detected for survivor serum but not for control serum, when plates were coated 
with irradiated cell lysates prepared from MARV-infected cell cultures (Figure 8A).  
		
Figure 8. Isolation of human mAbs against Marburg virus. (A) Serum of MARV survivor contains MARV-
specific antibodies; plate was coated with irradiated lysates prepared from MARV-infected cells. (B) EBV-
transformed B cells secrete MARV-specific antibodies. (C) Mabs that bind to MARV infected-cell lysate but 
not to GP target MARV internal proteins.	
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The hybridoma generation protocol developed in the Crowe lab is mostly amenable to 
isolation of monoclonal antibodies from circulating memory B cells. To show that samples 
obtained from the MARV survivor contained memory B cells capable of secreting filovirus-
specific antibodies, I transformed in total 80 million PBMCs from the subject with Epstein-
Barr virus and, after 7 days, I screened supernates from the plates for the presence of 
MARV antigen-specific B cell lines. I used three different ELISA assays for screening: plates 
were coated either with recombinant MARV GP expressed in an insect cell line or irradiated 
MARV virions purified on sucrose gradient or irradiated lysates prepared from MARV-
infected cell cultures. Multiple wells with a high signal were observed in all three assays, 
suggesting that memory B cells capable of secreting antibodies to MARV antigen are 
present in PBMCs from the MARV survivor and that those cells are transformable by the 
hybridoma method (Figure 8B). 
During the next step of the hybridoma generation protocol, cells from wells with 
supernates reacting in the MARV antigen ELISAs were fused with myeloma cells using an 
electrofusion technique. This is the most critical step of hybridoma generation, as the 
success of the fusion can be impacted by multiple factors, such as the initial transformation 
efficiency, viability of the myeloma and target B cells, and the total number of antigen-
specific B cells in the fusion suspension. In total, I fused 247 antigen-specific B cell lines 
and, after the cloning, I was able to generate 51 monoclonal hybridomas secreting MARV-
specific human mAbs (21% success rate).  
Thirty-nine of these mAbs were specific to the MARV GP, while 12 bound to infected-
cell lysate but not to GP; these latter mAbs were shown in secondary screens to bind to 
MARV internal proteins (NP, VP35, or VP40) (Figure 8C).  
 
 
 
	 28 
Neutralization activity 
 
To evaluate the inhibitory activity of the mAbs, we collaborated with Dr. Alexander 
Bukreyev’s group at UTMB. The Bukreyev Lab performed in vitro neutralization studies 
using a chimeric vesicular stomatitis virus with MARV GP from Uganda strain on its surface 
(VSV/GP-Uganda). Eighteen of the 39 MARV GP-specific mAbs exhibited neutralization 
activity against VSV/GP-Uganda (Figures 9A, 10). Of those 18 nAbs, 9 displayed strong 
(IC50 < 10 µg/mL), 8 nAbs displayed moderate (IC50: 10-99 µg/mL), and one displayed weak 
(IC50: 100-1,000 µg/mL) neutralizing activity against VSV/GP-Uganda. We also tested the 
neutralization potency of all nAbs that bound to MARV GP in a plaque reduction assay using 
		
Figure 9. Neutralizing and binding activities of MARV mAbs. (A) Neutralization activity of MR77 (non-
neutralizing antibody) or MR213 (neutralizing antibody) against VSV/GP-Uganda (red circles) or MARV-
Uganda (black circles). Error bars represent the SE of the experiment performed in triplicate. (B) Binding of 
representative mAbs from four distinct binding groups to the MARV GP (blue squares) or MARV GPΔmuc 
(green squares). A dotted line indicates 0.5 µg/ml threshold for categorizing group 3 antibodies as 
possessing low (3A) or high (3B) EC50 values.			
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viable MARV-Uganda virus. Of 18 Abs 
that neutralized VSV/GP-Uganda, 10 
Abs exhibited neutralizing activity 
against MARV-Uganda (Figure 9A, 10). 
These data suggest that VSV/GP, often 
used to study neutralizing potency of 
Abs because of its BSL-2 containment  
level, is more susceptible to Ab-
mediated neutralization than viable 
MARV. This difference is likely 
explained by the significantly lower copy 
number of MARV GP molecules that 
incorporate into VSV particles compared 
with the large number of GP molecules 
on the surface of filovirus filaments 
(Beniac et al., 2012; Thomas et al., 
1985).  
Comparison of MARV neutralizing and 
non-neutralizing antibodies at 
concentration up to 1.6 mg/mL revealed 
dose-dependent activity of those mAbs 
that neutralized. The neutralization 
activity of nAbs was not enhanced by 
the presence of complement. As expected, we did not detect neutralizing activity for any of 
the 12 Abs specific to MARV NP, VP35, or VP40 proteins. 
 
	
 
Figure 10. Heatmap showing the neutralization 
potency of MARV GP-specific mAbs. The IC50 value 
for each virus-mAb combination is shown, with dark red, 
orange, yellow, or white shading indicating high, 
intermediate, low, or no potency, respectively. IC50 
values greater than 1,000 µg/ml are indicated by >. 
Neutralization assays were performed in triplicate.	
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Recognition of varying forms of GP 
 
To characterize the binding of isolated Abs to recombinant MARV GPs, I performed binding 
assays using either a recombinant MARV GP ectodomain containing the mucin-like domain 
(MARV GP) or a recombinant GP lacking residues 257-425 of the mucin-like domain (MARV 
GPΔmuc). Based on OD405 values at the highest Ab concentration tested (Emax) and 50% 
effective concentration (EC50), I divided the MARV-GP-specific Abs into four major groups, 
based on binding phenotype (designated Binding Groups 1, 2, 3A and 3B; Figure 9B and 
Figure 12). Binding Group 1 mAbs had an Emax to GP < 2 [i.e., these mAbs never exhibited 
a maximal binding level to MARV GP]; Binding Group 2 mAbs had an Emax to GP >2, with 
EC50 for GP < EC50 for GPΔmuc [i.e., these mAbs bound to the mucin-like domain or glycan 
cap]; Binding Group 3 had an Emax to GP > 2, with EC50 for GP ≈ EC50 for GPΔmuc [i.e., 
these mAbs bound equally well to full-length and mucin-deleted forms of GP], with the 
Group 3A mAbs having an EC50 for GP < 0.5 µg/mL and the Group 3B mAbs having an EC50 
for GP > 0.5 µg/mL. 
Abs that lacked neutralization activity against VSV/GP-Uganda or MARV-Uganda fell 
principally into Binding Groups 1, 2, and 3A. Interestingly, all VSV/GP-Uganda nAbs 
displayed a unique binding pattern and segregated into Binding Group 3B (Figure 10). It 
was interesting that while both mAbs from Groups 3A and 3B bound equally well to the full-
length MARV GP and to the GPΔmuc, EC50 values for nAbs from Binding Group 3B were 
higher than those for non-neutralizing Abs from Group 3A. 
 
Competition-binding studies 
 
To determine whether mAbs from distinct binding groups targeted different antigenic 
regions on the MARV GP surface, I performed a competition-binding assay using a real-time 
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biosensor. Antibodies are assigned to distinct antigenic regions (or functional regions) if they 
both can bind the antigen. Antibodies are assigned to the same antigenic region if one 
antibody blocks the binding of another antibody. I tested 18 MARV nAbs from Binding Group 
3B, four Abs from Binding Group 3A, and one Ab from Binding Group 2 in a tandem blocking 
assay in which biotinylated GPΔmuc was attached to a streptavidin biosensor. Abs from  
Group 1 and the two non-neutralizing Abs from Binding Group 3B did not bind to biotinylated   
	
 
Figure 11. MARV-neutralizing mAbs target a distinct antigenic region on the GP surface. Data 
from competition binding assays using mAbs from binding groups 2, 3A, or 3B. Numbers indicate the 
percent binding of the competing mAb in the presence of the first mAb, compared to binding of 
competing mAb alone. MAbs were judged to compete for the same site if maximum binding of the 
competing mAb was reduced to <30% of its un-competed binding (black boxes with white numbers). 
MAbs were considered non-competing if maximum binding of the competing mAb was >70% of its un-
competed binding (white boxes with red numbers). Gray boxes with black numbers indicate an 
intermediate phenotype (between 30 and 70% of un-competed binding). 	
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GPΔmuc in the competition assay and were excluded from the analysis. While non-
neutralizing Abs from Binding Groups 2 and 3A did not prevent binding of the Binding Group 
3B nAbs to GPΔmuc, all nAbs blocked binding of each of the other nAbs to the antigen and 
segregated into a single competition-binding group (Figure 11). These data suggested that 
all of the nAbs target a single major antigenic region on the MARV GP surface. 
		
Figure 12. Binding patterns of MARV GP-specific antibodies. 
Antibodies were segregated into four Binding Groups based on the binding to MARV GP (blue squares) or 
MARV GPΔmuc (green squares). Binding was categorized based on the OD405 values at the highest antibody 
concentration tested (Emax) and half maximal effective concentration (EC50). 	
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Electron microscopy studies of antigen-antibody complexes 
 
To determine the location of the antigenic region targeted by MARV nAbs, in 
collaboration with Andrew Ward’s group, we performed negative stain single-particle 
electron microscopy (EM) studies using complexes of GPΔmuc with Fab fragments of seven 
nAbs from Binding Group 3B. The EM reconstructions clearly showed that Fab fragments for 
 
 
Figure 13. Neutralizing mAbs from a human survivor of MARV bind to the receptor-binding site of GP  
(A) Representative reference-free 2D class averages of the MARV GPΔMuc:MR Fab complexes. 
(B) EM reconstructions of seven Fab fragments of neutralizing antibodies bound to MARV GPΔmuc (side 
views). All seven antibodies target a similar epitope on the top of GP. 
(C) These antibodies can be subdivided based on their angles of approach: (1) those that bind toward the top 
and side of GP1 at a shallow angle relative to the central 3-fold axis (MR72 in red, MR78 in orange, MR201 in 
yellow, or MR82 in green) and (2) those that bind at a steeper angle toward the top of GP1 (MR191 in cyan, 
MR111 in blue, or MR198 in purple). 
(D) The crystal structure of EBOV GPΔmuc (GP1 in white and GP2 in dark gray) is modeled into the MARV GP 
density (mesh), and the angles of approach of the neutralizing antibodies are indicated with arrows, colored as 
in (B). The footprint of the antibodies is indicated by a black circle targeting residues in the putative receptor-
binding site (RBS) through a variety of approach angles. 	
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all seven nAbs bind at the top of the GP in or near the NPC1 protein receptor-binding site 
(Figure 13A,B). The binding pattern of these Abs could be divided further into two major 
groups based on their relative angle of approach to the GP head domain. MAbs MR72, 
MR78, MR201 and MR82 bound toward the top and side of GP1 at a shallow angle relative 
to the central three-fold axis, while mAbs MR191, MR111 and MR198 bound at a steeper 
angle toward the top of GP1 (Figure 13C,D).  
 
Antibody neutralization escape mutant viruses 
 
As an additional strategy to define residues on MARV GP involved in binding to nAbs, 
we generated VSV/GP-Uganda variant viruses that escaped neutralization, and then we 
determined the sequence of the GP of those mAb escape viruses. Vero E6 cells were 
inoculated with VSV/GP-Uganda in the presence of MR72 or MR78 nAbs. Two escape 
mutant viruses were isolated: virus variant VSV/GP-72.5 contained three missense 
mutations in the MARV GP gene (N129S in the putative NPC1 receptor-binding site, S220P 
in the glycan cap and P455L in the mucin-like domain) and virus variant VSV/GP-78.1 
possessed missense mutation C226Y in the glycan cap (Figure 14A). Consistent with the 
EM data, six of seven nAbs tested displayed a higher level of neutralization activity against 
the wild-type VSV/GP-Uganda than to the VSV/GP-72.5 or VSV/GP-78.1 escape mutant 
viruses, suggesting these nAbs recognize MARV GP in a similar fashion (Figure 14B). MAb 
MR198 exhibited equal neutralization potency against wild-type VSV/GP-Uganda or the two 
escape mutant viruses (Figure 14B). As all nAbs segregated into one competition group 
(Figure 11), bound the MARV GP at the NPC1 receptor-binding site (Figure 13), and 
displayed a similar profile of neutralization of escape mutant viruses (Figure 14), I proposed 
that blocking of MARV GP binding to NPC1 is the principal mechanism of MARV 
neutralization by these naturally-occurring human Abs.  
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Cross-reactive binding of MARV antibodies with EBOV GP 
 
It is surprising that human MARV nAbs recognize the putative NPC1 protein receptor-
binding site on GP, since previous studies suggested that the NPC1 protein receptor-binding 
	
 
Figure 14. Generation of escape mutants for MARV neutralizing antibodies. (A) VSV-MARV-72.5 
(dotted lines) or VSV-MARV-78.1 (dashed line) escape mutations mapped onto the domain schematic 
of MARV GP. RBS = Receptor-binding site; GLC = glycan cap; MUC = mucin-like domain. 
(B) Neutralization activity of antibodies from Binding Group 3B against wild-type VSV/GP-Uganda 
(circles, straight curves), VSV/GP-72.5 (squares, dotted curves) or VSV/GP-78.1 (triangles, dashed 
curves) escape mutant viruses. 	
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site on EBOV GP may be obscured from Ab binding by the presence of the highly 
glycosylated glycan cap and mucin-like domain (Lee et al., 2008). To determine whether the 
MARV nAbs we isolated also could bind in a cross-reactive manner to the EBOV GP 
receptor-binding site, I performed ELISA binding assays using three recombinant forms of 
MARV and EBOV GPs: full-length GP ectodomain containing the glycan cap and mucin-like 
domain (designated MARV or EBOV GP), ectodomains lacking residues 257-425 (MARV) or 
314-462 (EBOV) of the mucin-like domain (designated MARV or EBOV GPΔmuc) and 
cleaved GP ectodomains enzymatically treated to remove the mucin-like domain and glycan 
cap (designated MARV or EBOV GPcl). Three of the MARV nAbs, designated MR78, 
MR111 and MR191, recognized the EBOV GPcl that lacked the glycan cap and mucin-like 
domain (Figure 15A). Remarkably, the MARV nAb MR72 bound all three forms of both 
EBOV and MARV GPs with similar EC50 and Emax values, indicating that its epitope, and the 
EBOV receptor-binding site which it likely overlaps, might be partially accessible for Ab 
binding even in the full-length form (Figure 15A). We tested the breadth of neutralization of 
MARV nAbs for filoviruses using a panel of different MARV and EBOV isolates. While 
multiple MARV Abs displayed neutralizing activity towards different MARV strains, MARV 
nAbs did not exhibit detectable neutralization activity against EBOV or VSV/EBOV (Figure 
15B). Structural analysis of MARV and EBOV GP revealed that the glycan cap and mucin-
like domain likely obscure the receptor-binding domain in EBOV but not MARV (Hashiguchi 
T. et al., 2015).    
In vivo testing of Marburg virus antibodies 
In collaboration with Alexander Bukreyev’s group, we tested the in vivo protective 
activity of the mAbs in a murine model using mouse-adapted MARV strain Ci67 (Warfield et 
al., 2007; Warfield et al., 2009). Inoculation of mice with MARV Ci67 causes clinical disease, 
and in a proportion of animals causes lethal disease, although typically less than 100% 
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Figure 15. Breadth of binding or neutralization of human MARV-specific mAbs for diverse 
filoviruses. (A) A heat map showing the binding in ELISA of neutralizing mAbs from Binding Group 3B to 
the MARV and EBOV GPs. EC50 value for each antigen-mAb combination is shown, with dark red shading 
indicating lower EC50 values and orange or yellow shading indicating intermediate or higher EC50 values. 
EC50 values greater than 1,000 µg/mL are	indicated by >. (B) A heat map showing the neutralization 
breadth of mAbs from Binding Group 3B. The IC50 value for each virus-mAb combination is shown, with 
dark red	shading indicating increased potency and orange or yellow shading indicating intermediate or low 
potency. IC50 values greater than 1,000 µg/mL are indicated by >.  	
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lethality in mice (Warren et al., 2014). We selected four mAbs among those with the lowest 
in vitro neutralization IC50 values: MR72, MR82, MR213, and MR232. The IC50 values in 
neutralization assays with MARV Uganda or mouse-adapted MARV strain Ci67 were 
comparable (within two-fold). Seven week-old BALB/c mice were injected with 100 µg of 
antibody by the intraperitoneal route and challenged with 1,000 PFU of Ci67. Twenty four 
hours later, antibody treatment was repeated. By day 6, all five control mice developed 
progressive loss of weight and symptoms of the disease, including dyspnea, recumbency, 
and unresponsiveness, and on days 8 and 9, two animals were found dead and one animal 
was found moribund and euthanized. The remaining two animals demonstrated recovery by 
day 11. In contrast, all animals treated with four antibodies survived and did not display 
elevation of disease score, with the exception of two animals treated with MR72, which 
showed a transient marginal loss of weight and increase in disease score on days 6-9, 
which did not exceed 1 (Figure 16). The observed level of protection was remarkable given 
the relatively modest in vitro neutralizing potency of the antibodies.  
		
Figure 16. Survival and clinical overview of mice treated with MARV mAbs. 
Groups of mice at 5 animals per group were injected with individual mAbs by the intraperitoneal route twice: 1 
h prior and 24 h after MARV challenge at 100 µg per treatment. Untreated animals served as controls. 
(A) Kaplan–Meier survival curves. (B) Body weight (C) Illness score 	
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Discussion 
 
There is an obvious urgent need for prophylactic and therapeutic interventions for 
filovirus infections given the recurrence of MARV outbreaks including in October 2014 in 
Uganda and a massive outbreak of EBOV in West Africa in 2013-2015. There is very little 
information about the structural determinants of neutralization on which to base the rational 
selection of antibodies, and for MARV there have been no reported human nAbs.  
 
This study reveals that naturally occurring human MARV nAbs isolated from the B cells 
of a recovered donor principally target the MARV NPC1 protein receptor-binding site, 
suggesting that a major mechanism of MARV neutralization is inhibition of binding to 
receptor. Remarkably, some of the isolated antibodies also bound to the EBOV GP. This 
mechanism of MARV neutralization was unexpected, because previous studies with EBOV 
showed that the putative receptor-binding domain on GP is obscured on the surface of 
virions by the presence of the glycan cap and mucin-like domain, only becoming exposed 
following cleavage by cathepsins in the endosome. These studies suggest that the 
configuration of the MARV GP differs significantly from that of EBOV GP because the 
receptor-binding domain must be accessible for immune recognition on MARV GP. Indeed, 
determination of the structure of the MARV GP and structural analysis of the interaction of 
mAb MR78 with MARV and EBOV GP molecules shows this to be the case (Hashiguchi et 
al., 2015).  
 
The information obtained from these studies can be used to inform development of 
new therapeutics and structure-based vaccine designs against filoviruses. Furthermore, as 
these nAbs are fully human and exhibit inhibitory activity, they might be useful as a 
component of a prophylactic or therapeutic approach for filovirus infection and disease. The 
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challenge studies using mice here show clear evidence of in vivo activity and suggest 
additional preclinical studies in other species such as guinea pigs and macaques are 
warranted. Their ability to bind a broad range of MARV isolates indicates that they may offer 
detection of or efficacy against new viral strains yet to emerge. Although some of these 
mAbs bind to certain forms of EBOV GP, these antibodies are not likely to be effective 
against natural Ebola infection because the EBOV receptor-binding site is obscured on the 
viral surface. However, such mAbs might neutralize EBOV if they could be delivered to the 
endosome where the EBOV receptor-binding site is exposed following GP cleavage. 
 
Material and Methods 
 
Donor 
The donor was an otherwise healthy adult woman who contracted Marburg virus 
(MARV) infection in 2008 following exposure to fruit bats in the Python Cave in Queen 
Elizabeth National Park, Uganda. The donor’s clinical course was documented previously 
(CDC, 2009). Peripheral blood from the donor was obtained in 2012, four years after the 
illness, following informed consent. The study was approved by the Vanderbilt University 
Institutional Review Board. 
 
Viruses 
MARV strain 200702854 Uganda (MARV-Uganda) was isolated originally from a 
subject designated “Patient A” during the outbreak in Uganda in 2007 (CDC, 2009; Towner 
et al., 2009) and underwent 4 passages in Vero E6 cells. MARV strain Musoke (MARV-
Musoke) was isolated during the outbreak in Kenya in 1980 (Smith et al., 1982) and 
passaged 5 times in Vero E6 cells. MARV strain 200501379 Angola (MARV-Angola) was 
isolated during the outbreak in Angola in 2005 (Towner et al., 2006) and passaged 3 times 
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in Vero E6 cells. MARV Ravn virus (Ravn) was isolated from a patient in 1987 in Kenya 
(Johnson et al., 1996) and passaged 4 times in Vero E6 cells. All strains of MARV were 
obtained originally from the Special Pathogens Branch, U.S. Centers for Disease Control 
(CDC) and deposited at the World Reference Center of Emerging Viruses and Arboviruses 
(WRCEVA) housed at UTMB. The recombinant Ebola Zaire strain Mayinga (EBOV) 
expressing eGFP was generated in our laboratory by reverse genetics (Lubaki et al., 2013; 
Towner et al., 2005) from plasmids provided by the Special Pathogens Branch at CDC and 
passaged 3 times in Vero E6 cells. For analysis of antibody binding by ELISA, viruses were 
gamma-irradiated with the dose of 5 x 106 rad. The recombinant VSV in which the VSV GP 
protein was replaced with that of MARV strain Musoke (VSV/GP-Musoke) or EBOV strain 
Mayinga (Garbutt et al., 2004) were provided by Dr. Thomas Geisbert (UTMB) and Dr. Heinz 
Feldmann (NIH), respectively; a similar virus with GP from MARV (strain 200702854 
Uganda) was constructed as described below. All work with EBOV and MARV was 
performed within the Galveston National Laboratory BSL-4 laboratories. 
We used a mouse-adapted strain of MARV for testing the effect of mAbs in vivo. The 
mouse-adapted Ci67 strain of Marburg virus (Warfield et al., 2007) was provided by Dr. Sina 
Bavari (U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland) 
and amplified by a single passage in Vero-E6 cells.  
 
Generation of a chimeric strain of VSV in which VSV G protein was replaced with the GP 
protein of MARV strain Uganda (VSV/GP-Uganda). 
The plasmid pVSV-XN2 carrying cDNA of the full-length VSV anti-genome sequence 
and the support plasmids pBS-N, pBS-L and pBS-P encoding the internal VSV proteins 
under control of the T7 promoter were kindly provided by Dr. John Rose (Yale University). 
The plasmid pC-T7, encoding the T7 polymerase, was kindly provided by Dr. Yoshihiro 
Kawaoka (University of Wisconsin). For generation of the VSV/GP-Uganda construct, Vero 
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E6 cell monolayers were inoculated with MARV strain 200702854 and total cellular RNA 
was isolated and reverse-transcribed. MARV GP ORF was PCR-amplified from cDNA using 
forward primer 5´-CATGTACGACGCGTCAACATGAGGACTA-3´ and reverse primer 5´-
TCTAGCAGCTCGAGCTATCCAATATATTTAGTAAAGATACGACAA-3´ (underlined are 
MluI and XhoI endonuclease sites, respectively; italicized are the start and the end of MARV 
GP ORF – direct and complementary sequences, respectively). To replace VSV G with 
MARV GP, the resulting PCR-product was cloned into pVSV-XN2 using the unique MluI and 
XhoI endonuclease sites located between the VSV G gene-start and gene-end signals and 
flanking its ORF, resulting in the plasmid pVSV/GP-Uganda. To recover the recombinant 
virus, 1 x 106 BSR-T7 cells, kindly provided by Dr. Ursula Buchholz (U.S. National Institute 
of Allergy and Infectious Diseases), were transfected with the following plasmids: pVSV/GP-
Uganda, 5 µg; pBS-N, 1.5 µg; pBS-P, 2.5 µg; pBS-L, 1 µg; pC-T7, 5 µg. After 48 hours, 
transfected BSR-T7 cells were collected with a cell scraper and transferred, along with the 
supernates, to Vero E6 cell monolayers for amplification of the recovered VSV/GP-Uganda.  
 
Generation of human hybridomas secreting monoclonal antibodies (mAbs) 
Peripheral blood mononuclear cells (PBMCs) from the donor were isolated with Ficoll-
Histopaque by density gradient centrifugation. The cells were cryopreserved immediately 
and stored in the vapor phase of liquid nitrogen until use. Previously cryopreserved samples 
were thawed, and 10 million PBMCs were plated into 384-well plates (Nunc #164688) using: 
17 mL of cell culture medium (ClonaCell-HY Medium A, Stemcell Technologies #03801), 8 
µg/mL of the TLR agonist CpG (phosphorothioate-modified oligodeoxynucleotide 
ZOEZOEZZZZZOEEZOEZZZT, Invitrogen), 3 µg/mL Chk2 inhibitor (Sigma #C3742), 1 
µg/mL cyclosporine A (Sigma #C1832) and 4.5 mL of clarified supernate from cultures of 
B95.8 cells (ATCC VR-1492) containing Epstein-Barr virus (EBV). After 7 days, cells from 
each 384-well culture plate were expanded into four 96-well culture plates (Falcon #353072) 
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using cell culture medium containing 8 µg/mL CpG, 3 µg/mL Chk2i and 10 million irradiated 
heterologous human PBMCs (Nashville Red Cross) and incubated for an additional four 
days. Plates were screened for MARV antigen-specific antibody-secreting cell lines using 
enzyme-linked immunosorbent assays (ELISAs). Cells from wells with supernates reacting 
in a MARV antigen ELISA were fused with HMMA2.5 myeloma cells using an established 
electrofusion technique (Yu et al., 2008). After fusion, hybridomas were resuspended in 
medium containing 100 µM hypoxanthine, 0.4 µM aminopterin, 16 µM thymidine (HAT 
Media Supplement, Sigma #HO262) and 7 µg/mL ouabain (Sigma #O3125) and incubated 
for 18 days before screening hybridomas for antibody production by ELISA. 
 
Human mAb and Fab production and purification 
After fusion with HMMA2.5 myeloma cells, hybridomas producing MARV-specific 
antibodies were cloned biologically by two rounds of limiting dilution and by single-cell 
fluorescence-activated cell sorting. After cloning, hybridomas were expanded in post-fusion 
medium (ClonaCell-HY Medium E, STEMCELL Technologies #03805) until 50% confluent in 
75-cm2 flasks (Corning #430641). For antibody production, cells from one 75-cm2 flask were 
collected with a cell scraper and expanded to four 225-cm2 flasks (Corning #431082) in 
serum-free medium (Hybridoma-SFM, Gibco #12045-076). After 21 days, supernates were 
clarified by centrifugation and sterile filtered using 0.2-µm pore size filter devices. HiTrap 
Protein G or HiTrap MabSelectSure columns (GE Healthcare Life Sciences #17040501 and 
#11003494 respectively) were used to purify antibodies from filtered supernates. Fab 
fragments were generated by papain digestion (Pierce Fab Preparation Kit, Thermo 
Scientific #44985) and purified by chromatography using a two-column system where the 
first column contained protein G resin (GE Healthcare Life Sciences #29048581) and the 
second column contained either anti-kappa or anti-lambda antibody light chain resins (GE 
Healthcare Life Sciences #17545811 and #17548211 respectively). 
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Expression and purification of MARV and EBOV GPs 
Angola strain MARV GP ectodomains, containing the mucin-like domain (MARV GP) 
or lacking residues 257-425 of the mucin-like domain (MARV GPΔmuc), were used to 
screen supernates of transformed B cells and human hybridomas separately. Recombinant 
proteins for Ravn strain cleaved GP, EBOV Mayinga strain GP, EBOV Mayinga strain 
GPΔmuc and EBOV Mayinga strain cleaved GP were designed and expressed similarly. 
Large-scale production of recombinant GP or GPΔmuc was performed by transfection of 
Drosophila Schneider 2 (S2) cells with modified pMTpuro vectors, followed by stable 
selection of transfected cells with 6 µg/mL puromycin. Secreted GP ectodomain expression 
was induced with 0.5 mM CuSO4 for 4 days. Proteins were engineered with a modified 
double strep tag at the C terminus (enterokinase cleavage site followed by a strep 
tag/linker/strep tag) to facilitate purification using Strep-Tactin resin (Qiagen #2-1201). 
Proteins were purified further by Superdex 200 size exclusion chromatography in 10 mM 
Tris, 150 mM NaCl, pH 7.5 (1X TBS). 
 
Lysates of MARV-infected cells 
Lysates were prepared as previously described (Ksiazek et al., 1999). Briefly, Vero E6 
cell monolayers in 850 cm2 roller bottles were inoculated with approximately 106 PFU MARV 
or EBOV and incubated at 37 °C until partial destruction of monolayer occurred 
(approximately 9-10 days). Cell monolayers were detached using 3 mm glass beads, and 
cell suspensions were centrifuged at 16,000 x g for 10 min at 4 °C. Supernates were 
discarded, cell pellets were resuspended in 10X excess of borate buffer saline (10 mM 
Na2B4O7, 150 mM NaCl, pH 9.0), and centrifuged at 16,000 x g for 10 min at 4 °C. 
Supernates were discarded, cell pellets were resuspended in cold 1% Triton X-100 (Fisher 
Scientific) in borate buffer saline, vortexed and gamma-irradiated on dry ice at 5 x 106 rad. 
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The lysates were sonicated with a 600 W Tekmar Sonic Disruptor TM600 (Tekmar) using a 
cuphorn sonicator at maximum power setting and 50% duty cycle for 10 min, centrifuged at 
16,000 x g and the supernates aliquoted. 
 
Screening ELISA 
ELISA plates were coated with lysates of MARV infected cells (diluted 1:1,000 in 
Dulbecco phosphate buffered saline, DPBS) or recombinant MARV GP or MARV GPΔmuc 
proteins (20 µg in 10 mL DPBS per plate) and incubated at 4 °C overnight. Plates were 
blocked with 100 µL of blocking solution/well for 1 h. Blocking solution consisted of 10 g 
powdered milk, 10 mL of goat serum, 100 mL of 10X DPBS, and 0.5 mL of Tween-20 mixed 
to a 1 L final volume with distilled water. The presence of antibodies bound to the GP was 
determined using goat anti-human IgG horseradish peroxidase conjugated secondary 
antibodies (Southern Biotech #2040-05, 1:4,000 dilution) and 1-Step Ultra TMB-ELISA 
substrate (Thermo Scientific #34029), with optical density read at 450 nM after stopping the 
reaction with 1M HCl. 
 
Half maximal effective concentration (EC50) binding analysis 
MARV or EBOV GPs, MARV or EBOV GPΔmuc, or Ravn or EBOV cathepsin-cleaved 
GPs were coated onto 384-well plates (Thermo Scientific Nunc #265203) in DPBS at 2 
µg/mL overnight, then antigen was removed and plates were blocked with blocking solution 
made as above. Antibodies were applied to the plates at a concentration range of 1.5 µg/mL 
to 270 ng/mL (Binding Groups #1, #2 and 3A) and 0.1 µg/mL to 10 ng/mL (Binding Group 
#3B) using three-fold serial dilutions. The presence of antibodies bound to the GP was 
determined using goat anti-human IgG alkaline phosphatase conjugate (Meridian Life 
Science #W99008A, 1:4,000 dilution) and p-nitrophenol phosphate substrate tablets (Sigma 
#S0942), with optical density read at 405 nM after 120 minutes. A non-linear regression 
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analysis was performed on the resulting curves using Prism version 5 (GraphPad) to 
calculate EC50 values. 
 
MARV and EBOV neutralization experiments 
Dilutions of mAbs in triplicate were mixed with 150 PFU of MARV or EBOV expressing 
eGFP in MEM containing 10% FBS (HyClone), 50 µg/mL gentamicin (Cellgro #30-005-CR) 
with or without 5% guinea pig complement (MP Biomedicals #642836) in a total volume of 
0.1 mL, and incubated for 1 hour at 37 °C for virus neutralization. Following neutralization, 
virus-antibody mixtures were placed on monolayers of Vero E6 cells in 24-well plates, 
incubated for 1 hour at 37 °C for virus adsorption, and overlayed with MEM containing 2% 
FBS and 0.8% methylcellulose (Sigma-Aldrich #M0512-1KG). After incubation for 5 days, 
medium was removed, cells were fixed with 10% formalin (Fisher Scientific #245-684), 
plates were sealed in plastic bags and incubated for 24 hours at room temperature. Sealed 
plates were taken out of the BSL-4 laboratory according to approved SOPs, and monolayers 
were washed three times with phosphate buffered saline. Viral plaques were immunostained 
with the serum of rabbits that had been hyperimmunized with MARV, or with a mAb against 
EBOV, clone 15H10 (BEI Resources #NR-12184). Alternatively, following virus adsorption, 
monolayers were covered with MEM containing 10% FBS and 1.6% tragacanth (Sigma-
Aldrich #G1128). After incubation for 14 days, medium was removed, cells were fixed with 
10% formalin, plates were sealed in plastic bags, incubated for 24 hours at room 
temperature, and taken out of the BSL-4 laboratory as above. Fixed monolayers were 
stained with 10% formalin containing 0.25% crystal violet (Fisher Scientific #C581-100), and 
plaques were counted. 
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VSV-MARV and VSV-EBOV neutralization tests 
Neutralization assays were performed in triplicate, as described above for MARV and 
EBOV. Following neutralization, virus-antibody mixtures were placed on monolayers of Vero 
E6 cells in duplicate, incubated for 1 hour at 37 °C for virus adsorption, and overlayed with 
MEM containing 2% FBS containing 0.9% methylcellulose. After incubation for 3 days, 
medium was removed, monolayers were fixed and stained with 10% formalin containing 
0.25% crystal violet, and plaques were counted. 
 
Generation and sequencing of VSV/GP-Uganda escape mutants 
Vero E6 cell monolayers with two-fold dilutions of mAbs (12.5 – 200 µg/mL) added to 
the medium were inoculated with 200 PFU of recombinant VSV/GP-Uganda and incubated 
at 37 °C for 2-4 days. To determine which samples contained live virus, supernates were 
collected, virus was titrated in Vero E6 cell monolayers under methylcellulose overlay, 
monolayers were incubated at 37 °C for 3-4 days, and plaques were counted. Supernates 
with the highest concentrations of mAbs, which were found to contain live virus by plaque 
titration, were incubated in presence of serially diluted mAbs followed by titration of virus as 
above. The procedure was performed a total of three times. Escape mutant viruses 
harvested after the third passage were cloned biologically by plaque purification. For 
biological cloning, Vero E6 cell monolayers in 24-well plates were inoculated with dilutions of 
the escape mutant viruses in the presence of the corresponding mAbs (200 µg/mL of MR72 
or 100 µg/mL of MR78) and covered with 0.7% low melting temperature SeaPlaque agarose 
(Lonza #50100). Monolayers were incubated at 37 °C for 6 days, plaques were visualized 
with 0.01% neutral red aqueous solution (Electron Microscopy Sciences), picked, 
resuspended in medium and transferred to Vero E6 cell monolayers in 24-well plates in 
presence of the corresponding mAbs (200 µg/mL of MR72 or 100 µg/mL of MR78) for virus 
propagation. In 2-5 days, based on the extent of CPE observed, virus was harvested, and 
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cells were dissolved in Trizol reagent (Life Technologies 315596018). Total cellular RNA 
was extracted and reverse-transcribed and amplified by PCR with the primers described 
above for generation of a chimeric strain of VSV. Two overlapping fragments covering 
MARV GP ORF were PCR-amplified from cDNA using forward primer 5´-
CATGTACGACGCGTCAACATGAGGACTA-3´ and reverse primer 5´-
ACTAAGCCCTGCTGCCAGGT-3´ or forward primer 5´-ACAACAATGTACCGAGGCAA-3´ 
and reverse primer 5´-TCTAGCAGCTCGAGCTATCCAATATATTTAGTAAAGATACGACAA-
3´, and the nucleotide sequences of the GP ORFs were determined using standard 
procedures.  
 
Analysis of growth kinetics of VSV/GP-Uganda escape mutant viruses 
Vero E6 cell monolayers in 24-well plates were inoculated in triplicate with VSV/GP-
Uganda escape mutants or non-mutated virus at an MOI of 0.00025 PFU/cell in the 
presence of varying concentrations of the corresponding mAbs. Aliquots of medium were 
collected every 12 hours and frozen for titration at a later time. Titration of virus in aliquots 
was performed as above, without adding antibodies to the culture medium. 
 
Biolayer interferometry competition binding assay 
Biotinylated GP or GPΔmuc (EZ-link® Micro NHS-PEG4-Biotinylation Kit, Thermo 
Scientific #21955) (1 µg/mL) was immobilized onto streptavidin-coated biosensor tips 
(ForteBio #18-5019) for 2 minutes. After measuring the baseline signal in kinetics buffer 
(KB: 1X PBS, 0.01% BSA and 0.002% Tween 20) for two minutes, biosensor tips were 
immersed into the wells containing primary antibody at a concentration of 100 µg/mL for 10 
minutes. Biosensors then were immersed into wells containing competing mAbs at a 
concentration of 100 µg/mL for 5 minutes. The percent binding of the competing mAb in the 
presence of the first mAb was determined by comparing the maximal signal of competing 
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mAb applied after the first mAb complex to the maximal signal of competing mAb alone. 
MAbs were judged to compete for binding to the same site if maximum binding of the 
competing mAb was reduced to <30% of its un-competed binding. MAbs were considered 
non-competing if maximum binding of the competing mAb was >70% of its un-competed 
binding. A level of 30-70% of its un-competed binding was considered intermediate 
competition. 
 
Sequence analysis of antibody variable region genes 
Total cellular RNA was extracted from clonal hybridomas that produced MARV 
antibodies, and RT-PCR reaction was performed using mixtures of primers designed to 
amplify all heavy chain or light chain antibody variable regions. The generated PCR 
products were purified and cloned into the pJet 1.2 plasmid vector (Thermo Scientific, 
#K1231) for sequence analysis. The nucleotide sequences of plasmid DNAs were 
determined using an ABI3700 automated DNA sequencer. Heavy chain or light chain 
antibody variable region sequences were analyzed using the IMGT/V-Quest program 
(Brochet et al., 2008; Giudicelli et al., 2011). The analysis involved the identification of 
germline genes that were used for antibody production, location of complementary 
determining regions (CDRs) and framework regions (FRs) as well as the number and 
location of somatic mutations that occurred during affinity maturation.  
 
Statistical analysis 
EC50 values for neutralization were determined by finding the concentration of mAb at 
which a 50% reduction in plaque counts occurred after incubation of virus with neutralizing 
antibody. A logistic curve was fit to the data using the count as the outcome and the log-
concentration as the predictor variable. The results of the model then were transformed 
back to the concentration scale. Results are presented as the concentration at the dilution 
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that achieve a 50% reduction from challenge control with accompanying 95% confidence 
intervals. Each antibody was treated as a distinct analysis in a Bayesian non-linear 
regression model. 
 
Sample preparation for EM studies 
A Ravn strain MARV GP mucin-deleted construct (GP∆muc) was produced by stable 
cell line expression in Drosophila S2 cells, as described above. Human Fab proteins for 
MARV-specific antibodies were generated as described above. Fabs were added in molar 
excess to GP∆muc and allowed to incubate overnight at 4 °C. Complexes then were purified 
by Superdex 200 size exclusion chromatography in TBS. 
 
Electron microscopy and sample preparation 
A 4 µL aliquot of each complex that had been diluted to a concentration of ~0.03 
µg/mL with TBS buffer was placed for 15 seconds onto carbon-coated 400 Cu mesh grids 
that had been plasma cleaned for 20 s (Gatan), blotted off on the edge of the grid, then 
immediately stained for 30 s with 4 µL of 2% uranyl formate. The stain was blotted off on the 
edge of the grid and the grid was allowed to dry. Data were automatically collected with 
Leginon (Carragher et al., 2000; Potter et al., 1999; Suloway et al., 2005) using a FEI Tecnai 
F20 electron microscope operating at 120 keV with an electron dose of 30 e-/Å2 and a 
magnification of 52,000X that resulted in a pixel size of 2.65 Å at the specimen plane when 
collected with Tietz CMOS 4k x 4k CCD camera. Particle orientations appeared to be 
generally isotropic and images were acquired at a constant defocus value of -1.0 µm at 0° 
stage tilt.  
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Image processing of protein complexes 
Particles were picked automatically using DoG Picker (34) and placed into a particle 
stack using the Appion software (Lander et al., 2009). Reference-free 2D class averages 
were generated with the Xmipp clustering 2D alignment software (van Heel et al., 1996) and 
sorted into an initial 300 classes. Non-GP particles were removed and the stack was further 
sub-classified into classes with ~100 particles per class in order to generate the final particle 
stack used for the reconstruction. Various numbers of class averages were chosen to create 
initial models using EMAN2 common lines software (Tang et al., 2007). A model that best 
matched its projected classes was then used for refinement against the raw particle stack, 
imposing C3 symmetry, and the reconstruction was generated with 10 rounds of refinement 
and increasingly smaller angular sampling rates with EMAN2 (Tang et al., 2007). All model 
fitting and manipulation was completed using UCSF Chimera (Pettersen et al., 2004).  
 
In vivo testing. The animal protocol for testing of mAbs in mice was approved by the 
Institutional Animal Care and Use Committee of the University of Texas Medical Branch at 
Galveston. Seven-week-old BALB/c mice (Harlan) were placed in the ABSL-4 facility of the 
Galveston National Laboratory. Groups of mice at 5 animals per group were injected with 
individual mAbs by the intraperitoneal route twice: one h prior and 24 h after MARV 
challenge, using 100 µg per treatment. Untreated animals served as controls. For the 
challenge, mice were injected with 1,000 PFU of the mouse-adapted MARV strain Ci67 by 
the intraperitoneal route. Animals were weighed and monitored daily over the three-week 
period after challenge. Once animals were symptomatic, they were examined twice per day. 
The disease was scored using the following parameters: dyspnea (possible scores 0-5), 
recumbency (0-9), unresponsiveness (0-5), and bleeding/hemorrhage (0-5); the individual 
scores for each animal were summarized.  
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CHAPTER III 
 
CROSS-REACTIVE AND POTENT NEUTRALIZING ANTIBODY RESPONSES IN 
HUMAN SURVIVORS OF EBOLAVIRUS INFECTION 
 
“The putative index patient was a 26-year-old woman from Kabango village, Kasitu subcounty, in 
Bundibugyo district. Hunting spears were found at her home, but hunting as a practice was denied.” 
(Wamala et al., 2010) 
 
Introduction 
 
The ability of mAbs to bind conserved neutralizing epitopes present on the surface of 
highly variable viral proteins has been documented extensively for HIV (Burton et al., 2012), 
influenza viruses (Pappas et al., 2014), dengue virus (Rouvinski et al., 2015), 
paramyxoviruses (Corti et al., 2013), and alphaviruses (Fox et al., 2015). Despite similar 
requirements for virus entry into the cell (Misasi et al., 2012), GPs from BDBV, EBOV, and 
SUDV strains differ by over 30% at the amino acid level (Towner et al., 2008). This overall 
genetic divergence between species of genus Ebolavirus has hampered the development of 
ebolavirus cross-neutralizing Abs. The key components of multiple antibody cocktails 
developed over the last decade neutralize only viruses of species Zaire ebolavirus. A weakly 
neutralizing mAb c13C6 cross-reacts with SUDV GPs (Wilson et al., 2000), but it is unknown 
whether this mAb neutralizes SUDV.  Cross-reactive antibodies in serum can be elicited 
during natural infection in humans or vaccination of animals. The serum of individuals who 
survived BDBV, EBOV, or SUDV infections contained ebolavirus cross-reactive IgG but not 
IgM (Macneil et al., 2011). Other studies demonstrated that mice immunized with a vaccine 
bearing the GP of EBOV generated cross-reactive polyclonal mAbs to other ebolaviruses 
such as BDBV and SUDV (Meyer et al., 2015; Ou et al., 2012). Four broadly reactive non-
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neutralizing mAbs were isolated in mice after vaccinating animals with recombinant 
vesicular stomatitis virus (rVSV) expressing EBOV GP and then boosting initial immune 
response with the heterologous virus containing SUDV GP (Hernandez et al., 2015). The 
epitopes recognized by such cross-reactive mAbs are unknown. 
In this chapter, I describe the isolation of a large panel of BDBV-specific and 
Ebolavirus cross-reactive mAbs from B cells of survivors of BDBV infection. The results 
show that a large proportion of mAbs with potent neutralizing activity against BDBV bind to 
the glycan cap and recognize diverse epitopes within this major antigenic site. We identified 
several glycan cap-specific mAbs that neutralized multiple Ebolavirus species and a cross-
reactive mAb that completely protected guinea pigs from the lethal challenge with 
heterologous EBOV when used as monotherapy. Several of these naturally occurring 
antibodies exhibit the most potent protective capacity reported, and they possessed 
unprecedented cross-reactivity for multiple Ebolavirus species including SUDV for which 
neutralizing human mAbs have not been reported. 
I acknowledge Alexander Bukreyev’s group for performing neutralization, protection 
experiments as well as escape mutants generation, Andrew Ward’s group for studying 
EBOV-specific mAbs by negative-stain single-particle EM, Erica Saphire’s group for 
providing Ebolavirus GPs, and Ben Doranz team for performing epitope mapping of selected 
mAbs using saturation mutagenesis. 
 
Isolation of Human MAbs 
 
To generate human cell lines secreting human mAbs to BDBV, I transformed 
peripheral blood B cells from seven survivors of the 2007 Uganda BDBV outbreak with EBV. 
To determine the breadth of antibody response in survivors of ebolavirus infection, I 
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screened supernatants from EBV-transformed B cell lines for binding to GPs from diverse 
representatives of filovirus species: BDBV, EBOV, or MARV (Figure 17). I also used the 
same GP panel to screen supernatants from transformed B cell lines derived from a survivor 
of the 2014 EBOV outbreak (Figure 17B) or from a donor who survived MARV infection 
(Figure 17). I color-coded GP-reactive supernatants based on the cross-reactivity pattern: 
species-specific cell lines are highlighted in black; cross-reactive lines to 2 or 3 species are 
shown in yellow or blue, respectively (Figure 17A-C). While approximately half of GP-
specific B cell lines obtained from BDBV survivors produced antibodies specific to BDBV 
GP, 24-50% of GP-reactive B cell culture supernatants also cross-reacted with EBOV GP 
(Figure 17A, Table 3). Similarly, 36% of GP-specific B cell lines obtained from the EBOV 
survivor cross-reacted with the heterologous BDBV GP (Figure 17B, Table 3). Despite the 
apparent presence of B cells encoding cross-reactive antibodies in survivors of BDBV or 
EBOV infections to GPs from heterologous Ebolavirus species, I detected a very limited 
cross-reactivity with GPs from MARV, which belongs to a different genus in the family 
Filoviridae (Figure 17A, Table 3). In line with this finding, 90% of GP-reactive B cell lines 
obtained from the MARV survivor reacted with autologous GP, and only 2% of antigen-
specific B cell lines produced Ebolavirus cross-reactive Abs (Figure 17C, Table 3). The 
limited cross-reactivity of mAbs to GPs from Ebolavirus and Marburgvirus species likely is 
due in part to low sequence conservation between GPs from two genera (only 27% amino 
acid identity between BDBV and MARV GP) as well as differences in epitope availability 
caused by different positions of the mucin-like domains on the GP surface of Ebolavirus and 
Marburgvirus (Flyak et al., 2015; Fusco et al., 2015; Hashiguchi et al., 2015). 
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Figure 17. Cross-reactive B cell responses in filovirus immune donors. Supernatants from EBV-
transformed PBMC samples isolated from survivors were screened in ELISA binding assays using 
BDBV, EBOV or MARV GPs (A-C). Results for four BDBV survivors (A), one EBOV survivor (B) or one 
MARV survivor (C) are shown. Height of the bars indicates OD405 nm values in ELISA binding to full-
length extracellular domain of GP of the indicated virus species. Reactive supernates are color-coded 
based on the cross-reactivity pattern: species-specific cell lines are highlighted in black; cross-reactive 
lines to 2 or 3 species are shown in yellow or blue, respectively. 
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Binding and Neutralizing Activity of Human MAbs 
 
I fused transformed cells from B cell lines producing BDBV GP-reactive Abs with 
myeloma cells and generated 90 cloned hybridomas secreting BDBV GP-reactive human 
mAbs. To determine the breadth of mAb binding, I screened the mAbs in ELISA binding 
assays using recombinant GPs from multiple filoviruses: BDBV, EBOV, SUDV, or MARV 
GPs. While 33 Abs recognized only the autologous BDBV GP (designated Groups 1A, 1B), 
20 Abs recognized both BDBV and EBOV GPs (Groups 2A, B), and 37 Abs recognized GPs 
from BDBV, EBOV and SUDV (Groups 3A, B) (Figure 18A, 19A). The relative proportions 
of antibodies that recognize glycoproteins from 1, 2, or 3 Ebolavirus species did not 
correlate fully with the B cell line frequencies in the initial screen, which can be explained by 
our prioritization on recovery of a high number of cross-reactive mAbs. I was not able to 
isolate Abs that bind to the heterologous MARV GP (Figure 18A). 
I further characterized the binding of species-specific or cross-reactive mAbs to 
recombinant GPs by performing a binding assay with the recombinant form of GP that is 
secreted from the cell to the extracellular space during natural infection (sGP, secreted GP) 
(Sanchez et al., 1996; Volchkov et al., 1995). While the Ebolavirus GP is a trimer, sGP 
forms dimers in which each protomer shares only the amino-terminal 295 amino acids with 
GP. The majority of mAbs recognized epitopes shared between BDBV GP and BDBV sGP  
	
  Table 3. Percentages of lines secreting antibodies species-specific, or cross-reactive antibodies  	
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Figure 18. Cross-neutralizing antibodies from survivors of natural BDBV infection. (A) Heat map 
showing the binding of BDBV mAbs to a panel of filovirus GPs. The EC50 value for each GP-mAb 
combination is shown, with dark red, orange, yellow, or white shading indicating high, intermediate, low, or 
no detectable binding, respectively. EC50 values greater than 10,000 ng/mL are indicated by the > symbol. 
NAb names are highlighted in red.  (B) Heat map showing the neutralization potency of BDBV GP-specific 
mAbs against BDBV. IC50 values greater than 10,000 ng/mL are indicated by the > symbol. 	
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Figure 19. Binding and neutralizing activities of BDBV mAbs. (C) Binding 
of representative mAbs from six distinct binding groups to the filovirus GP. (D) 
Neutralization activity of representative neutralizing mAbs from three binding 
groups against BDBV, EBOV or SUDV. Error bars represent the SE of the 
experiment, performed in triplicate. 
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BDBV sGP in ELISA (designated Groups 1B, 2B, or 3B) (Figure 18A, 19A). Antibodies from 
Groups 1B, 2B, or 3B also bound the recombinant GP form that lacks highly glycosylated 
mucin-like domains (BDBV GPΔmuc), suggesting that mAbs from these three groups target 
epitopes outside of mucin-like domains (Figure 20). 
To evaluate the inhibitory activity of isolated mAbs, in collaboration with Dr. Bukreyev’s 
group, we tested mAbs in a BDBV neutralization assay. Thirty-one of the 90 BDBV GP-
reactive mAbs had half-maximal inhibitory concentration (IC50) values < 10 µg/mL, and we 
defined these as neutralizing antibodies (nAbs) (Figure 18B where nAb names are 
highlighted in red). Several nAbs displayed an extremely high neutralizing potency, with 
IC50 values below 1 ng/mL (Figure 18B). Eighteen of 31 nAbs bound only to BDBV GP in 
ELISA, 6 nAbs recognized BDBV and EBOV GPs, and the remaining 7 nAbs bound to GPs 
from representatives of three Ebolavirus species: BDBV, EBOV, and SUDV. These results 
suggest that cross-reactive mAbs in our panel possess neutralizing activity to multiple 
ebolaviruses.  To test this hypothesis, we screened BDBV425 (a Group 2A nAb) in an 
EBOV neutralization assay as the nAb with the lowest EC50 value to the heterologous EBOV 
GP, and we determined that BDBV425 neutralized the heterologous EBOV. Encouraged by 
this result, we tested nAbs from Groups 3A and 3B in EBOV or SUDV neutralization assays 
to determine whether cross-reactive nAbs can neutralize three Ebolavirus species. We 
found two cross-reactive nAbs from Group 3A (BDBV43 and BDBV324) that neutralized all 
three Ebolaviruses: BDBV, EBOV and SUDV (Figure 19B, BDBV43). The remaining 5 nAbs 
from Group 3A and 3B neutralized BDBV and EBOV but failed to neutralize SUDV (Figure 
19B, BDBV289).  
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Figure 20. Antibodies from groups 1B, 2B and 3B recognize BDBV GP and BDBV GPΔmuc 
but not BDBV sGP in ELISA binding assay. The binding of selected antibodies to BDBV GP, 
BDBV GPΔmuc and BDBV sGP proteins was tested at a single mAb concentration 10 µg/mL.	
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Major Antigenic Sites Recognized by Human MAbs 
To determine whether Abs from distinct binding groups targeted different antigenic 
regions on the BDBV GP surface, I performed a quantitative competition-binding assay 
using a real-time biosensor. I tested 4 BDBV nAbs from binding Group 1A, 5 nAbs from 
binding Group 1B, 4 nAb from Group 3A and 3 nAbs from Group 3B in a tandem blocking 
assay in which BDBV GP was attached to the biosensor. I also tested 5 non-neutralizing 
antibodies from Group 1A to determine whether non-neutralizing antibodies target a unique 
epitope on GP surface. 
Non-neutralizing and neutralizing mAbs from Group 1A and nAbs from Group 3A 
blocked binding of each other to the GP antigen and segregated into a single competition-
binding group (Figure 21). These results suggest that mAbs from Group 1A and Group 3A 
target a single antigenic region that contains epitopes shared between GP and sGP (Figure 
18A). NAbs from Group 3B that did not recognize sGP in ELISA (Figure 18A) segregated 
into a separate competition-binding group. Group 1B antibodies were interesting in that two 
nAbs in this group competed for binding with Group 3B nAbs, while three nAbs from the 
group competed for binding with antibodies from Group 3A (Figure 21). 
These findings suggest based on competition-binding studies that there are at least 
two major antigenic regions recognized by human BDBV nAbs. The first major antigenic 
region contains epitopes which both sGP and GP share (recognized by mAbs from Groups 
1A, 3A) as well as epitopes that are present only on the GP surface (recognized by three 
mAbs from Group 1B). The second major antigenic region contains only epitopes that are 
present on the GP surface but not sGP (recognized by two mAbs from Group 1B and three 
mAbs from Group 3B).  
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Figure 21. BDBV-neutralizing antibodies target at least two distinct antigenic regions of the GP 
surface. Data from competition-binding assays using non-neutralizing mAbs from binding Group 1A 
(white background) and neutralizing mAbs from binding Groups 1A, 1B, 3A or 3B (pink background). 
Numbers indicate the percent binding of second mAb in the presence of the first mAb, compared to 
binding of un-competed second mAb. MAbs were judged to compete for the same site if maximum 
binding of second mAb was reduced to <30% of its un-competed binding (black boxes with white 
numbers). MAbs were considered non-competing if maximum binding of second mAb was >70% of its 
un-competed binding (white boxes with red numbers). Grey boxes with black numbers indicate an 
intermediate phenotype (competition resulted in between 30 and 70% of un-competed binding). Blue, 
purple, and green dashed lines indicate what appear to be major competition groups; the blue and 
purple groups overlap substantially but not completely. 
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Diverse Patterns of Molecular Recognition Defined by Negative Stain Electron 
Microscopy 
 
To determine the location of the two major antigenic regions targeted by human BDBV 
nAbs, we performed negative-stain single-particle electron microscopy (EM) studies using 
antibodies from Groups 1A and 1B, in collaboration with Andrew Ward’s group. The EM 
class averages and reconstructions showed clearly that the two major antigenic regions, 
defined in competition-binding experiments, corresponded to two distinct sites on GP 
surface: the glycan cap and the GP base.  
Comparison of the structures of glycan cap-directed mAbs from Group 1A with those in 
Group 1B revealed that the antibodies have partially overlapping epitopes, but approach the 
glycan cap at distinct angles (Figure 22A, B). We fitted a previously determined atomic 
resolution structure of Sudan virus (SUDV) GPΔmuc (Bale et al., 2012), which reveals more 
residues of the glycan cap region than the equivalent EBOV structure, into the envelope of 
GP from the EM reconstructions and determined the regions targeted by each mAb (Figure 
22D, E). BDBV335, which binds GP and sGP equally well, mainly targets a region between 
residues 274-282. This region appears well defined in the BDBV335 EM map, indicated by 
the large lobe on the outside of the glycan cap that closely resembles that region in the GP 
crystal structure. When viewed along the three-fold axis of GP, BDBV41 binds to the right of 
BDBV335, further up on the glycan cap, close to a loop that extends from residue 266 to 
277. BDBV41 also may make contacts with a loop that extends toward the mucin-like 
domains, from residue 309 to 312 or further in regions that were unresolved in the GP 
crystal structure. BDBV432 binds to the left of BDBV335, at the top of a helix-loop at 
residues 259-266, and likely makes extensive contacts with a loop from residues around 
302-312. Despite a lack of binding to sGP, BDBV432, as well as BDBV353, bind in the 
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glycan cap region, suggesting that these mAbs make contacts with residues that are 
exclusive to GP. 
The other antibodies in Group 1B bind an epitope at the base of GP. These 
antibodies, including BDBV255 and BDBV259, bind further down on GP than has been 
observed previously with murine mAbs, possibly contacting residues within GP2 that are 
part of the membrane proximal external region (MPER) (Figure 22C, D, and E). These 
antibodies were refractory to a reconstruction by EM due to predominant side views of the 
particles and also apparent flexibility. The class averages, however, clearly show that these 
antibodies bind an epitope that extends below the base of GP. Three Fabs can be seen in 
some of the class averages, indicating that despite the apparent small size of this region, 
three antibodies can be accommodated on one GP trimer. Although the Fabs adopt various 
positions in each class average, there is not a continuous range of flexibility since the Fabs 
themselves are well resolved. These antibodies may require the full MPER and 
transmembrane (TM) regions, as well as a membrane, in order to bind stably. These 
features are all lacking in the current recombinant protein used here, a soluble form of the 
extracellular domain of GP. While the GP2 region is well conserved across the filoviruses, 
these BDBV-specific mAbs likely bind non-conserved regions in GP2 proximal to the TM 
region. 
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Figure	22.	BDBV-neutralizing	antibodies	bind	to	the	glycan	cap	or	base	region	of	GP.	(A)	Shown	are	negative-stain	electron	microscopy	reference-free	2D	class	averages	of	Group	1A	antibodies	that	bind	both	the	glycan	cap	of	GP	and	sGP,	and	Group	1B	antibodies	that	bind	the	glycan	cap	of	GP	but	not	sGP.	BDBV	GP	or	GPΔmuc	was	used	to	generate	complexes.	(B)	3D	reconstructions	of	glycan	cap	binders	from	Groups	1A	and	1B	reveal	that	these	antibodies	bind	the	glycan	cap	at	overlapping	but	distinct	epitopes.	Top	(left)	and	side	(right)	views	of	the	complexes	are	shown.	(C)	Reference	free	2D	class	averages	of	Group	1B	antibodies	(left)	reveals	that	these	antibodies	bind	an	epitope	below	the	base	of	GP	that	is	flexible.	In	the	middle	image,	GP	is	colored	yellow	and	each	Fab	colored	green.	The	right-hand	panel	illustrates	a	superimposition	of	crystal	structures	of	SUDV	GPΔmuc	(PDB	3VE0)	and	Fabs	(PDB	3CSY)	to	demonstrate	how	Fabs	may	bind	to	GP.	(D)	The	composite	model	delineates	the	epitopes	of	the	glycan	cap	mAbs	in	Group	1A	or	1B.	Side	(above)	and	top	(below)	views	are	shown.	(E)	Docking	a	crystal	structure	of	SUDV	GPΔmuc	(PDB	3VE0)	(Bale	et	al.,	2012),	which	contains	a	more	complete	model	of	the	glycan	cap	region	targeted	by	Group	1A/B	mAbs,	reveals	how	Group	1A/B	mAbs	target	a	broad	region	in	the	GP1	centered	on	the	glycan	cap,	near	the	beginning	of	the	mucin-like	domains.	Group	1B	mAbs	that	target	the	base	likely	bind	to	a	loop	near	the	membrane	proximal	external	region)	that	is	flexible	and	has	not	yet	been	resolved	at	high	resolution.	TM	=	transmembrane	region;	CT	=	cytoplasmic	tail.	
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Epitope Mapping of Group 3A MAbs Using Saturation Mutagenesis and Negative Stain 
Electron Microscopy 
 
As the Group 3A (cross-reactive) nAbs competed for binding with Group 1A (BDBV-
specific) nAbs (Figure 18), I hypothesized that some structural features of the glycan cap 
are conserved between GPs from multiple Ebolavirus species. In collaboration with Ben 
Doranz’s group at Integral Molecular, we sought to identify amino acids that define epitopes 
for three Group 3 nAbs (BDBV270, BDBV289, and BDBV324) using a comprehensive 
EBOV GP alanine-scanning mutation library. Epitope mapping identified critical residues for 
binding by each nAb, W275 for BDBV270, W275 and Y241 for BDBV289, W275 and L273 
for BDBV324. Residues for which mutation reduced binding of three nAbs from Group 3A 
were visualized on the surface of the high-resolution structure of EBOV GP (PDB ID 3CSY). 
This finding suggests that each of these antibodies recognize overlapping epitopes in the 
GP glycan cap (Figure 23A, B). The previously described murine nAbs 2G4 and 4G7 and 
the human nAb KZ52 bind the base region of the GP (Lee et al., 2008a; Murin et al., 2014), 
and mutations of the W275 or L273 residues did not reduce the binding of these nAbs 
(Figure 23C). Dr. Bukreyev’s lab tied to passage VSV/BDBV-GP in the presence of 
BDBV223 or BDBV289 in an attempt to generate escape mutant viruses, but could not 
isolate neutralization-resistant viruses. An isolate passaged in the presence of BDBV223 
with a R574H polymorphism in heptad repeat 1 (HR1) region was identified, and for 
BDBV289 an isolate with an I584M polymorphism in the HR1 region alone or in combination 
with an E149K substitution in the receptor-binding domain. However, none of these 
mutations was associated with the ability of those viruses to resist neutralization by the 
corresponding mAb. 
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In collaboration with Andrew Ward’s group, we further characterized the antibody 
BDBV289 by single particle EM studies of antibody in complex with GP. BDBV289 binds the 
glycan cap region of GP, centered on the residues W275 and Y241 (Figure 23D). The angle 
of approach resembles that of the mAb 1H3 from the antibody cocktail ZMab, although 1H3 
is specific to EBOV and is weakly neutralizing (Murin et al., 2014; Qiu et al., 2011). Further, 
BDBV289 also binds sGP, which shares the first 295 amino acids of GP1 with GP, including 
the glycan cap region (Sanchez et al., 1996; Volchkov et al., 1995). Therefore, despite 
		
Figure 23. Epitope mapping of Group 3A mAbs using saturation mutagenesis and negative stain 
electron microscopy. Epitope residues for three nAbs from Group 3A (BDBV270, BDBV289 and 
BDBV324) were identified as those for which mutation to alanine specifically reduced binding of these 
antibodies (A-B). GP residue W275 was common to all three nAbs, while L273 was specific for BDBV324, 
and Y241 was specific for BDBV289. The mutated residues are shown in space filling forms on a ribbon 
diagram of the EBOV GP structure, based on PDB 3CSY. (C) Binding values for nAbs and previously 
isolated mAbs KZ52, 2G4 and 4G7 to library clones with mutations at residues L273, W275 and Y241. The 
Ab reactivities against each mutant EBOV GP clone were calculated relative to reactivity with wild-type 
EBOV GP. (D) BDBV289 (brown) binds at the top of the viral GP near the glycan cap region. Complexes 
are of BDBV antibody Fab fragments bound to BDBV GPΔTM with side view (top panel) or top view 
(bottom panel). A representative Fab crystal structure is fit in the Fab density for each reconstruction (from 
PDBID 3CSY). A monomer of the GP trimer crystal structure (PDBID 3CSY) is also fit in the GP density, 
with white corresponding to GP1 and black to GP2. Two critical residues for binding by BDBV289 (W275 
and Y241, determined using saturation mutagenesis) are highlighted in green. 
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previous hypotheses that propose that sGP is an immune decoy and that cleavage of the 
glycan cap prevents neutralizing antibodies from binding this region (Mohan et al., 2012; 
Murin et al., 2014), we have now identified several antibodies that challenge these ideas. 
Interestingly, BDBV289 targets an overlapping epitope with antibodies that we identified to 
be specific to BDBV and that do not bind sGP (Figure 19). Therefore, the glycan cap region 
is a major antigenic site that contains epitopes with subtle features that influence sGP and 
GP binding, neutralization, and species cross-reactivity of targeting mAbs.  
 
Therapeutic Efficacy of Human MAbs in Small Animal Models of EBOV Infection 
 
Finally, in collaboration with Alexander Bukreyev’s group, we set out to test the in vivo 
efficacy of the cross-reactive nAbs using a guinea pig model of EBOV infection. We selected 
two nAbs from Groups 3A (BDBV289) and 3B (BDBV223) that bound non-overlapping 
antigenic regions in the competition-binding experiments (Figure 21). Five to six week-old 
guinea pigs, strain Hartley, were injected with 5 mg of antibody by the IP route once (day 1) 
or twice (days 1 and 3) after inoculation with 1,000 PFU of guinea pig-adapted EBOV, strain 
Mayinga. BDBV223 provided marginal protection, as only 1 of 5 animals survived the lethal 
challenge (Figure 24). Surprisingly, a glycan cap-specific nAb, BDBV289, fully protected 
guinea pigs when delivered twice after the virus challenge. The protective efficiency of 
BDBV289 with a single treatment against a heterologous EBOV (Figure 24, 3 of 5 survived) 
was higher than the protective efficiency of the equivalent glycan-cap-specific mAb c13C6, a 
component of the ZMapp cocktail (1 of 6 survived) (Qiu et al., 2014). To determine whether 
a combination of two mAbs that target two neutralizing epitopes on EBOV GP surface confer 
better protection than treatment with a single mAb alone, we tested the combination of 
BDBV223 and BDBV289 in guinea pigs. The combination of two antibodies provided 
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complete protection against a heterologous EBOV with only a single treatment (Figure 24). 
We isolated viral RNA from blood of representative animals that were treated with mAbs 
BDBV223 or BDBV289 but died and then sequenced the genes encoding the GP. Several 
polymorphisms were detected, but none appeared to be directly related to the epitope 
specificity of the mAb used for treatment. 
 
Discussion 
 
This study reveals that natural BDBV infection in humans induces the development of 
ebolavirus cross-reactive antibodies that target epitopes on the GP surface that are 
conserved in diverse species of genus Ebolavirus. During these studies we isolated 90 
human mAbs from humans following BDBV infection and found 57 cross-reactive mAbs that 
recognized heterologous EBOV GPs. Remarkably, some of the isolated cross-reactive 
mAbs not only bound but also neutralized multiple Ebolavirus species. The majority of cross-
reactive mAbs neutralized BDBV and EBOV, but we also isolated two antibodies that 
displayed potent neutralizing activity against representatives of three Ebolavirus species – 
BDBV, EBOV, and SUDV. We tested two cross-neutralizing mAbs in mice and guinea pigs 
and showed that they protected animals from lethal challenge with a heterologous species 
of EBOV. These data suggest that cross-neutralizing mAbs can be used to develop a 
universal treatment against multiple ebolaviruses and imply that highly immunogenic 
vaccines with proper presentation of GP from one species could induce some measure of 
cross-protection against viruses of the other species. The ability of these mAbs to bind and 
neutralize a broad range of Ebolavirus species also suggest that such antibodies might offer 
protection against emerging filoviruses in the future. 
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Figure 24. Survival and clinical signs of EBOV inoculated guinea pigs treated with BDBV mAbs. Groups 
of 5 guinea pigs per group were injected with individual mAbs by the intraperitoneal route 1 day or 1 and 3 days 
after EBOV challenge, using 5 mg of individual mAb (A) or 5 mg of the combination of two mAbs per treatment 
(B), as indicated. Animals treated with dengue virus-specific human mAb 2D22 served as controls. The survival 
curves are based on morning and evening observations. Mortality in the morning is shown in whole day 
numbers, in the evening in 1/2 day values. The body weight and illness scores are shown with one value per 
day 
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Several antibody-based treatments provided complete species-specific protection from 
EBOV in non-human primate model of infection (Qiu et al., 2014). However, antibody-based 
therapeutics against other members of the Ebolavirus genus, such and BDBV and SUDV, 
are not available. While one strategy would be to develop separate antibody treatments for 
each filovirus infection, an alternative strategy would be to have a universal treatment 
effective against diverse Ebolavirus species. The development of universal antibody 
treatments for ebolaviruses seems inevitable, given recent progress in the identification of 
broad and potent neutralizing antibodies against viruses that exhibit more antigenic diversity 
than the filoviruses such as HIV (Burton et al., 2012), influenza viruses (Pappas et al., 
2014), dengue virus (Rouvinski et al., 2015), alphaviruses (Fox et al., 2015), and 
paramyxoviruses (Corti et al. 2013). Our results provide a roadmap to develop a single 
antibody-based treatment effective against multiple Ebolavirus infections. I propose that the 
principal components of such treatment should include cross-neutralizing mAbs that target 
conserved elements of the non-overlapping major neutralizing antigenic sites on the GP 
surface. 
 
Materials and Methods 
 
Donors 
De-identified peripheral blood mononuclear cells (PBMCs) from 7 survivors of the 2007 
BDBV outbreak in Uganda (Towner et al., 2008) were obtained from a repository at 
Makerere University (Kampala, Uganda) managed in collaboration with the U.S. Military HIV 
Research Program MHRP, which is part of the Walter Reed Army Institute of Research. 
PBMCs were obtained after informed consent from a U.S. survivor of Ebola virus Zaire 
(EBOV) infection who was infected while delivering health care in Liberia during the 2014 
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Ebola virus outbreak with Makona virus. Cells from the EBOV survivor were obtained about 
11 weeks after infection and about 7 weeks after discharge from hospital, following several 
negative PCR tests for presence of virus. PBMCs were obtained from a U.S. survivor of 
Marburg virus (MARV) infection who developed the disease in early 2008 following 
exposure to fruit bats in the Python Cave in Queen Elizabeth National Park, Uganda. This 
donor’s clinical course was documented previously (Centers for Disease and Prevention, 
2009), and we have previously reported isolation of human antibodies from this donor (Flyak 
et al., 2015). Peripheral blood from the donor was obtained in 2012, four years after the 
illness, following informed consent. The studies were approved by the Vanderbilt University 
Institutional Review Board. 
 
Viruses 
BDBV strain 200706291 Uganda was isolated originally from the serum of a patient 
during the first recorded outbreak caused by this virus (Towner et al., 2008) and passaged 
three times in Vero E6 cells. The virus was provided originally by the Special Pathogens 
Branch of the U.S. Centers for Disease Control and Prevention (CDC) and deposited at the 
World Reference Center of Emerging Viruses and Arboviruses (WRCEVA), housed at the 
University of Texas Medical Branch (UTMB), Galveston, TX. The mouse-adapted EBOV 
strain Mayinga was originally generated by Dr. Mike Bray (U.S. Army Medical Research 
Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland) (Bray et al., 1998). The 
virus was provided originally by the Special Pathogens Branch of CDC, deposited at 
WRCEVA, and amplified by one passage in Vero-E6 cells. The guinea pig-adapted EBOV 
strain Mayinga was generated originally by Dr. Brett Cononolly (U.S. Army Medical 
Research Institute of Infectious Diseases) (Connolly et al., 1999) and was provided by Dr. 
Alexander Freiberg (UTMB) through Dr. Heinz Feldmann (Special Pathogens Program, 
National Microbiology Laboratory, Canadian Science Centre for Human and Animal Health, 
	 73 
Winnipeg, Canada) and amplified by one passage in Vero-E6 cells. The recombinant EBOV 
strain Mayinga expressing eGFP was generated by a reverse genetics technique (Lubaki et 
al., 2013) as previously described (Towner et al., 2005) from plasmids provided by Drs. 
Jonathan Towner and Stuart Nichol (CDC) and Drs. Yoshihiro Kawaoka (University of 
Wisconsin) and Heinz Feldmann (NIH), and passaged three times in Vero E6 cells. The 
EBOV Makona strain from the 2014-2015 West African outbreak, which was provided by Dr. 
T. Geisbert (UTMB), was isolated originally from serum of a fatally infected patient in early 
2014 in Guekedou, Guinea, and was passaged two times in Vero E6 cells. The chimeric 
EBOV/BDBV-GP, EBOV/MARV-GP and EBOV/SUDV-GP constructs expressing eGFP 
were obtained by replacing the gene encoding EBOV GP with that of BDBV, MARV or 
SUDV, respectively (Ilinykh P., unpublished data) , and passaged two times in Vero E6 
cells.      
 
Generation of human hybridomas secreting monoclonal antibodies (mAbs) 
Human hybridomas were generated as described previously (Flyak et al., 2015). In 
brief, previously cryopreserved samples were transformed with Epstein-Barr virus, CpG and 
additional supplements. After 7 days, cells from each well of the 384-well culture plates were 
expanded into four 96-well culture plates using cell culture medium containing irradiated 
heterologous human PBMCs (recovered from blood unit leukofiltration filters, Nashville Red 
Cross) and incubated for an additional four days. Plates were screened for BDBV GP 
antigen-specific antibody-secreting cell lines using enzyme-linked immunosorbent assays 
(ELISAs). Cells from wells with supernates reacting with antigen in an ELISA were fused 
with HMMA2.5 myeloma cells using an established electrofusion technique (Yu et al., 2008).  
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Human mAb and Fab production and purification 
After fusion, hybridoma cell lines were cloned by single-cell fluorescence-activated cell 
sorting and expanded in post-fusion medium as previously described (Flyak et al., 2015). 
HiTrap Protein G or HiTrap MabSelectSure columns were used to purify antibodies from 
filtered supernates. Fab fragments were generated by papain digestion, as described 
previously (Flyak et al., 2015). 
 
Expression and purification of filovirus GPs 
BDBV GP ectodomain (BDBV GP, residues 1-637) or the secreted glycoprotein dimer 
(BDBV sGP, residues 1-316) were used to screen supernatants of transformed B cells. 
Recombinant glycoproteins were engineered with a C-terminal double strep tag and cloned 
into a modified pMTpuro vector for expression in Drosophila S2 cells.  Briefly, plasmids were 
transfected into S2 cells using Effectene reagent (Qiagen) followed by stable cell selection 
with 6 µg/mL puromycin. S2 cells first were cultured in Schneider’s medium supplemented 
with 10% (v/v) FCS (Lonza), and later adapted to Insect Xpress medium for large-scale 
expression in 2L shaker flasks. Stable cells were induced with 0.5 mM CuSO4 and 
harvested after 4 to 5 days at 27°C. Tangential flow filtration then was used to buffer 
exchange the supernatants into 100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 15 µg/mL 
avidin pH 8.0, and target proteins were purified using Streptactin Superflow affinity (Qiagen). 
GP ectodomains were purified further with S200 size exclusion chromatography (SEC); sGP 
was purified with S75 SEC. Recombinant ectodomains for EBOV, SUDV or MARV were 
designed and expressed similarly.   
 
Screening and half maximal effective concentration (EC50) ELISA binding analysis. 
Soluble forms of the full-length extracellular domain of BDBV, EBOV, SUDV or MARV GPs 
or the sGP form of BDBV GP were coated overnight onto 384-well plates at 1 µg/mL. For 
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screening ELISA, 10 µL of supernate from a well of a tissue-culture plate were transferred to 
each well of a 384-well ELISA plate. For EC50 binding analysis by ELISA, purified antibodies 
were applied to the plates at a concentration range of 30 µg/mL to 170 ng/mL, using three-
fold serial dilutions. The presence of antibodies bound to the GP was determined using goat 
anti-human IgG alkaline phosphatase conjugate and p-nitrophenol phosphate substrate 
tablets, with optical density read at 405 nm after 120 minutes. A non-linear regression 
analysis was performed on the resulting curves using Prism version 5 (GraphPad) to 
calculate EC50 values. The Circos software package was used for data visualization 
(Krzywinski et al., 2009). 
 
EBOV and MARV neutralization experiments 
Isolated mAbs were screened initially in a high-throughput neutralization assay using 
EBOV/BDBV-GP with or without 5% guinea pig complement (MP Biomedicals, Santa Ana, 
CA) (Ilinykh P., unpublished data). The mAbs that exhibited neutralizing activity also were 
screened for neutralization of eGFP-expressing EBOV (Towner et al., 2005). BDBV223 was 
tested for neutralization of EBOV/SUDV-GP and EBOV/MARV-GP by the same approach. 
In addition, neutralizing activity of BDBV223 was tested against the EBOV Makona strain by 
a classic plaque reduction assay, which was performed as follows. Triplicate samples of 150 
PFU of the virus were mixed with serial dilutions of mAbs, with or without 5% guinea pig 
complement in a total volume of 100 µL, incubated for 1 hour at 37°C, and placed on Vero 
E6 cell monolayers. After a 1 hour-long virus adsorption at 37°C, cells were overlaid with 
0.8% tragacanth (Spectrum Chemical Mfg. Corp., New Brunswick, NJ) solution in Minimal 
Essential Medium containing 10% FBS (HyClone, Logan, Utah) and 0.1% gentamicin 
(Mediatech, Manassas, VA), and incubated for 14 days. Plaques were visualized by staining 
of monolayers with 0.25% crystal violet (Thermo Fisher Scientific, Waltham, MA) in 10% 
formalin.         
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Biolayer interferometry competition binding assay 
Competition binding studies using biolayer interferometry and biotinylated BDBV GP 
(EZ-link® Micro NHS-PEG4-Biotinylation Kit, Thermo Scientific #21955) (5 µg/mL) were 
performed on an Octet RED biosensor (ForteBio, Menlo Park, CA), as described previously 
(Flyak et al., 2015). In brief, the antigen was immobilized onto streptavidin-coated biosensor 
tips. After a brief washing step, biosensor tips were immersed first into the wells containing 
first antibody at a concentration of 100 µg/mL and then into the wells containing a second 
mAb at a concentration of 100 µg/mL. The percent binding of the second mAb in the 
presence of first mAb was determined by comparing the maximal signal of the second mAb 
applied after the first mAb complex to the maximal signal of the second mAb alone.  
 
Sequence analysis of antibody variable region genes 
Antibody variable gene sequence analysis was performed as previously described 
(Flyak et al., 2015). Heavy chain antibody variable region sequences were analyzed using 
the IMGT/V-Quest program (Brochet et al., 2008; Giudicelli et al., 2011).  
 
Electron microscopy and sample preparation 
Fabs were added in 10 molar excess to BDBV GPdMuc and subsequently purified and 
stained as previously described (Murin et al., 2014). 
 
Image processing of protein complexes 
Particles were automatically picked using DoG Picker (Voss et al., 2009) and particle 
stacks were generated using Appion (Lander et al., 2009). Subsequently, reference-free 2D 
class averages were generated using iterative MRA/MSA (van Heel et al., 1996). Non-GP 
complexes and those with a clear lack of full saturation by Fab were removed to generate a 
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final stack for reconstructions. In some cases, orientation bias or flexibility of Fabs prevented 
convergence of an acceptable model, although examination of class averages allowed a 
general assignment of the epitope. Final stack class averages were used to generate initial 
models using EMAN2 common lines (Tang et al., 2007). A model matching its reference 
projections was further refined using the entire raw particle stack with EMAN2, as described 
previously (Murin et al., 2014). For the BDBV41 reconstruction, the EMAN2 reconstruction 
lacked important features that were present in the class averages, indicating that perhaps 
some particles lacked full Fab saturation. In order to circumvent this problem, we utilized the 
Relion package, which allows 3D-classification to remove particles that may only contain 2 
Fabs, significantly improving the quality of the final EM map (Scheres, 2012). Modeling 
fitting and EM figures were generated using UCSF Chimera (Pettersen et al., 2004). 
 
Epitope mapping using an EBOV GP alanine-scan mutation library 
Comprehensive high-throughput alanine scanning (‘shotgun mutagenesis’) was carried 
out on an expression construct for EBOV GP (Yambuku-Mayinga variant GP; Uniprot 
accession number Q05320). Residues 33-676 of full-length EBOV GP were mutagenized to 
create a library of clones, each representing an individual point mutant. Residues were 
changed to alanine (with alanine residues changed to serine). GP residues 1-32, which 
constitute the GP signal peptide, were not mutagenized. The resulting EBOV GP alanine-
scan library covered 99.5% of target residues (641 of 644). Clones were arrayed into 384-
well plates, one mutant per well. The EBOV GP mutation library was transfected into HEK-
293T cells and allowed to express for 22 hours. Cells were fixed in 4% paraformaldehyde in 
PBS plus calcium and magnesium, or were left unfixed, and were then incubated with an Ab 
diluted in 10% normal goat serum (NGS) (Sigma-Aldrich, St. Louis, MO). The cells were 
incubated with primary antibody for 1 hour at room temperature, followed by a 30 minute 
incubation with Alexa Fluor 488-conjugated secondary antibody (Jackson ImmunoResearch 
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Laboratories, Westgrove, PA) in 10% NGS. Cells were washed twice with PBS without 
calcium or magnesium and resuspended in Cellstripper (Cellgro, Manassas, VA) plus 0.1% 
BSA (Sigma-Aldrich, St. Louis, MO). Cellular fluorescence was detected using the Intellicyt 
high throughput flow cytometer (Intellicyt, Albuquerque, NM). Background fluorescence was 
determined by fluorescence measurement of vector-transfected control cells. Ab reactivities 
against each mutant EBOV GP clone were calculated relative to wild-type EBOV GP 
reactivity by subtracting the signal from mock-transfected controls and normalizing to the 
signal from wild-type GP-transfected controls. 
 
Before screening, the immunoreactivities of MAbs BDBV270, BDBV289, and 
BDBV324 were optimized by determining reactivity with fixed or unfixed cells over a range of 
mAb concentrations to identify optimal signal-to-background ratios (>5:1) and to ensure that 
signals were within the linear range of detection. MAb BDBV289 also screened as a Fab 
after conversion by papain digestion. Control mAbs 2G4 and 4G7 were kindly provided by 
Gary Kobinger, Public Health Agency of Canada. 
 
Mutated residues within critical clones were identified as critical to the Ab epitope if 
they did not support reactivity of the test Ab but did support reactivity of other control EBOV 
mAbs. This counter-screen strategy facilitates the exclusion of GP mutants that are locally 
misfolded or that have an expression defect. The detailed algorithms used to interpret 
shotgun mutagenesis data are described elsewhere (patent application 61/938,894), 
(Davidson and Doranz, 2014). 
 
Generation and Sequence Analysis of VSV/BDBV GP Escape Mutants 
Briefly, 200 PFUs of VSV/BDBV-GP virus were pre-incubated with 2-fold decreasing 
concentrations of mAbs before each passage, starting from 200 µg/mL, and serially 
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passaged 3-10 times under selective pressure of the corresponding mAbs. After each 
passage, virus aliquots were harvested and titrated. A suspension containing 200 PFUs 
from the virus-positive aliquot with the highest mAb concentration was used for the next 
passage. Finally, viruses were plaque-purified, and the genes encoding the BDBV GPs were 
sequenced. Viral samples derived from plaques containing any amino acid substitutions 
were propagated further in the presence of the corresponding mAb, and tested for 
neutralization resistance by plaque reduction assay. 
 
In vivo testing 
The animal protocols for testing of mAbs in mice and guinea pigs were approved by 
the Institutional Animal Care and Use Committee of the University of Texas Medical Branch 
at Galveston. Seven-week-old BALB/c mice (Charles River Laboratories) were placed in the 
ABSL-4 facility of the Galveston National Laboratory. Groups of mice at 5 animals per group 
were injected with 1,000 PFU of the mouse-adapted EBOV by the intraperitoneal route. 
Twenty-four or seventy four hours later, animals were injected with individual mAbs by the 
intraperitoneal route using 100 µg per treatment. Animals treated with the antibody specific 
to dengue virus 2D22 served as controls. Animals were weighed and monitored daily over 
the two-week period after challenge. Once animals were symptomatic, they were examined 
no less than twice per day. The disease was scored using the following parameters: 
dyspnea (possible scores 0-5), recumbency (0-9), unresponsiveness (0-5), and 
bleeding/hemorrhage (0-5). To test the protective efficacy of mAbs in guinea pigs, five to six 
week-old animals (strain Hartley) were placed in the ABSL-4 facility of the Galveston 
National Laboratory. Groups of 5 animals per group were injected with 1,000 PFU of guinea 
pig-adapted EBOV, by the intraperitoneal route. Twenty-four hours later and 72 hours later, 
animals were injected with individual mAbs (5 mg per treatment), or a cocktail of two mAbs 
(2.5 mg of each mAb per treatment). Animals were weighted and monitored daily for 14 
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days. After animals became symptomatic, they were examined no less than twice per day. 
The disease was scored using the following parameters: appearance (possible scores 0-3), 
body condition (0-3), natural behavior (0-3), and provoked behavior (0-3).
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CHAPTER IV 
 
CROSS-REACTIVE HUMAN ANTIBODIES TO THE HR2/MPER REGION OF EBOLA 
GLYCOPROTEIN 
 
“…the warriors against Ebola understand that they face a long struggle against 
a formidable enemy. Many of their weapons will fail, but some will begin to work” 
Richard Preston, Inside the Ebola Wars, The New Yorker 
 
Introduction 
 
The antibody cocktail ZMappTM is effective in nonhuman primate models of infection 
(Qiu et al., 2014) and has been used under compassionate-treatment protocols in humans 
(Lyon et al., 2014). ZMappTM is a mixture of three humanized murine mAbs (Olinger et al., 
2012b; Qiu et al., 2011; Qiu et al., 2012b; Wilson et al., 2000) that target EBOV-specific 
epitopes on the surface GP (Davidson et al., 2015; Murin et al., 2014). As a result, ZMappTM 
mAbs do not neutralize other viruses from the Ebolavirus genus, such as BDBV or SUDV. 
In this chapter, I describe three naturally-occurring human cross-reactive mAbs from 
BDBV survivors that target a new antigenic site in the canonical heptad repeat 2 (HR2) 
region near the membrane proximal region of EBOV GP. I found that cross-reactive 
HR2/MPER-specific antibodies do not compete with previously isolated EBOV-specific 
mAbs that recognize other regions in the GP, such as the glycan cap, base, or mucin-like 
domain, but rather they bind a site near the viral membrane. The identification of a 
conserved protective antigenic site in the GP suggests that these mAbs can be used to 
design antibody therapeutics against multiple filovirus infection. Furthermore, structural 
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features formed by conserved residues in the protective site could be used to develop an 
epitope-based vaccine against infection caused by diverse Ebolavirus species.  
I acknowledge Alexander Bukreyev’s group for performing neutralization, protection 
experiments as well as escape mutants generation, Andrew Ward’s group for studying 
EBOV-specific mAbs by negative-stain single-particle EM, Erica Saphire’s group for 
providing Ebolavirus GPs, Ben Doranz’s team for performing epitope mapping of selected 
mAbs using saturation mutagenesis, and David Wright’s group for peptide synthesis.  
 
Cross-reactive neutralizing antibodies bind a unique region on GP surface  
 
In Chapter III, I described the isolation of a large panel of neutralizing mAbs using 
peripheral B cells from survivors of the 2007 BDBV outbreak in Uganda. Among seven 
cross-reactive mAbs that bound to GPs from multiple ebolaviruses (BDBV, EBOV, and 
SUDV), I found three neutralizing mAbs (designated BDBV223, BDBV317, and BDBV340) 
that bound to the recombinant trimeric form of GP ectodomain but did not bind to the dimeric 
form of GP that is secreted from cells during infection (sGP, secreted GP) (Figure 18A, 
19A). As BDBV223, BDBV317, and BDBV340 recognized all three GPs from BDBV, EBOV, 
and SUDV (Figure 18A, Group 3B), we next sought to determine whether these cross-
reactive mAbs could neutralize viruses from those three Ebolavirus species. All three mAbs 
neutralized autologous BDBV as well as heterologous EBOV.  Although these human mAbs 
recognized SUDV GP in ELISA, BDBV223, BDBV317, and BDBV340 failed to neutralize 
SUDV (Figure 25A). Among three mAbs, BDBV223 displayed an extremely high 
neutralizing potency, with BDBV IC50 values – 0.01 ng/mL and EBOV IC50 values – 1.8 
µg/mL (Figure 25A). 
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To determine the therapeutic activity of these cross-neutralizing Abs, we tested these three 
antibodies in mice. Seven week-old BALB/c mice received 100 µg of antibody by the IP 
route 1 day after inoculation with 1,000 PFU of mouse-adapted EBOV, strain Mayinga (Bray 
et al., 1998). Both BDBV223 and BDBV317 fully protected mice from lethal challenge with 
heterologous species of EBOV (Figure 25B). We did not observe a protective effect in mice 
receiving treatment with BDBV340 or dengue-specific antibody 2D22 (Figure 25B). 
There are several neutralizing mAbs that bind to the base region of the filovirus GP, 
including two chimerized murin-origin antibodies from the ZMappTM cocktail (c2G4 and 
c4G7) (Qiu et al., 2011; Qiu et al., 2012b), the human phage-display library-derived mAb 
KZ52 (Maruyama et al., 1999), and the murine SUDV-specific mAb 16F6 (Dias et al., 
2011a). The epitopes bound by these mAbs were defined crystallographically (KZ52 and 
16F6) (Dias et al., 2011a; Lee et al., 2008a), by negative-stain single-particle EM (c2G4 and 
	
 
Figure 25. Neutralizing and protective activity of Group 3B cross-reactive mAbs. (A) Neutralization activity 
of BDBV223, BDBV317 and BDBV340 against BDBV, EBOV, and SUDV. (B) Survival of EBOV inoculated mice 
treated with Group 3B neutralizing mAbs. Groups of 5 mice per group were injected with individual mAbs by the 
intraperitoneal route 1 day after EBOV challenge, using 0.1 mg of individual mAb. Animals treated with dengue 
virus-specific human mAb DENV 2D22 served as controls. 	
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c4G7) (Murin et al., 2014), or by alanine-scanning mutagenesis (KZ52, KZ52, c2G4, and 
c4G7) (Davidson et al., 2015), and mapped to the GP1/GP2 interface, in the vicinity of the 
heptad repeat 1 (HR1) region. 
To determine whether BDBV223, BDBV317, and BDBV340 compete for binding with 
these Ebolavirus-specific mAbs, I performed quantitative competition-binding assay using an 
Octet biosensor (Figure 26). I also included in this analysis a previously isolated potently 
neutralizing human mAb (BDBV289) that recognizes the glycan cap (Figure 23) as well as 
	
 
Figure 26. Cross-reactive neutralizing antibodies from Group 3B bind a unique region on GP surface. 
Data from competition binding assays using BDBV223, BDBV317 and BDBV340; antibodies from ZMapp 
cocktail (c2G4, c4G7 and 13C6) and previously isolated human antibodies KZ52 and BDBV289. Numbers 
indicate the percent binding of the second mAb in the presence of the first mAb, compared to binding of second 
mAb alone. MAbs were judged to compete for the same site if maximum binding of the second mAb was 
reduced to <30% of its un-competed binding (black boxes with white numbers). MAbs were considered non-
competing if maximum binding of the second mAb was >70% of its un-competed binding (white boxes with red 
numbers). Grey boxes with black numbers indicate an intermediate phenotype (between 30 and 70% of un-
competed binding). 	
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the glycan cap-specific mAb c13C6 from the ZMappTM cocktail (Wilson et al., 2000). As 
expected, the glycan cap-specific mAbs (c13C6 and BDBV289) and the base region-binding 
mAbs (KZ52, c2G4, and c4G7) segregated into two independent competition-binding groups 
(Figure 26). BDBV223, BDBV317, and BDBV340 did not compete with either glycan-cap 
specific mAbs or base region-binding mAbs, suggesting that thesse new mAbs target a 
unique antigenic region on the GP surface (Figure 26). 
 
Electron microscopy studies of cross-reactive mAbs from Group 3B 
 
To determine the location of the cross-reactive antigenic site on the GP base targeted 
by these human mAbs, we performed negative-stain single-particle EM studies in 
collaboration with Andrew Ward’s group. The EM class averages clearly showed that 
BDBV223, BDBV317, and BDBV340 each bind to the bottom of GP, in the canonical heptad 
repeat 2 (HR2) domain near the membrane proximal external region (MPER) (Figure 27A). 
Overlaying a class average of BDBV223 Fab bound to BDBV GP (Figure 27B) over a class 
average of c13C6 Fab:c4G7 Fab bound to EBOV GP (Figure 27C) showed that BDBV223, 
and the two other new mAbs bound more virion proximal on the GP, well below the epitope 
of the mAb c4G7 site of vulnerability at the GP1/GP2 interface (Figure 27D). Measurements 
of the distance from the bottom of the GP globular head to the mid-point of the Fab in the 
class averages showed a distance of ~60 Å, which corresponds to the length of the HR2 
region previously crystalized as post-fusion GP2 (PDBID 1EBO) (Figure 27E). Three 
BDBV317 Fabs can be seen in the class average images, indicating that three mAbs  
can bind simultaneously to the HR2/MPER region, which lies in a close proximity to the viral 
membrane  (Figure 27A). In Chapter III, I described species-specific neutralizing human 
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mAbs that bound the BDBV GP near the MPER region and competed for binding with cross-
reactive mAbs BDBV223, BDBV317, and BDBV340, although their epitopes were not 
determined (Figure 21, 22). Also, a previous study described generation of a murine cross-
reactive non-neutralizing mAb to the HR2/MPER region (15H10) (Yu et al., 2006). 
Therefore, HR2 and MPER regions are complex major antigenic sites containing species-
specific, cross-reactive as well as neutralizing and non-neutralizing epitopes. 
 
Analysis of GP residues required for mAb cross-reactivity and neutralization 
 
To define the epitope of cross-reactive human mAbs more precisely, we collaborated 
with Ben Doranz’s group at Integral Molecular and tested the binding of BDBV223, 
BDBV317, and BDBV340 or the ZMappTM antibody c4G7 to individual GP members of an 
		
Figure 27 Cross-reactive neutralizing antibodies from Group 3B bind near the membrane proximal 
region of GP (A) Representative negative stain class averages of antibodies that bind GP2 exclusively in the 
membrane proximal region. Complexes are of BDBV Fabs bound to BDBV GPdMuc. (B) A class average of 
BDBV GPdMuc bound to BDBV223 demonstrates the location of each component, with the core GP colored 
blue and the Fabs in green. Crystal structures of GPdMuc (PDBID 3CSY) and a representative Fab (PDBID 
3CSY) are overlaid on their corresponding region in the class average. (C) A class average of c13C6 Fab:c4G7 
Fab bound to EBOV GPdTM (Top, with c13C6 in dark blue, c4G7 in yellow and GP core in light blue. (D) 
Overlaying a class average of c13C6 Fab:c4G7 Fab bound to EBOV GPdTM (Top, with c13C6 in dark blue, 
c4G7 in yellow and GP core in light blue) over a class average of BDBV223 Fab bound to BDBV GPdTM (with 
BDBV223 in green and GP core in light blue), demonstrates that BDBV223 binds significantly lower down on 
GP, well below the epitope of the c4G7 site of vulnerability at the GP1/GP2 interface. (E) A model of the c13C6 
Fab:c4G7 Fab bound to EBOV GPdTM is shown with the relative location of BDBV223 Fab. Measurements of 
the distance from the bottom of the GP core to the mid-point of the Fab in the class averages showed a 
distance of ~60A, which corresponds to the length of the HR2 region previously crystalized as post-fusion GP2 
(PDBID 1EBO).			
	 87 
alanine-scan mutant library of EBOV GP.  Several critical residues were identified previously 
for c4G7, including D552 in the internal fusion loop and C556, which is part of the HR1 
(Davidson et al., 2015). Consistent with the EM data, we identified critical residues in GP2 
for BDBV223, BDBV317, and BDBV340 that spanned the C-terminal part of HR2 and N-
terminal part of the MPER (Figure 28A). A single critical residue in HR2 was identified for 
BDBV340 (D624), and one residue in MPER was identified for BDBV317 (K633). Two 
critical residues were identified for BDBV223 (D624 and D632) (Figure 28A). 
The HR2 α-helix ends at residue D632 (Malashkevich et al., 1999; Weissenhorn et al., 
1998), indicating that HR2/MPER peptides might adopt an α-helical conformation that is 
recognized by the Ebolavirus cross-reactive mAbs. To determine whether BDBV223, 
BDBV317, or BDB340 can recognize a linear conserved epitope in HR2/MPER, we 
synthesized peptides spanning the GP amino acids 620-635 in the HR2/MPER of three virus 
species (designated peptides BDBV2, EBOV2, and SUDV2) as well as a control peptide 
from the N-terminus of HR2 (amino acids 599-613), designated the BDBV1 peptide. I 
determined that BDBV223, BDBV317, and BDBV340 recognize BDBV2 peptide containing 
the essential residues determined by alanine-scanning mutagenesis but not the negative 
control BDBV1 peptide from HR2, as expected (Figure 28B). While BDBV223 bound to 
BDBV2, EBOV2, and SUDV2 peptides, BDBV317 and BDBV340 recognized only BDBV2 
and EBOV2 peptides (Figure 28B). Interestingly, I noticed similarities between the extent of 
binding of the three mAbs to the HR2/MPER peptides (Figure 28B) and their neutralization 
potencies in vitro (Figure 25B). BDBV317 bound equally well to BDBV2 and EBOV2 
peptides and neutralized BDBV and EBOV with the same potency. BDBV223 and BDBV340 
bound better to BDBV2 peptide, and the same antibodies neutralized BDBV with higher 
potency than EBOV (Figure 25B). 
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To determine the basis of mAb cross-reactivity to multiple Ebolavirus GPs and 
peptides, we synthesized a panel of chimeric BDBV peptides containing polymorphic 
residues from EBOV or SUDV. There are two amino acid differences between BDBV2 and 
EBOV2 peptides (at residues 631 and 634), located in the C-terminus of the peptide (Figure 
	
 
Figure 28. Structural and functional analysis of GP residues important for mAb cross-reactivity and 
neutralization. (A) Sequence alignment of GP2 from the BDBV, EBOV and SUDV. The numbers above 
the sequence correspond to the amino acid position in GP. Amino acids identical to BDBV are indicated by 
dots. Color-coded shapes indicate the position of residues at which alanine substitutions disrupts mAbs 
binding, as determined by alanine-scanning mutagenesis. BDBV1, BDBV2, EBOV2 and SUDV2 peptide 
sequences are indicated by grey, black, blue and purple lines, respectively. (B) Binding of BDBV223, 
BDBV317 and BDBV340 to BDBV1, BDBV2, EBOV2 and SUDV2 peptides. (C) Binding or BDBV223, 
BDBV317 and BDBV340 to the panel of chimeric BDBV peptides 	
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28C). To identify polymorphisms responsible for the enhanced binding of BDBV223 to 
BDBV2 peptide, we synthesized two chimeric BDBV peptides with single substitutions at 
residues 631 or 634 (designated peptides BDBV2A and BDBV2B). While BDBV223 bound 
equally well to BDBV2 and BDBV2A peptide, it bound relatively weakly to the BDBV2B 
peptide, suggesting that the P634T substitution in BDBV2B peptide is responsible for 
reduced binding of BDBV223 to the EBOV2 peptide (Figure 28C). We also synthesized 
chimeric BDBV2C and BDBV2D peptides to introduce two SUDV substitutions at residues 
624 and 633. While both BDBV223 and BDBV317 bound equally well to BDBV2D and 
BDBV2 peptides, they failed to recognize the BDBV2C peptide, suggesting that the N624 
residue is required for neutralization of SUDV by MPER/HR-specific mAbs. To investigate 
the role residue D624 in the context of a live filovirus, we constructed a recombinant BDBV 
bearing D624N mutation, which was found to be completely resistant to BDBV223 but 
sensitive to BDBV317 (Figure 29A). 
We passaged the chimeric filovirus with BDBV GP (Ilinykh et al., 2016) in the presence 
of HR2/MPER-specific mAbs and generated antibody escape mutant viruses for mAbs 
BDBV223 and BDBV317. For BDBV223, an isolate with a P634H mutation in the MPER was 
identified, and for BDBV317 an isolate with a K633R mutation in the MPER was identified 
(Figure 29B). We found that while the BDBV223 escape mutant was resistant to 
neutralization by both BDBV223 and BDBV317, BDBV223 was able to neutralize the 
BDBV317 escape mutant (Figure 29B). This finding is consistent with the results from the 
alanine-scanning and peptide ELISA binding experiments, in which the K633 residue was 
identified as a critical residue only for BDBV317 (Figure 28A), Also, BDBV317, but not 
BDBV223, failed to bind in ELISA to the BDBV3D peptide with a K633N substitution (Figure 
28C). 
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Discussion 
 
In this chapter, I describe three human cross-reactive antibodies from Group 3B that 
target a new antigenic region near the MPER of EBOV GP. These antibodies do not 
compete with therapeutic antibodies used in the past to treat EBOV infection, suggesting 
that these MPER-specific mAbs could be used to design a new universal antibody 
therapeutic cocktail against multiple species of viruses causing Ebolavirus infection. 
Alternatively, the mAbs might be beneficial to include in existing experimental therapeutic 
antibody cocktails to increase the potency and breadth of those combinations. Although 
these mAbs are the first reported neutralizing antibodies directed to the MPER of filoviruses, 
the MPER in the GP of enveloped viruses increasingly is recognized as an important region 
for recognition by broad and potent human mAbs. Several mAbs that neutralize a broad 
	
Figure 29. Neutralization activity of Group 3B mAbs against recombinant BDBV isolate and escape 
mutants. (A) Neutralization activity of BDBV223 or BDBV317 against wild-type BDBV (diamonds, black curves) 
or a recombinant BDBV D624N isolate (diamonds, red curves). (B) Neutralization activity of BDBV223 or 
BDBV317 against wild-type BDBV (diamonds, straight curves), BDBV223 escape mutant (triangles, dashed 
curves), or BDBV317 escape mutant (circles, dotted curves). 
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range of HIV strains bind conserved epitopes in the HIV gp41 MPER (Muster et al., 1993; 
Zwick et al., 2001). The identification of potent HIV MPER-specific mAbs has facilitated 
important progress in the effort to design HIV vaccines rationally using antigens designed to 
induce such mAbs (Montero et al., 2008). Neutralizing mAbs that recognize the influenza 
hemagglutinin surface protein stem region (Corti et al., 2011; Ekiert et al., 2009; Sui et al., 
2009) also have simulated research into the possibility of a universal influenza vaccine.  
Here, I report structural and functional information about conserved epitopes in the MPER of 
EBOV GP that can be used to inform the development of an MPER-based EBOV vaccine 
effective against multiple filoviruses.  
 
Materials and Methods 
 
Human mAb and Fab expression and purification 
Human hybridoma cell lines were expanded in post-fusion medium, as previously 
described (Flyak et al., 2015). HiTrap Protein G or HiTrap MabSelectSure columns were 
used to purify antibodies from filtered supernates. Fab fragments were generated by papain 
digestion, as described previously (Flyak et al., 2015). 
 
 
Expression and purification of filovirus GPs 
Recombinant GP ectodomains containing the mucin-like domain (GPΔTM) or lacking 
residues 312–463 of the mucin-like domain (GPΔmuc) (Lee et al., 2009; Lee et al., 2008b) 
were produced by transfection of Drosophila Schneider 2 (S2) cells with modified pMTpuro 
vectors, followed by stable selection of transfected cells with 6 µg/mL puromycin. Secreted 
GP ectodomain expression was induced with 0.5 mM CuSO4 for 4 d. Proteins were 
engineered with a modified double strep tag at the C terminus (enterokinase cleavage site 
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followed by a strep tag/linker/strep tag) to facilitate purification using Strep-Tactin resin 
(Qiagen). Proteins were purified further by Superdex 200 (S200) SEC in 10 mM Tris and 
150 mM NaCl, pH 7.5 (1× TBS).  
 
Screening and half maximal effective concentration (EC50) ELISA binding analysis 
Soluble forms of the full-length extracellular domain of BDBV, EBOV, SUDV or MARV 
GPs or the sGP forms were coated overnight onto 384-well plates at 1 µg/mL. For screening 
ELISA, 10 µL of supernate from a well of a tissue-culture plate were transferred to each well 
of a 384-well ELISA plate. For EC50 binding analysis by ELISA, purified antibodies were 
applied to the plates at a concentration range of 30 µg/mL to 170 ng/mL, using three-fold 
serial dilutions. The presence of antibodies bound to the GP was determined using goat 
anti-human IgG alkaline phosphatase conjugate and p-nitrophenol phosphate substrate 
tablets, with optical density read at 405 nm after 120 minutes. A non-linear regression 
analysis was performed on the resulting curves using Prism version 5 (GraphPad) to 
calculate EC50 values.  
 
Antibody neutralization experiments 
All work with filoviruses, including the chimeric filoviruses, was performed in the BSL-4 
facility of the Galveston National Laboratory. Antibody neutralization assays were performed 
against the recombinant EBOV expressing green fluorescent protein from an added gene 
(Towner et al., 2005) and its derivatives in which GP was replaced with its counterpart from 
BDBV (strain 200706291 Uganda) or SUDV (strain 200011676 Gulu) (Ilinykh et al., 2016) to 
which we refer in Results as EBOV, BDBV and SUDV for simplicity. The assays were 
performed in a high-throughput format, as previously described (Ilinykh et al., 2016).  
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Generation of recombinant BDBV with the D624N mutation 
To introduce the D624N mutation in BDBV GP of the chimeric filovirus used in the 
study (Ilinykh et al., 2016) the pEBOwtΔBamHI-SbfI,AscI-PspOMI subclone of the full-length 
clone encoding the viral genome(Ilinykh et al., 2016) was mutagenized using the 
QuikChange site-directed mutagenesis kit (Stratagene). Then the ApaI-SacI fragment of the 
subclone, which includes the mutated GP, was used to replace the corresponding fragment 
of the chimeric filovirus full-length clone. The mutagenized chimeric virus was recovered as 
previously as described (Lubaki et al., 2013).             
 
Generation and testing of antibody escape filovirus mutants 
To generate escape mutants, 100 PFU of recombinant chimeric EBOV with GP 
derived from BDBV were combined with 2-fold dilutions of mAbs starting at 200 µg/mL in U-
bottom 96-well plates and incubated for 1 hr at 37°C. Mixtures were placed on Vero-E6 cell 
monolayer clutures in 96-well plates and incubated for 1 hr. Supernatants were removed, 
fresh mAbs were added at the same concentrations in 200 µL of MEM supplemented with 
2% FBS, and plates were incubated for 7 days at 37°C. Viruses that replicated in the 
presence of the highest concentrations of mAbs, as determined by UV microscopy, were 
collected. 20 µL aliquots were incubated with 2-fold dilutions of mAbs starting at 200 µg/mL, 
and viruses were propagated in the presence of mAbs as above. The procedure was 
repeated once more with mAb dilutions starting at 400 µg/mL. Viruses that replicated at the 
highest mAb concentrations were amplified in Vero-E6 cell culture monolayers in 24-well 
plates in the presence of mAbs at 200 µg/mL for 7 days. Cells were used for isolation of 
RNA using TRIzol reagent, and GP genes were PCR-amplified and sequenced. To 
determine susceptibility of the isolated escape mutants to mAbs, 100 PFU of the viruses in 
MEM supplemented with 2% FBS in triplicate were combined in U-bottom 96-well plates with 
8 to 12 two-fold dilutions of mAbs, staring at 200 µg/mL, in total volumes of 50 µL, and 
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incubated for 1 hr at 37°C. The virus/antibody mixtures then were placed in triplicate Vero-
E6 cell culture monolayers in 96-well plates, incubated for 1 hr at 37°C, washed with MEM, 
overlaid with 200 µL of MEM containing 2% FBS and 0.8% methylcellulose, and incubated 
for 48 hrs at 37°C. Plates were fixed with 10% phosphate-buffered formalin (Fisher) and 
taken out of the BSL-4 facility according the UTMB BSL-4 standard operating procedures. 
Plaques were counted using a fluorescence microscope.  
 
Biolayer interferometry competition binding assay 
Competition-binding studies using biolayer interferometry and biotinylated EBOV GP 
(EZ-link® Micro NHS-PEG4-Biotinylation Kit, Thermo Scientific #21955) (5 µg/mL) were 
performed on an Octet RED biosensor (ForteBio Menlo Park, CA), as described previously 
(Flyak et al., 2015). In brief, the antigen was immobilized onto streptavidin-coated biosensor 
tips. After a brief washing step, biosensor tips were immersed first into the wells containing 
primary antibody at a concentration of 100 µg/mL and then into the wells containing 
competing mAbs at a concentration of 100 µg/mL. The percent binding of the competing 
mAb in the presence of the first mAb was determined by comparing the maximal signal of 
competing mAb applied after the first mAb complex to the maximal signal of competing mAb 
alone. 
 
 
Electron microscopy 
To determine the epitope of HR2/MPER-directed mAbs, BDBV223, 317, or 340 Fabs 
were generated as described above and added in 10M excess to BDBV GPΔmuc and 
allowed to bind overnight at 4°C (Flyak et al., 2016). Complexes were subsequently purified 
by size exclusion chromatography on an S200 Increase column (GE) and stained as 
previously described (Murin et al., 2014). Particles were visualized using an FEI Tecnai 
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Spirit electron microscope operating at 120kV and images were collected on a TVIPS 
TemCam-F416 (4k x 4k) CCD camera using Leginon (Suloway et al., 2005) with the 
following settings: magnification of 52,000X that resulted in a pixel size of 2.05Å at the 
specimen plane, a constant defocus of -1.00 µm and an electron dosage of ~30e-/Å2. 
Images were processed using the Appion platform (Lander et al., 2009). Particles were 
picked using DoG Picker (Voss et al., 2009) stacks were created and 2D reference-free 
class averages were generated using iterative MRA-MSA (van Heel et al., 1996). For all 
complexes, there was a strong bias toward side-views. Further, the region containing the 
HR2/MPER epitope in our soluble GP constructs is flexible, as indicated by the variety of 
positions that bound Fabs adopted in the class averages. Therefore, our data was refractory 
to a reconstruction, although class averages could be compared to previous class averages 
of known complexes to determine the spatial location of the epitope on GP. 
 
Epitope mapping using an EBOV GP alanine-scan mutation library 
Epitope mapping was carried out as described previously8. Comprehensive high-
throughput alanine scanning (‘shotgun mutagenesis’) was carried out on a full-length EBOV 
GP expression construct (based on the Yambuku-Mayinga variant GP sequence), 
mutagenizing GP residues 33-676 to create a library of clones, each representing an 
individual point mutant. Residues were changed to alanine (with alanine residues changed 
to serine). The resulting library, covering 641 of 644 (99.5%) of target residues was arrayed 
into 384-well plates, one mutant per well, then transfected into HEK-293T cells and allowed 
to express for 22 hours. Cells, unfixed or fixed in 4% paraformaldehyde, were incubated with 
primary antibody then with an Alexa Fluor 488-conjugated secondary antibody (Jackson 
ImmunoResearch Laboratories, Westgrove, PA). After washing, cellular fluorescence was 
detected using the Intellicyt high throughput flow cytometer (Intellicyt, Albuquerque, NM). 
MAb reactivity against each mutant EBOV GP clone was calculated relative to wild-type 
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EBOV GP reactivity by subtracting the signal from mock-transfected controls and 
normalizing to the signal from wild-type GP-transfected controls. 
Mutated residues within clones were identified as critical to the MAb epitope if they did 
not support reactivity of the test mAb but did support reactivity of other control EBOV mAbs. 
This counter-screen strategy facilitated the exclusion of GP mutants that were misfolded 
locally or that exhibited an expression defect. The detailed algorithms used to interpret 
shotgun mutagenesis data were described previously (Davidson and Doranz, 2014) 
 
Peptide synthesis and purification 
Peptides were synthesized using standard Fmoc solid-phase methods on a Peptide 
Machines Discovery-4 synthesizer on rink resin (Atherton, 1988; Bodanszky and 
Bodanszky, 1994; Fields and Noble, 1990; Grant, 1992; Stuber et al., 1989). All coupling 
reactions were performed with ten-fold excess (vs. load capacity of the resin) of activated 
amino acid (Aapptec or Advanced Chemtech), using FMOC amino acids/HBTU/HoBt/DIEA 
(1:1:1:2.5) in DMF for 60 minutes. Deprotection of the FMOC group was accomplished in 
20% v/v piperidine diluted in DMF for 30 minutes. Peptides used for ELISA experiments 
were acetylated at the N-terminus by reaction with 1:1:2 v/v acetic anhydride:DIEA:DMF. 
Peptides used for biolayer interferometry assays were functionalized with PEG6-biotin 
(Quanta BioDesigns) at the N-terminus.  
The peptides were cleaved by exposure to a 90:5:3:2 v/v mixture of trifluoroacetic acid, 
thioanisole, ethanedithiol, and anisole for two hours. Peptides were precipitated by addition 
of cold diethyl ether, lyophilized and purified by reverse-phase HPLC (Waters Prep LC 
4000) equipped with a Waters 2487 detector and C18 column. Final purified fractions were 
lyophilized until further use.  Isolation of the target peptide was confirmed by MALDI mass 
spectrometry. 
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
“If Ebola can change, we can change, too, and maybe faster than Ebola” 
Richard Preston, Inside the Ebola Wars, The New Yorker 
 
Thesis summary 
 
Filoviruses cause a highly lethal disease in humans, with untreated mortality rates 
approaching 90%. Multiple experimental strategies are being investigated for treatment of 
Ebolavirus infection. Among these drug candidates, antibody combinations exceed the 
efficacy and treatment window of other experimental therapeutics described so far (Qiu et 
al., 2014). The key components of such therapeutic cocktails contain antibodies that bind to 
neutralizing epitopes on the GP surface. Most of our knowledge about neutralizing antibody 
responses against filovirus infections has come from studies of murine mAbs that recognize 
EBOV GP. As a result, there is little information available about human antibody responses 
to EBOV infection, and we have very limited knowledge about neutralizing antibodies 
against other filoviruses, such as BDBV, SUDV and MARV. 
I began studies of human antibody responses to filovirus infection by generating a 
large panel of MARV-specific human mAbs from B cells of an individual who contracted 
MARV infection in 2008 following exposure to fruit bats in the Python Cave in Queen 
Elizabeth National Park in Uganda (Chapter II). Among the 39 MARV GP-specific mAbs, we 
found 18 mAbs that exhibited neutralization activity against chimeric vesicular stomatitis 
virus with MARV GP from the Uganda strain on its surface (VSV/GP-Uganda). All VSV/GP-
Uganda neutralizing Abs displayed unique binding patterns in ELISA and blocked the 
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binding of each of the other neutralizing Abs to the antigen in an Octet competition 
experiment. These data suggested that MARV-specific neutralizing Abs bind a single 
antigenic region on the GP surface. 
To determine the location of the antigenic region targeted by MARV neutralizing Abs, 
we performed negative stain single-particle EM studies using antibody-GP complexes. We 
observed that all of the neutralizing antibodies bind to MARV GP at or near the predicted 
region of the NPC1 receptor-binding site. As all neutralizing Abs segregated into a single 
competition group and bound the MARV GP at the NPC1 receptor-binding site, I proposed 
that blocking of MARV GP binding to NPC1 is the principal mechanism of MARV 
neutralization by naturally-occurring human Abs. 
To determine whether MARV-specific human Abs could also bind in a cross-reactive 
manner to the EBOV GP receptor-binding site, I performed ELISAs using EBOV GP. I found 
that three of the MARV neutralizing Abs recognized the EBOV GPcl that lacked the glycan 
cap and mucin-like domain. However, structural analysis of MARV and EBOV GPs revealed 
that the glycan cap and mucin-like domain likely obscure the receptor-binding domain in 
EBOV. In agreement with the structural data, MARV neutralizing Abs did not exhibit 
detectable neutralization activity against EBOV or VSV/EBOV. 
While I was not able to generate pan-filovirus neutralizing Abs using B cells from a 
MARV survivor, I decided to test the idea that functionally important regions of GP can be 
conserved between multiple species from the Ebolavirus genus. The serum of individuals 
who survived BDBV, EBOV, or SUDV infections contained Ebolavirus cross-reactive 
antibodies, suggesting that conserved neutralizing epitopes can be found on the surface of 
Ebolavirus GP.  In Chapter III, I describe the isolation and characterization of a large panel 
of human antibodies using B cells obtained from survivors of a BDBV outbreak.  
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I found that 57 of 90 mAbs generated from B cells of BDBV survivors recognized 
heterologous EBOV GPs. Some of the isolated cross-reactive mAbs also neutralized 
multiple Ebolavirus species. The majority of cross-reactive mAbs neutralized BDBV and 
EBOV, but I also isolated two antibodies that displayed neutralizing activity against 
representatives of three Ebolavirus species – BDBV, EBOV, and SUDV. We tested two 
cross-neutralizing mAbs in mice and guinea pigs and showed that they protected animals 
from lethal challenge with a heterologous species of EBOV. We demonstrate that glycan 
cap-specific mAbs exhibit very potent neutralizing activity, and they recognize diverse 
epitopes within this major antigenic region. 
In Chapter IV, I describe three cross-reactive mAbs isolated from BDBV survivors that 
bind to a new antigenic site in the HR2 region near the EBOV GP MPER. I found that these 
cross-reactive HR2/MPER-specific antibodies do not compete with previously isolated 
EBOV-specific mAbs that recognize other regions in the GP, such as the glycan cap, base, 
or mucin-like domain. We used a series of protein, virologic, and structural biology studies to 
define the GP residues important for HR2/MPER mAb cross-reactivity and neutralization.  
Collectively, findings presented in this thesis enhance our understanding of human 
antibody responses to filovirus infection. The new knowledge gained from this study could 
help develop broad-spectrum protective mAbs and detection capabilities for existing 
filoviruses, and new viral strains that may emerge in the future. Information gathered from 
this thesis reveals mechanisms of filovirus neutralization by human mAbs and provides 
information about conserved epitopes on GP that can be used to inform the development of 
vaccines effective against multiple filoviruses.  
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Future directions 
 
Bispecific antibodies as pan-filovirus therapeutic agents 
 
In Chapter II, I described a large panel of MARV neutralizing mAbs isolated from B 
cells of an individual who contracted MARV infection. Among MARV-specific neutralizing 
Abs, I found several that recognize the EBOV receptor-binding site (Figure 15A), 
suggesting that the binding site for the essential intracellular receptor NPC1 could be an 
attractive target for broadly neutralizing Abs. However, the glycan cap and mucin-like 
domain obscure the receptor-binding site in EBOV GP, complicating the development of 
pan-filovirus Ab treatment. Protein engineering approaches could be employed to deliver 
neutralizing Abs that bind to the filovirus receptor-binding site to late endosomes or 
lysosomes, where the NPC1-binding site is unmasked by host proteases. 
Bispecific Abs (bsAbs) combine specificities of two Abs and can simultaneously bind to 
different antigens or epitopes. The bsAbs	have two heavy and two light chains, one each 
from two different Abs. The two Fab regions are directed against two antigens or epitopes. 
While the generation of bsAbs in a practical and efficient manner has been a longstanding 
challenge, platforms have been developed that improve bsAb product homogeneity and 
yield (Labrijn et al., 2014; Lewis et al., 2014). For example, in a Fab-arm exchange method, 
two parental Abs containing single matching point mutations in the CH3 domain are mixed 
under permissive redox conditions to enable recombination of half-molecules (Figure 30). 
This method could be employed to generate pan-filovirus bsAbs. For this approach, a bsAb 
could be designed to contain variable domains for a human neutralizing Ab that binds to the 
conserved NPC1 receptor-binding site and an Ebolavirus cross-reactive Ab that binds to the 
glycan cap.  
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During the Ebolavirus infection, the cross-reactive glycan cap-specific Fab-fragment 
would bind to conserved epitopes on EBOV GP surface and deliver neutralizing Fab-
fragment that binds to the receptor-binding site to endosomes where EBOV NPC1 receptor-
binding site is exposed for Ab binding. Such a bsAb should display neutralizing activity 
against multiple MARV and EBOV species. Neutralization and protection experiments could 
be performed to test the inhibitory and protective effect of such bsAb. 
 
Mechanisms of Ebolavirus neutralization by glycan cap-specific mAbs 
 
In Chapter III, I highlight the neutralization and protective potencies of human glycan 
cap-specific antibodies. Glycan cap-binding mAbs might not neutralize well because host 
cathepsins remove this region during viral entry (Murin et al., 2014). However, several of the 
BDBV glycan cap-specific mAbs described in Chapter III exhibit very potent neutralizing 
activity and recognize diverse epitopes within this major antigenic site. Furthermore, a single 
glycan cap-specific neutralizing Ab, BDBV289, provides complete protection in EBOV-
challenged guinea pigs. The mechanism used by glycan cap-binding mAbs to neutralize the 
	
Figure 30. Generation of bsAbs by Fab-arm exchange method. IgG1 molecules containing matching 
point mutations, K409R and F405L in their CH3 domains are separately expressed and subjected to the 
controlled Fab-arm exchange protocol. *Yield may be lower when small volumes or low-concentration 
solutions are used. 2-MEA – 2-mercaptoethylamine, CEX – cation-exchange chromatography, HIC – 
hydrophobic interaction chromatography, ESI-MS – electrospray ionization mass spectrometry. Adapted from 
(Labrijn et al., 2014)  
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virus in vitro is unclear. While the amino acid sequence of the GP1 region is generally less 
well conserved than that of GP2 in viruses of diverse filovirus species, the five neutralizing 
glycan cap mAbs described in Chapter III target conserved residues, suggesting that these 
regions are important to the viral lifecycle. Therefore, these mAbs may inhibit some yet 
undefined function of the glycan cap. 
The glycan cap-specific Abs could neutralize EBOV in several ways: by blocking virion 
attachment to cells, preventing virus internalization, or inhibiting GP cleavage by host 
cathepsins, which is required to unmask the NPC1 receptor-binding site. To test whether 
neutralizing Abs to the glycan cap interfere with virus attachment to host cells, the target 
Abs can be tested in pre-attachment neutralizing assays where mAbs are pre-incubated with 
virus or virus-like particles at 4°C before being inoculated onto cell monolayers (1 hour at 
4°C). The virus or virus-like particles/antibody mixtures then can be placed onto cell culture 
monolayers and incubated for 1 hr at 4°C. After non-absorbed virus or virus-like particles are 
removed, cell monolayers can be overlaid with media contraining methylcellulose and 
incubated for 48 hrs at 37°C. Plaques can be counted using a fluorescence microscope. 
The glycan cap-specific antibodies described here bind to sites distant from the 
putative cathepsin cleavage site (located at residue 190), so they are unlikely to interfere 
with GP cleavage. To test whether glycan-cap specific mAbs inhibit the proteolytic cleavage 
of EBOV surface protein, EBOV GP could be incubated with the mAbs for 1 hour at 37°C 
and then treated with cathepsins B and L for an additional hour. The cleavage of EBOV GP 
can be verified in western blot by the presence of a 19 kDa cleaved form of GP. 
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Mechanisms of Ebolavirus neutralization by  HR2/MPER-specific mAbs 
 
Multiple neutralizing mAbs bind to the GP base, including two of three murine-origin 
Abs from the ZMappTM cocktail (c2G4 and c4G7) and the human neutralizing antibody 
obtained from a phage-display library (KZ52). The epitopes of these mAbs were mapped to 
a conformationally-sensitive region at the GP1/GP2 interface in the GP base. These 
GP1/GP2 interface-specific Abs might neutralize EBOV by blocking fusogenic 
rearrangement and membrane insertion by GP2, where the HR1 sequence in the pre-fusion 
GP2 (GP2pre, Figure 31) rearrange to form an unbroken α-helix (GP2extended), placing 
the GP2 internal fusion loop into the target membrane. 
In Chapter IV, I describe three neutralizing human Abs (BDBV223, BDBV317 and 
BDBV340) that bind to a new antigenic region in the HR2/MPER region of GP2. We used a 
comprehensive alanine-scanning approach and identified critical residues in GP2 for these 
neutralizing Abs. The critical residues spanned the C-terminal part of HR2 region and the N-
terminal part of the MPER which form an α-helix. Therefore, in contrast to GP1/GP2 
interface-specific Abs that block the transition from GP2pre to GP2extended conformation, 
HR2/MPER-specific Abs might block the further rearrangement of GP2 from extended 
conformation to the six-helix bundle (GP26HB), where HR2 packs against trimeric HR2 coiled 
coil to form the six-helix bundle (Figure 32).  
To define the residues in the HR2 α-helix required for binding by HR2/MPER-specific 
mAbs, crystallographic studies could be performed with cross-reactive mAbs complexed 
with either recombinant EBOV GP or HR2/MPER peptides. Comparison of crystal structures 
of neutralizing and protective mAbs (BDBV223 and BDBV317) with the structure of non-
protective mAb BDBV340 could further inform the development of an HR2/MPER-based 
EBOV vaccine effective against multiple filoviruses. 
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A real-time assay for EBOV GP triggering and lipid mixing has been described 
(Spence et al., 2016). This system uses the VSV particles bearing EBOV GP, a fluorescent 
monomeric NeonGreen protein fused to EBOV phosphoprotein, and lipophilic dye DiD (1,1'-
Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine), which is incorporated into the viral 
membrane. When incorporated into virions, DiD displays fluorescent self-quenching. Lipid 
mixing between viral and host membranes enables lateral diffusion of DiD dye, which yields 
a sharp increase in the fluorescent signal. Such real-time systems could be used to 
determine whether HR2/MPER-specific mAbs inhibit conformational rearrangements of GP2 
		
Figure 31. Proposed structural rearrangements in GP2 during entry. Structures from PDB ids: 3CSY 
(Lee et al., 2008a) and 1EBO (Weissenhorn et al., 1998). Fusion loops in GP2extended and GP26HB are 
derived from the GP pre-fusion structure 3CSY, and their positions are indicated for illustration only. 
GP2extended is hypothetical. From (Miller and Chandran, 2012). GP1/GP2 interface-specific Abs likely 
neutralize EBOV by blocking the transition of GP2pre to GP2extended conformation. Functional and 
structural information presented in Chapter IV suggest that HR2/MPER-specific mAbs inhibit the GP26HB 
formation.  	
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that ultimately lead to the fusion of viral and host membranes. The HR2/MPER-specific 
mAbs could be tested in the presence or absence of GP1/GP2 interface-specific mAbs to 
investigate the type of interaction between mAbs that target two separate antigenic regions 
on the GP base (additive, synergistic, or antagonistic). 
 
B cell repertoire diversities of filovirus-specific antibodies  
 
High-throughput sequencing technologies can be used to explore Ab gene signatures 
in humans (Arnaout et al., 2011; Wu et al., 2010). For some neutralizing epitopes, the Ab 
repertoire is restricted to a limited set of Ab genes (Scheid et al., 2011). Convergent Ab 
gene rearrangement signatures of the dengue virus-specific B-cell population occur during 
the acute phase of dengue virus infection (Parameswaran et al., 2013). It is not known 
whether the limited number of neutralizing epitopes on EBOV or MARV GPs can serve as a 
constraint mediating the development of convergent Ab sequences that are specific to 
memory B-cell populations of filovirus survivors. 
To analyze the Ab repertoire of filovirus survivors, total RNA could be extracted from 
PBMC samples of BDBV survivors and, after cDNA synthesis, PCR amplification could be 
performed with mixtures of primers designed to amplify antibody gene segments (Smith et 
al., 2009). The purified PCR products could be submitted for high-throughput sequencing 
using an Illumina platform. The resulting sequence data could be analyzed using the clonal 
lineage identification methods to identify filovirus-specific signatures in the B-cell repertoire 
of survivors. The phylogenic analysis could be performed using nucleotide sequences 
obtained from hybridomas expressing filovirus-specific neutralizing Abs to find sequence 
families for Ab somatic variants. Ab variants identified by high-throughput sequence analysis 
could be tested in a binding assays with MARV and EBOV GPs.
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The mechanisms by which neutralizing antibodies
inhibit Marburg virus (MARV) are not known. We iso-
lated a panel of neutralizing antibodies from a human
MARV survivor that bind to MARV glycoprotein (GP)
and compete for binding to a single major antigenic
site. Remarkably, several of the antibodies also
bind to Ebola virus (EBOV) GP. Single-particle EM
structures of antibody-GP complexes reveal that all
of the neutralizing antibodies bind to MARV GP at
or near the predicted region of the receptor-binding
site. The presence of the glycan cap or mucin-like
domain blocks binding of neutralizing antibodies to
EBOV GP, but not to MARV GP. The data suggest
that MARV-neutralizing antibodies inhibit virus by
binding to infectious virions at the exposedMARV re-
ceptor-binding site, revealing a mechanism of filovi-
rus inhibition.INTRODUCTION
Marburg virus (MARV) and Ebola virus (EBOV), which are mem-
bers of the family Filoviridae, infect humans and non-human pri-
mates, causing a hemorrhagic fever with mortality rates up to
90% (Brauburger et al., 2012). There have been a dozen out-
breaks of Marburg virus infection in humans reported to date,
including the most recent report from Uganda of a 30-year-old
male health worker who died in September 2014 (WHO,
2014a). As of January 7, 2015, there have been in excess of
20,000 confirmed, probable, and suspected cases of Ebola virus
disease (EVD) in the current EBOV outbreak in nine affected
countries (Guinea, Liberia, Mali, Nigeria, Senegal, Sierra Leone,Spain, the United Kingdom, and the United States of America),
with more than 8,000 deaths (WHO, 2014b).
There is no licensed treatment or vaccine for filovirus infection.
Recently, several studies showed that filovirus glycoprotein
(GP)-specific neutralizing antibodies (nAbs) can reduce mortality
following experimental inoculation of animals with a lethal dose
of EBOV (Dye et al., 2012; Marzi et al., 2012; Olinger et al.,
2012; Qiu et al., 2012, 2014; Pettitt et al., 2013) or MARV (Dye
et al., 2012). The primary target of these nAbs, the filovirus sur-
face GP, is a trimer composed of three heavily glycosylated
GP1-GP2 heterodimers (Figure S1). The GP1 subunit can be
divided further into base, head, glycan cap, and mucin-like do-
mains (Lee et al., 2008). During viral entry, the mucin-like domain
and glycan capmediate binding to multiple host attachment fac-
tors present on the cell membrane. After the virus enters the host
cell by macropinocytosis (Nanbo et al., 2010; Saeed et al., 2010),
the GP is cleaved by host proteases that remove approximately
80% of the mass of the GP1 subunit, including the mucin-like
domain and glycan cap (Chandran et al., 2005; Dube et al.,
2009). After cleavage of GP in the endosome, the receptor-bind-
ing sites on GP become exposed, and the GP1 head then is able
to bind to its receptor, Niemann-Pick C1 (NPC1) protein (Carette
et al., 2011; Chandran et al., 2005; Coˆte´ et al., 2011). Subsequent
conformational changes in GP facilitate fusion between viral and
endosomal membranes.
The dense clustering of glycans on the glycan cap and mucin-
like domain likely shield much of the surface of EBOV GP from
humoral immune surveillance, leaving only a few sites on the
EBOV GP protein at which nAbs could bind without interference
by glycans (Cook and Lee, 2013). Most of our knowledge about
humoral response against filovirus infections has come from
studies of murine Abs that recognize EBOV GP. From those
studies, we learned that mouse nAbs preferentially target pep-
tides exposed in upper, heavily glycosylated domains or lower
areas (the GP1 base), where rearrangements occur that driveCell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc. 893
fusion of viral and host membranes (Saphire, 2013). Abs have not
been identified that target protein features of the GP1 head sub-
domain, where the receptor-binding site to NPC1 protein is
located. Ab KZ52, the only reported human EBOV GP-specific
mAb, was obtained from a phage display library that was con-
structed from bone marrow RNA obtained from a survivor
(Maruyama et al., 1999). KZ52 binds a site at the base of the
GP and neutralizes EBOV,most likely by inhibiting the conforma-
tional changes required for fusion of viral and endosomal mem-
branes (Lee et al., 2008). Some murine Abs also have been
reported to bind to the base region of Ebola virus GPs (Dias
et al., 2011, Murin et al., 2014). In contrast, very little is known
about the mechanisms by which Abs neutralize MARV. Two mu-
rine Abs that bound the mucin-like domain of MARV GP reduced
MARV budding from infected cells in culture but failed to
neutralize virus directly (Kajihara et al., 2012). Polyclonal
MARV-specific Abs were shown to protect non-human primates
when administrated passively after challenge (Dye et al., 2012).
The epitopes recognized by such polyclonal nAbs, and the
mechanism of neutralization by which these Abs act, are un-
known. In this study, we isolated a large panel of human nAbs
from B cells of a human survivor of severe MARV infection and
used these Abs to define the molecular basis of MARV neutrali-
zation by human Abs. The results show that MARV nAbs recog-
nize the NPC1 receptor-binding domain of MARV GP and, in
some cases, also recognize conserved structural features in
the equivalent receptor-binding domain on EBOV GP.
RESULTS
Isolation of Monoclonal Antibodies
We tested plasma of a MARV survivor previously infected in
Uganda for the 50% neutralization activity against the Uganda
strain of MARV and found a serum-neutralizing titer of 1:1,010.
To generate human hybridoma cell lines secreting mAbs to
MARV, we screened supernatants from EBV-transformed B
cell lines derived from the survivor for binding to several recom-
binant forms of MARV GP or to irradiated cell lysates prepared
from MARV-infected cell cultures. We fused transformed cells
from B cell lines producing MARV-reactive Abs to the MARV
antigens with myeloma cells and generated 51 cloned hybrid-
omas secreting MARV-specific human mAbs. Thirty-nine of
these mAbs were specific to the MARVGP, while 12 bound to in-
fected-cell lysate, but not to GP; these latter mAbs were shown
in secondary screens to bind to MARV internal proteins (NP,
VP35, or VP40; data not shown). Analysis of the Ab heavy- and
light-chain variable domain sequences revealed that all MARV-
specific mAbs were encoded by unique Ab genes.
Neutralization Activity
To evaluate the inhibitory activity of themAbs, we first performed
in vitro neutralization studies using a chimeric vesicular stomati-
tis virus with MARV GP from Uganda strain on its surface (vesic-
ular stomatitis virus/Marburg glycoprotein recombinant VSV/
GP-Uganda). Eighteen of the 39 MARV GP-specific mAbs ex-
hibited neutralization activity against VSV/GP-Uganda (Figures
1A and 1C; Figures S2 and S4). Of those 18 nAbs, 9 displayed
strong (IC50 < 10 mg/ml), 8 nAbs displayed moderate (IC50: 10–894 Cell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc.99 mg/ml), and one displayed weak (IC50: 100–1,000 mg/ml)
neutralizing activity against VSV/GP-Uganda. We also tested
the neutralization potency of all nAbs that bound to MARV GP
in a plaque reduction assay using live MARV-Uganda virus. Of
18 Abs that neutralized VSV/GP-Uganda, 11 Abs exhibited
neutralizing activity against MARV-Uganda (Figures 1A and 1C;
Figures S3 and S4). These data suggest that VSV/GP, often
used to study neutralizing potency of Abs because of its BSL-2
containment level, is more susceptible to Ab-mediated neutrali-
zation than live MARV. This difference is likely explained by the
significantly lower copy number of MARV GP molecules that
incorporate into VSV particles compared with the large number
of GP molecules on the surface of filovirus filaments (Beniac
et al., 2012; Thomas et al., 1985). Comparison of MARV-neutral-
izing and non-neutralizing antibodies at concentration up to
1.6 mg/ml revealed dose-dependent activity of those mAbs
that neutralized. The neutralization activity of nAbs was not
enhanced by the presence of complement (data not shown).
As expected, we did not detect neutralizing activity for any of
the 12 Abs specific to MARV NP, VP35, or VP40 proteins.
Recognition of Varying Forms of GP
To characterize the binding of isolated Abs to recombinant
MARV GPs, we performed binding assays using either a recom-
binant MARV GP ectodomain containing the mucin-like domain
(MARVGP) or a recombinant GP lacking residues 257–425 of the
mucin-like domain (MARV GPDmuc). Based on OD405 values at
the highest Ab concentration tested (Emax) and 50% effective
concentration (EC50), we divided the MARV-GP-specific Abs
into four major groups, based on binding phenotype (designated
binding groups 1, 2, 3A, and 3B; Figures 1B and S5). Binding
group 1 mAbs had an Emax to GP <2 (i.e., these mAbs never ex-
hibited a maximal binding level to MARV GP); binding group 2
mAbs had an Emax to GP >2, with EC50 for GP <EC50 for GPDmuc
(i.e., these mAbs bound to the mucin-like domain or glycan cap);
and binding group 3 had an Emax to GP >2, with EC50 for
GPzEC50 for GPDmuc (i.e., these mAbs bound equally well to
full-length and mucin-deleted forms of GP), with the group 3A
mAbs having an EC50 for GP <0.5 mg/ml and the group 3B
mAbs having an EC50 for GP >0.5 mg/ml (suggesting that, as a
class, the group 3B mAbs possess a lower steady-state KD of
binding to GP than did group 3A mAbs).
Abs that lacked neutralization activity against VSV/GP-
Uganda or MARV-Uganda fell principally into binding groups 1,
2, and 3A. Interestingly, all VSV/GP-Uganda nAbs displayed a
unique binding pattern and segregated into binding group 3B
(Figure 1C). It was interesting that while both mAbs from groups
3A and 3B bound equally well to the full-length MARV GP and to
the GPDmuc, EC50 values for nAbs from binding group 3B were
higher than those for non-neutralizing Abs from group 3A.
Competition-Binding Studies
To determine whether mAbs from distinct binding groups tar-
geted different antigenic regions on the MARV GP surface, we
performed a competition-binding assay using a real-time
biosensor. We tested 18 MARV nAbs from binding group 3B, 4
Abs from binding group 3A, and 1 Ab from binding group 2 in a
tandem blocking assay in which biotinylated GPDmuc was
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Figure 1. MARV-Neutralizing mAbs Display a Unique Binding Pattern and Target a Distinct Antigenic Region on the GP Surface
(A) Neutralization activity of MR77 (non-neutralizing antibody) or MR213 (neutralizing antibody) against VSV/GP-Uganda (red circles) or MARV-Uganda (black
circles). Error bars represent the SE of the experiment performed in triplicate.
(B) Binding of representative mAbs from four distinct binding groups to the MARV GP (blue squares) or MARV GPDmuc (green squares). A dotted line indicates
0.5 mg/ml threshold for categorizing group 3 antibodies as possessing low (3A) or high (3B) EC50 values.
(C) Heatmap showing the neutralization potency of MARV GP-specific mAbs against VSV/GP-Uganda or MARV-Uganda. The IC50 value for each virus-mAb
combination is shown, with dark red, orange, yellow, or white shading indicating high, intermediate, low, or no potency, respectively. IC50 values greater than
1,000 mg/ml are indicated by >. Neutralization assays were performed in triplicate.
(D) Data from competition binding assays using mAbs from binding groups 2, 3A, or 3B. Numbers indicate the percent binding of the competing mAb in the
presence of the first mAb, compared to binding of competing mAb alone. MAbs were judged to compete for the same site if maximum binding of the competing
mAb was reduced to <30% of its un-competed binding (black boxes with white numbers). MAbs were considered non-competing if maximum binding of the
competing mAb was >70% of its un-competed binding (white boxes with red numbers). Gray boxes with black numbers indicate an intermediate phenotype
(between 30 and 70% of un-competed binding).
See also Figures S2, S3, S4, and S5.attached to a streptavidin biosensor. Abs from group 1 and the
two non-neutralizing Abs from binding group 3B did not bind
to biotinylated GPDmuc in the competition assay and were
excluded from the analysis. While non-neutralizing Abs frombinding groups 2 and 3A did not prevent binding of the binding
group 3B nAbs to GPDmuc, all nAbs blocked binding of each
of the other nAbs to the antigen and segregated into a single
competition-binding group (Figure 1D). These data suggestedCell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc. 895
A B C D
Figure 2. Neutralizing Antibodies from a Human Survivor of MARV Bind to the Receptor-Binding Site of GP at Two Distinct Angles of
Approach
(A) Representative reference-free 2D class averages of the MARV GPDMuc:MR Fab complexes.
(B) EM reconstructions of seven Fab fragments of neutralizing antibodies bound to MARV GPDmuc (side views). All seven antibodies target a similar epitope on
the top of GP.
(C) These antibodies can be subdivided based on their angles of approach: (1) those that bind toward the top and side of GP1 at a shallow angle relative to the
central 3-fold axis (MR72 in red, MR78 in orange, MR201 in yellow, or MR82 in green) and (2) those that bind at a steeper angle toward the top of GP1 (MR191 in
cyan, MR111 in blue, or MR198 in purple).
(D) The crystal structure of EBOV GPDmuc (GP1 in white and GP2 in dark gray) is modeled into the MARV GP density (mesh), and the angles of approach of the
neutralizing antibodies are indicated with arrows, colored as in (B). The footprint of the antibodies is indicated by a black circle targeting residues in the putative
receptor-binding site (RBS) through a variety of approach angles.
See also Figure S1.that all of the nAbs target a single major antigenic region on the
MARV GP surface.
Electron Microscopy Studies of Antigen-Antibody
Complexes
To determine the location of the antigenic region targeted by
MARV nAbs, we performed negative stain single-particle elec-
tron microscopy (EM) studies using complexes of GPDmuc
with Fab fragments of seven nAbs from Binding Group 3B. The
EM reconstructions clearly showed that Fab fragments for all
seven nAbs bind at the top of the GP in or near the NPC1 protein
receptor-binding site (Figures 2A and 2B). The binding pattern of
these Abs could be divided further into two major groups based
on their relative angle of approach to the GP head domain. MAbs
MR72, MR78, MR201, andMR82 bound toward the top and side
of GP1 at a shallow angle relative to the central 3-fold axis, while896 Cell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc.mAbs MR191, MR111, and MR198 bound at a steeper angle
toward the top of GP1 (Figures 2C and 2D). When we compared
IC50 values for nAbs that bound in the two binding poses, we did
not detect a significant difference in neutralization potency
based on the angle of approach (Figure 1C).
Antibody Neutralization Escape Mutant Viruses
As an additional strategy to determine residues on MARV GP
involved in binding to nAbs, we generated VSV/GP-Uganda
variant viruses that escaped neutralization, and then we deter-
mined the sequence of the GP of those mAb escape viruses.
Vero E6 cells were inoculated with VSV/GP-Uganda in the pres-
ence of MR72 or MR78 nAbs. Two escape mutant viruses were
isolated: virus variant VSV/GP-72.5 contained three missense
mutations in the MARV GP gene (N129S in the putative NPC1 re-
ceptor-binding site, S220P in the glycan cap and P455L in the
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Figure 3. Generation of Escape Mutants for
MARV-Neutralizing Antibodies
(A) VSV-MARV-72.5 (dotted lines) or VSV-MARV-
78.1 (dashed line) escape mutations mapped onto
the domain schematic of MARV GP. RBS, receptor
binding site; GLC, glycan cap; MUC, mucin-like
domain.
(B) Neutralization activity of antibodies from bind-
ing group 3B against wild-type VSV/GP-Uganda
(circles, straight curves), VSV/GP-72.5 (squares,
dotted curves), or VSV/GP-78.1 (triangles, dashed
curves) escape mutant viruses.mucin-like domain), and virus variant VSV/GP-78.1 possessed
missense mutation C226Y in the glycan cap (Figure 3A). Consis-
tent with the EM data, six out of seven nAbs tested displayed a
higher level of neutralization activity against the wild-type VSV/
GP-Uganda than to the VSV/GP-72.5 or VSV/GP-78.1 escape
mutant viruses, suggesting these nAbs recognize MARV GP in
a similar fashion (Figure 3B). MAb MR198 exhibited equal
neutralization potency against wild-type VSV/GP-Uganda or
the two escape mutant viruses (Figure 3B). As all nAbs segre-
gated into one competition group (Figure 1D), bound the
MARV GP at the NPC1 receptor-binding site (Figures 2A–2D),
and displayed a similar profile of neutralization of escape mutant
viruses (Figure 3B), we propose that blocking of MARV GP bind-
ing to NPC1 is the principal mechanism of MARV neutralization
by these naturally occurring human Abs. Thismodel is supported
by the data in the accompanying paper by Hashiguchi et al.
(2015; this issue of Cell) showing that MR78 inhibits binding of
NPC1 domain C to MARV GP.
Cross-Reactive Binding of MARV Antibodies with
EBOV GP
It is surprising that human MARV nAbs recognize the putative
NPC1 protein receptor-binding site on GP, since previous
studies suggested that the NPC1 protein receptor-binding site
on EBOV GP may be obscured from Ab binding by the presence
of the highly glycosylated glycan cap and mucin-like domainCell 160, 893–903,(Lee et al., 2008). To determine whether
the MARV nAbs we isolated also could
bind in a cross-reactive manner to the
EBOV GP receptor-binding site, we per-
formed ELISA using three recombinant
forms of MARV and EBOVGPs: full-length
GP ectodomain containing the glycan
cap and mucin-like domain (designated
MARV or EBOV GP), ectodomains lacking
residues 257–425 (MARV) or 314–462
(EBOV) of the mucin-like domain (desig-
nated MARV or EBOV GPDmuc), and
cleaved GP ectodomains enzymatically
treated to remove the mucin-like domain
and glycan cap (designated MARV or
EBOV GPcl). Three of the MARV nAbs,
designated MR78, MR111, and MR191,
recognized the EBOV GPcl that lackedthe glycan cap and mucin-like domain (Figure 4A). Remarkably,
the MARV nAb MR72 bound all three forms of both EBOV and
MARV GPs with similar EC50 and Emax values, indicating that
its epitope, and the EBOV receptor-binding site, which it likely
overlaps, might be partially accessible for Ab binding even in
the full-length form (Figure 4A). We tested the breadth of neutral-
ization of MARV nAbs for filoviruses using a panel of different
MARV and EBOV isolates. While multiple MARV Abs displayed
neutralizing activity toward different MARV strains, MARV nAbs
did not exhibit detectable neutralization activity against EBOV
or VSV/EBOV (Figure 4B). Structural analysis of MARV and
EBOV GP in the accompanying paper by Hashiguchi et al.
(2015) reveals that the glycan cap and mucin-like domain likely
obscure the receptor-binding domain in EBOV, but not in MARV.
In Vivo Testing
We tested the in vivo protective activity of the mAbs in a murine
model using mouse-adapted MARV strain Ci67 (Warfield et al.,
2007, 2009). Inoculation of mice with MARV Ci67 causes clinical
disease and, in a proportion of animals, causes lethal disease,
although typically less than 100% lethality in mice (Warren
et al., 2014). We selected four of the mAbs among those with
the lowest in vitro neutralization IC50 values: MR72, MR82,
MR213, and MR232. The IC50 values in neutralization assays
with MARV Uganda or mouse-adapted MARV strain Ci67 were
comparable (within 2-fold). Seven-week-old BALB/c mice wereFebruary 26, 2015 ª2015 Elsevier Inc. 897
A B Neutralization (µg/mL)Binding (µg/mL)
GP GP muc GPcl  GP GP muc  GPcl
MR65 8.3 7.5 5.0 > > >
MR72 3.0 4.7 0.8 6.1 2.1 <0.1
MR78 1.4 2.3 1.1 > > 107.4
MR82 1.0 1.5 0.5 > > >
MR103 8.8 14.2 4.8 > > >
MR111 2.5 4.3 1.5 > > 21.5
MR144 8.1 8.0 3.3 > > >
MR186 1.3 0.9 0.5 > > >
MR191 2.5 5.1 1.4 > > <0.1
MR198 1.4 1.4 0.8 > > >
MR201 1.5 1.9 0.5 > > >
MR208 5.6 7.3 2.8 > > >
MR209 4.0 5.4 2.0 > > >
MR213 2.8 3.6 1.1 > > >
MR229 1.8 2.9 1.2 > > >
MR232 2.0 1.3 0.5 > > >
MR238 6.8 11.7 4.9 > > >
MR241 2.2 4.0 1.2 > > >
mAb
MARV EBOV
VSV/GP- 
Musoke
VSV/GP- 
Uganda
MARV- 
Musoke
MARV- 
Uganda
MARV- 
Angola
MARV-
Ravn
VSV/GP- 
EBOV EBOV
MR65 31.0 224 > > 214 > > >
MR72 3.6 13.4 > 601 > 368 > >
MR78 3.8 4.5 > 93 > 286 > >
MR82 1.8 7.4 234 288 184 185 > >
MR103 16.5 27.5 > 291 > > > >
MR111 12.2 7.9 370 414 > 444 > >
MR144 43.1 37.3 900 > > 354 > >
MR186 1.5 1.5 24 > 97 64 > >
MR191 5.5 6.2 441 > 413 > > >
MR198 2.7 11.6 290 206 128 30 > >
MR201 6.6 8.0 343 572 358 832 > >
MR208 13.8 54.9 896 > > 106 > >
MR209 4.2 12.2 577 402 > 93 > >
MR213 7.6 9.7 > 305 207 121 > >
MR229 5.1 7.3 103 215 110 59 > >
MR232 3.9 4.0 > 114 103 127 > >
MR238 11.9 10.2 264 > 416 > > >
MR241 2.7 11.9 376 > 162 > > >
MARV EBOV
mAb
Figure 4. Breadth of Binding or Neutralization of Human MARV-Specific mAbs for Diverse Filoviruses
(A) A heatmap showing the binding in ELISA of neutralizing mAbs from binding group 3B to the MARV and EBOV GPs. EC50 value for each antigen-mAb
combination is shown, with dark red shading indicating lower EC50 values and orange or yellow shading indicating intermediate or higher EC50 values. EC50 values
greater than 1,000 mg/ml are indicated by >.
(B) A heatmap showing the neutralization breadth of mAbs from binding group 3B. The IC50 value for each virus-mAb combination is shown, with dark red
shading indicating increased potency and orange or yellow shading indicating intermediate or low potency. IC50 values greater than 1,000 mg/ml are indicated
by >. Neutralization assays were performed in triplicate.injected with 100 mg of antibody by the IP route and challenged
with 1,000 plaque-forming unit (PFU) of Ci67. Twenty-four hours
later, antibody treatment was repeated. By day 6, all five control
(untreated) mice developed progressive loss of weight and
symptoms of the disease, including dyspnea, recumbency,
and unresponsiveness, and on days 8 and 9, two animals were
found dead and one animal was foundmoribund and euthanized.
The remaining two animals demonstrated recovery by day 11. In
contrast, all animals treated with any antibody survived and did
not display the elevation of the disease score, with the exception
of two animals treated with MR72, which showed a transient
marginal loss of weight and increase of the disease score on
days 6–9, which did not exceed 1 (Figure 5). The observed level
of protection was remarkable given the relatively modest in-
vitro-neutralizing potency of the antibodies.
DISCUSSION
There is an obvious urgent need for prophylactic and therapeutic
interventions for filovirus infections given the recurrence of
MARV outbreaks, including that in Uganda in October 2014
and a massive outbreak of EBOV infections in West Africa
in 2014. There is very little information about the structural
determinants of neutralization on which to base the rational
selection of antibodies, and for MARV there have been no re-
ported human nAbs.
This study reveals that naturally occurring human MARV nAbs
isolated from the B cells of a recovered donor principally target
the MARV NPC1 protein receptor-binding site, suggesting that
a major mechanism of MARV neutralization could be inhibition
of binding to receptor. Remarkably, some of the isolated anti-898 Cell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc.bodies also bound to the EBOV GP. This mechanism of MARV
neutralization was unexpected, because previous studies with
EBOV showed that the putative receptor-binding domain on
GP is obscured on the surface of virions by the presence of the
glycan cap and mucin-like domain, only becoming exposed
following cleavage by cathepsin in the endosome. These studies
suggest that the configuration of the MARV GP differs signifi-
cantly from that of EBOV GP because the receptor-binding
domain must be accessible for immune recognition on MARV
GP. Indeed, determination of the structure of the MARV GP
and structural analysis of the interaction of mAb MR78 with
MARV and EBOV GP molecules shows this to be the case (see
Hashiguchi et al., 2015).
The information obtained from these studies can be used to
inform development of new therapeutics and structure-based
vaccine designs against filoviruses. Furthermore, as these
nAbs are fully human and exhibit inhibitory activity, they might
be useful as a component of a prophylactic or therapeutic
approach for filovirus infection and disease. The challenge
studies using amurine model here show clear evidence of in vivo
activity and suggest additional preclinical studies in other spe-
cies, such as guinea pigs and macaques, are warranted. Their
ability to bind a broad range of MARV isolates indicates they
may offer detection of or efficacy against new viral strains yet
to emerge. Although some of these mAbs bind to certain forms
of EBOV GP, these antibodies are not likely to be effective
against natural Ebola infection because the EBOV receptor-
binding site is obscured on the viral surface. However, such
mAbsmight neutralize EBOV if they could be delivered to the en-
dosome, where the EBOV receptor-binding site is exposed
following GP cleavage.
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Figure 5. Survival and Clinical Overview of Mice Treated with MARV mAbs
(A–C) Groups of mice at five animals per group were injected with individual mAbs by the intraperitoneal route twice: 1 hr prior and 24 hr after MARV challenge at
100 mg per treatment. Untreated animals served as controls. (A) Kaplan-Meier survival curves. (B) Body weight. (C) Illness score.EXPERIMENTAL PROCEDURES
Donor
The donor was an otherwise healthy adult woman who contracted Marburg
virus (MARV) infection in 2008 following exposure to fruit bats in the Python
Cave in Queen Elizabeth National Park, Uganda. The donor’s clinical course
was documented previously (CDC, 2009). Peripheral blood from the donor
was obtained in 2012, four years after the illness, following informed consent.
The study was approved by the Vanderbilt University Institutional Review
Board.
Viruses
MARV strain 200702854 Uganda (MARV-Uganda) was isolated originally from
a subject designated ‘‘patient A’’ during the outbreak in Uganda in 2007 (CDC,
2009; Towner et al., 2009) and underwent four passages in Vero E6 cells.
MARV strain Musoke (MARV-Musoke) was isolated during the outbreak in
Kenya in 1980 (Smith et al., 1982) and passaged five times in Vero E6 cells.
MARV strain 200501379 Angola (MARV-Angola) was isolated during the
outbreak in Angola in 2005 (Towner et al., 2006) and passaged three times
in Vero E6 cells. MARV Ravn virus (Ravn) was isolated from a patient in 1987
in Kenya (Johnson et al., 1996) and passaged four times in Vero E6 cells. All
strains of MARV were obtained originally from the Special Pathogens Branch,
U.S. Centers for Disease Control (CDC), and deposited at theWorld Reference
Center of Emerging Viruses and Arboviruses (WRCEVA) housed at UTMB. The
recombinant Ebola Zaire strain Mayinga (EBOV) expressing eGFP was gener-
ated in our laboratory by reverse genetics (Lubaki et al., 2013; Towner et al.,
2005) from plasmids provided by the Special Pathogens Branch at CDC and
passaged three times in Vero E6 cells. For analysis of antibody binding by
ELISA, viruses were gamma-irradiated with the dose of 5 3 106 rad. The re-
combinant VSV in which the VSV/GP protein was replaced with that of
MARV strain Musoke (VSV/GP-Musoke) or EBOV strain Mayinga (Garbutt
et al., 2004) were provided by Dr. Thomas Geisbert (UTMB) and Dr. Heinz
Feldmann (NIH), respectively; a similar virus with GP from MARV (strain200702854 Uganda) was constructed as described below. All work with
EBOV and MARV was performed within the Galveston National Laboratory
BSL-4 laboratories.
We used a mouse-adapted strain of MARV for testing the effect of mAbs
in vivo. The mouse-adapted Ci67 strain of Marburg virus (Warfield et al.,
2007) was provided by Dr. Sina Bavari (U.S. Army Medical Research Institute
of Infectious Diseases) and amplified by a single passage in Vero-E6 cells.
Generation of a Chimeric Strain of VSV in which VSV G Protein Was
Replaced with the GP Protein of MARV Strain Uganda
The plasmid pVSV-XN2 carrying cDNA of the full-length VSV anti-genome
sequence and the support plasmids pBS-N, pBS-L, and pBS-P encoding
the internal VSV proteins under control of the T7 promoter were kindly pro-
vided by Dr. John Rose (Yale University). The plasmid pC-T7, encoding the
T7 polymerase, was kindly provided by Dr. Yoshihiro Kawaoka (University of
Wisconsin). For generation of the VSV/GP-Uganda construct, Vero E6 cell
monolayers were inoculated with MARV strain 200702854, and total cellular
RNA was isolated and reverse transcribed. MARV GP open reading frame
(ORF) was PCR amplified from cDNA using forward primer 50-CATGTACG
ACGCGTCAACATGAGGACTA-30 and reverse primer 50-TCTAGCAGCTC
GAGCTATCCAATATATTTAGTAAAGATACGACAA-30 (MluI and XhoI endonu-
clease sites are underlined, respectively; the start and end of MARV GP ORF
direct and complementary sequences are italicized, respectively). To replace
VSV G with MARV GP, the resulting PCR product was cloned into pVSV-
XN2 using the unique MluI and XhoI endonuclease sites located between
the VSV G gene-start and gene-end signals and flanking its ORF, resulting in
the plasmid pVSV/GP-Uganda. To recover the recombinant virus, 1 3 106
BSR-T7 cells, kindly provided by Dr. Ursula Buchholz (U.S. National Institute
of Allergy and Infectious Diseases), were transfected with the following plas-
mids: pVSV/GP-Uganda, 5 mg, pBS-N, 1.5 mg, pBS-P, 2.5 mg, pBS-L, 1 mg,
and pC-T7, 5 mg. After 48 hr, transfected BSR-T7 cells were collected with a
cell scraper and transferred, along with the supernates, to Vero E6 cell mono-
layers for amplification of the recovered VSV/GP-Uganda.Cell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc. 899
Generation of Human Hybridomas Secreting Monoclonal Antibodies
Peripheral blood mononuclear cells (PBMCs) from the donor were isolated
with Ficoll-Histopaque by density gradient centrifugation. The cells were cry-
opreserved immediately and stored in the vapor phase of liquid nitrogen until
use. Previously cryopreserved samples were thawed, and ten million PBMCs
were plated into 384-well plates (Nunc #164688) using 17 ml of cell culture
medium (ClonaCell-HY Medium A, StemCell Technologies, #03801), 8 mg/ml
of the TLR agonist CpG (phosphorothioate-modified oligodeoxynucleotide
ZOEZOEZZZZZOEEZOEZZZT, Invitrogen), 3 mg/ml of the Chk2 inhibitor
(Sigma #C3742), 1 mg/ml of cyclosporine A (Sigma #C1832), and 4.5 ml of clar-
ified supernate from cultures of B95.8 cells (ATCC VR-1492) containing
Epstein-Barr virus (EBV). After 7 days, cells from each 384-well culture plate
were expanded into four 96-well culture plates (Falcon #353072) using cell cul-
ture medium containing 8 mg/ml CpG, 3 mg/ml Chk2i, and ten million irradiated
heterologous human PBMCs (Nashville Red Cross) and incubated for an addi-
tional 4 days. Plates were screened for MARV antigen-specific antibody-
secreting cell lines using ELISAs. Cells from wells with supernates reacting
in a MARV antigen ELISA were fused with HMMA2.5 myeloma cells using an
established electrofusion technique (Yu et al., 2008). After fusion, hybridomas
were resuspended in medium containing 100 mM hypoxanthine, 0.4 mM
aminopterin, 16 mM thymidine (HAT Media Supplement, Sigma #HO262),
and 7 mg/ml ouabain (Sigma #O3125) and incubated for 18 days before
screening hybridomas for antibody production by ELISA.
Human mAb and Fab Production and Purification
After fusion with HMMA2.5 myeloma cells, hybridomas producing MARV-spe-
cific antibodies were cloned biologically by two rounds of limiting dilution and
by single-cell fluorescence-activated cell sorting. After cloning, hybridomas
were expanded in post-fusion medium (ClonaCell-HY Medium E, STEMCELL
Technologies #03805) until 50% confluent in 75-cm2 flasks (Corning #430641).
For antibody production, cells from one 75-cm2 flask were collected with a cell
scraper and expanded to four 225-cm2 flasks (Corning #431082) in serum-free
medium (Hybridoma-SFM, GIBCO #12045-076). After 21 days, supernates
were clarified by centrifugation and sterile filtered using 0.2-mm pore size filter
devices. HiTrap Protein G or HiTrap MabSelectSure columns (GE Healthcare
Life Sciences #17040501 and #11003494, respectively) were used to purify
antibodies from filtered supernates. Fab fragments were generated by
papain digestion (Pierce Fab Preparation Kit, Thermo Scientific #44985) and
purified by chromatography using a two-column system in which the first
column contained protein G resin (GE Healthcare Life Sciences #29048581)
and the second column contained either anti-kappa or anti-lambda antibody
light chain resins (GE Healthcare Life Sciences #17545811 and #17548211,
respectively).
Expression and Purification of MARV and EBOV GPs
Angola strain MARV GP ectodomains, containing the mucin-like domain
(MARV GP) or lacking residues 257–425 of the mucin-like domain (MARV
GPDmuc), were used to screen supernates of transformed B cells and human
hybridomas separately. Recombinant proteins for Ravn strain cleaved GP,
EBOVMayinga strain GP, EBOVMayinga strain GPDmuc, and EBOVMayinga
strain cleaved GP were designed and expressed similarly. Large-scale pro-
duction of recombinant GP or GPDmuc was performed by transfection of
Drosophila Schneider 2 (S2) cells with modified pMTpuro vectors, followed
by stable selection of transfected cells with 6 mg/ml puromycin. Secreted GP
ectodomain expression was induced with 0.5 mM CuSO4 for 4 days. Proteins
were engineered with a modified double strep tag at the C terminus (enteroki-
nase cleavage site followed by a strep tag/linker/strep tag) to facilitate purifi-
cation using Strep-Tactin resin (QIAGEN #2-1201). Proteins were purified
further by Superdex 200 size-exclusion chromatography in 10 mM Tris and
150 mM NaCl (pH 7.5) (13 TBS).
Lysates of MARV-Infected Cells
Lysates were prepared as previously described (Ksiazek et al., 1999). Briefly,
Vero E6 cell monolayers in 850 cm2 roller bottles were inoculated with approx-
imately 106 PFUMARV or EBOV and incubated at 37C until partial destruction
of monolayer occurred (approximately 9–10 days). Cell monolayers were de-
tached using 3-mm glass beads, and cell suspensions were centrifuged at900 Cell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc.16,0003 g for 10 min at 4C. Supernates were discarded; cell pellets were re-
suspended in 103 excess of borate buffer saline (10mMNa2B4O7 and 150mM
NaCl [pH 9.0]) and centrifuged at 16,000 3 g for 10 min at 4C. Supernates
were discarded; cell pellets were resuspended in cold 1% Triton X-100 (Fisher
Scientific) in borate buffer saline, vortexed, and gamma-irradiated on dry ice at
53 106 rad. The lysates were sonicated with a 600 W Tekmar Sonic Disruptor
TM600 (Tekmar) using a cuphorn sonicator at maximum power setting and
50% duty cycle for 10 min and centrifuged at 16,000 3 g, and the supernates
were aliquoted.
Screening ELISA
ELISA plates were coated with lysates of MARV-infected cells (diluted 1:1,000
in Dulbecco’s PBS [DPBS]) or recombinant MARV GP or MARV GPDmuc pro-
teins (20 mg in 10 ml DPBS per plate) and incubated at 4C overnight. Plates
were blocked with 100 ml of blocking solution/well for 1 hr. Blocking solution
consisted of 10 g powdered milk, 10 ml of goat serum, 100 ml of 103
DPBS, and 0.5 ml of Tween-20 mixed to a 1 l final volume with distilled water.
The presence of antibodies bound to the GP was determined using goat anti-
human immunoglobulin G (IgG) horseradish peroxidase-conjugated second-
ary antibodies (Southern Biotech #2040-05, 1:4,000 dilution) and 1-Step Ultra
TMB-ELISA substrate (Thermo Scientific #34029), with optical density read at
450 nM after stopping the reaction with 1M HCl.
Half-Maximal Effective Concentration Binding Analysis
MARV or EBOV GPs, MARV or EBOV GPDmuc, or Ravn or EBOV cathepsin-
cleaved GPs were coated onto 384-well plates (Thermo Scientific Nunc
#265203) in DPBS at 2 mg/ml overnight, then antigen was removed, and plates
were blocked with blocking solution made as above. Antibodies were applied
to the plates at a concentration range of 1.5 mg/ml to 270 ng/ml (binding
groups #1, #2, and 3A) and 0.1 mg/ml to 10 ng/ml (binding group #3B) using
3-fold serial dilutions. The presence of antibodies bound to the GP was deter-
mined using goat anti-human IgG alkaline phosphatase conjugate (Meridian
Life Science #W99008A, 1:4,000 dilution) and p-nitrophenol phosphate sub-
strate tablets (Sigma #S0942), with optical density read at 405 nM after
120 min. A non-linear regression analysis was performed on the resulting
curves using Prism (v. 5) (GraphPad) to calculate EC50 values.
MARV and EBOV Neutralization Experiments
Dilutions of mAbs in triplicate were mixed with 150 PFU of MARV or EBOV
expressing eGFP in MEM containing 10% fetal bovine serum (FBS) (HyClone)
and 50 mg/ml gentamicin (Cellgro #30-005-CR) with or without 5% guinea
pig complement (MP Biomedicals #642836) in a total volume of 0.1 ml
and incubated for 1 hr at 37C for virus neutralization. Following neutralization,
virus-antibody mixtures were placed on monolayers of Vero E6 cells in 24-well
plates, incubated for 1 hr at 37C for virus adsorption, and overlayedwithMEM
containing 2% FBS and 0.8% methylcellulose (Sigma-Aldrich #M0512). After
incubation for 5 days, medium was removed, cells were fixed with 10%
formalin (Fisher Scientific #245-684), and plates were sealed in plastic bags
and incubated for 24 hr at room temperature. Sealed plates were taken out
of the BSL-4 laboratory according to approved SOPs, and monolayers were
washed three times with PBS. Viral plaques were immunostained with the
serum of rabbits that had been hyperimmunized with MARV, or with a mAb
against EBOV, clone 15H10 (BEI Resources #NR-12184). Alternatively,
following virus adsorption, monolayers were covered with MEM containing
10% FBS and 1.6% tragacanth (Sigma-Aldrich #G1128). After incubation for
14 days, medium was removed, cells were fixed with 10% formalin, and plates
were sealed in plastic bags, incubated for 24 hr at room temperature, and
taken out of the BSL-4 laboratory as above. Fixed monolayers were stained
with 10% formalin containing 0.25% crystal violet (Fisher Scientific #C581-
100), and plaques were counted.
VSV-MARV and VSV-EBOV Neutralization Tests
Neutralization assays were performed in triplicate, as described above for
MARV and EBOV. Following neutralization, virus-antibody mixtures were
placed on monolayers of Vero E6 cells in duplicate, incubated for 1 hr at
37C for virus adsorption, and overlayed with MEM containing 2% FBS con-
taining 0.9% methylcellulose. After incubation for 3 days, medium was
removed, monolayers were fixed and stained with 10% formalin containing
0.25% crystal violet, and plaques were counted.
Generation and Sequencing of VSV/GP-Uganda Escape Mutants
Vero E6 cell monolayers with 2-fold dilutions of mAbs (12.5–200 mg/ml) added
to the medium were inoculated with 200 PFU of recombinant VSV/GP-Uganda
and incubated at 37C for 2–4 days. To determine which samples contained
live virus, supernates were collected, virus was titrated in Vero E6 cell mono-
layers under methylcellulose overlay, monolayers were incubated at 37C for
3–4 days, and plaques were counted. Supernates with the highest concentra-
tions of mAbs, which were found to contain live virus by plaque titration, were
incubated in presence of serially diluted mAbs, followed by titration of virus as
above. The procedure was performed a total of three times. Escape mutant
viruses harvested after the third passage were cloned biologically by plaque
purification. For biological cloning, Vero E6 cell monolayers in 24-well plates
were inoculated with dilutions of the escape mutant viruses in the presence
of the corresponding mAbs (200 mg/ml of MR72 or 100 mg/ml of MR78) and
covered with 0.7% low melting temperature SeaPlaque agarose (Lonza
#50100). Monolayers were incubated at 37C for 6 days; plaques were visual-
ized with 0.01% neutral red aqueous solution (Electron Microscopy Sciences),
picked, resuspended in medium, and transferred to Vero E6 cell monolayers in
24-well plates in the presence of the corresponding mAbs (200 mg/ml of MR72
or 100 mg/ml of MR78) for virus propagation. In 2–5 days, based on the extent
of CPE observed, virus was harvested, and cells were dissolved in Trizol re-
agent (Life Technologies 315596018). Total cellular RNA was extracted,
reverse transcribed, and amplified by PCR with the primers described above
for generation of a chimeric strain of VSV. Two overlapping fragments
covering MARV GP ORF were PCR amplified from cDNA using forward primer
50-CATGTACGACGCGTCAACATGAGGACTA-30 and reverse primer 50-ACT
AAGCCCTGCTGCCAGGT-30 or forward primer 50-ACAACAATGTACCGAGG
CAA-30 and reverse primer 50-TCTAGCAGCTCGAGCTATCCAATATATTTAG
TAAAGATACGACAA-30, and the nucleotide sequences of the GP ORFs
were determined using standard procedures.
Analysis of Growth Kinetics of VSV/GP-Uganda Escape Mutant
Viruses
Vero E6 cell monolayers in 24-well plates were inoculated in triplicate with
VSV/GP-Uganda escape mutants or non-mutated virus at an MOI of
0.00025 PFU/cell in the presence of varying concentrations of the correspond-
ing mAbs. Aliquots of medium were collected every 12 hr and frozen for titra-
tion at a later time. Titration of virus in aliquots was performed as above,
without adding antibodies to the culture medium.
Biolayer Interferometry Competition Binding Assay
Biotinylated GP or GPDmuc (EZ-link Micro NHS-PEG4-Biotinylation Kit,
Thermo Scientific #21955) (1 mg/ml) was immobilized onto streptavidin-coated
biosensor tips (ForteBio #18-5019) for 2 min. After measuring the baseline
signal in kinetics buffer (KB; 13 PBS, 0.01% BSA, and 0.002% Tween 20)
for 2 min, biosensor tips were immersed into the wells containing primary anti-
body at a concentration of 100 mg/ml for 10 min. Biosensors then were
immersed into wells containing competing mAbs at a concentration of
100 mg/ml for 5min. The percent binding of the competingmAb in the presence
of the first mAb was determined by comparing the maximal signal of
competing mAb applied after the first mAb complex to the maximal signal of
competing mAb alone. MAbs were judged to compete for binding to the
same site if maximum binding of the competing mAb was reduced to <30%
of its un-competed binding. MAbs were considered non-competing if
maximum binding of the competing mAb was >70% of its un-competed bind-
ing. A level of 30%–70% of its un-competed binding was considered interme-
diate competition.
Sequence Analysis of Antibody Variable Region Genes
Total cellular RNAwas extracted from clonal hybridomas that producedMARV
antibodies, andRT-PCR reaction was performed usingmixtures of primers de-
signed to amplify all heavy-chain or light-chain antibody variable regions. The
generated PCR products were purified and cloned into the pJet 1.2 plasmid
vector (Thermo Scientific, #K1231) for sequence analysis. The nucleotide se-quences of plasmid DNAs were determined using an ABI3700 automated
DNA sequencer. Heavy-chain or light-chain antibody variable region se-
quences were analyzed using the IMGT/V-Quest program (Brochet et al.,
2008; Giudicelli et al., 2011). The analysis involved the identification of germline
genes that were used for antibody production, location of complementary
determining regions (CDRs), and framework regions (FRs), as well as the num-
ber and location of somatic mutations that occurred during affinity maturation.
Statistical Analysis
EC50 values for neutralization were determined by finding the concentration of
mAb at which a 50% reduction in plaque counts occurred after incubation of
virus with neutralizing antibody. A logistic curve was fit to the data using the
count as the outcome and the log-concentration as the predictor variable.
The results of the model then were transformed back to the concentration
scale. Results are presented as the concentration at the dilution that achieves
a 50% reduction from challenge control with accompanying 95% confidence
intervals. Each antibody was treated as a distinct analysis in a Bayesian non-
linear regression model.
Sample Preparation for EM Studies
A Ravn strain MARV GPmucin-deleted construct (GPDmuc) was produced by
stable cell line expression in Drosophila S2 cells, as described above. Human
Fab proteins for MARV-specific antibodies were generated as described
above. Fabs were added in molar excess to GPDmuc and allowed to incubate
overnight at 4C. Complexes then were purified by Superdex 200 size-exclu-
sion chromatography in TBS.
Electron Microscopy and Sample Preparation
A 4 ml aliquot of each complex that had been diluted to a concentration
of 0.03 mg/ml with TBS buffer was placed for 15 s onto carbon-coated
400 Cu mesh grids that had been plasma cleaned for 20 s (Gatan), blotted
off on the edge of the grid, and then immediately stained for 30 s with 4 ml of
2% uranyl formate. The stain was blotted off on the edge of the grid, and the
grid was allowed to dry. Data were automatically collected with Leginon (Car-
ragher et al., 2000; Potter et al., 1999; Suloway et al., 2005) using a FEI Tecnai
F20 electron microscope operating at 120 keV with an electron dose of
30 e/A˚2 and a magnification of 52,0003 that resulted in a pixel size of
2.65 A˚ at the specimen plane when collected with Tietz CMOS 4k 3 4k CCD
camera. Particle orientations appeared to be generally isotropic, and images
were acquired at a constant defocus value of 1.0 mm at 0 stage tilt.
Image Processing of Protein Complexes
Particles were picked automatically using DoG Picker (34) and placed into a
particle stack using the Appion software (Lander et al., 2009). Reference-
free 2D class averages were generatedwith the Xmipp clustering 2D alignment
software (van Heel et al., 1996) and sorted into an initial 300 classes. Non-GP
particles were removed, and the stack was further subclassified into classes
with 100 particles per class in order to generate the final particle stack
used for the reconstruction. Various numbers of class averages were chosen
to create initial models using EMAN2 common lines software (Tang et al.,
2007). A model that best matched its projected classes was then used for
refinement against the raw particle stack, imposing C3 symmetry, and the
reconstruction was generated with ten rounds of refinement and increasingly
smaller angular sampling rates with EMAN2 (Tang et al., 2007). All model fitting
andmanipulation was completed using UCSF Chimera (Pettersen et al., 2004).
In Vivo Testing
The animal protocol for testing of mAbs in mice was approved by the Institu-
tional Animal Care and Use Committee of the University of Texas Medical
Branch at Galveston. Seven-week-old BALB/c mice (Harlan) were placed in
the ABSL-4 facility of the Galveston National Laboratory. Groups of mice at
five animals per group were injected with individual mAbs by the intraperito-
neal route twice: 1 hr prior and 24 hr after MARV challenge, using 100 mg
per treatment. Untreated animals served as controls. For the challenge,
mice were injected with 1,000 PFU of the mouse-adapted MARV strain Ci67
by the intraperitoneal route. Animals were weighed and monitored daily over
the 3-week period after challenge. Once animals were symptomatic, theyCell 160, 893–903, February 26, 2015 ª2015 Elsevier Inc. 901
were examined twice per day. The disease was scored using the following
parameters: dyspnea (possible scores 0–5), recumbency (0–9), unresponsive-
ness (0–5), and bleeding/hemorrhage (0–5); the individual scores for each
animal were summarized.
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Thefiloviruses, includingMarburg andEbola, express
a single glycoprotein on their surface, termed GP,
which is responsible for attachment and entry of
target cells. Filovirus GPs differ by up to 70% in pro-
tein sequence, and no antibodies are yet described
that cross-react among them. Here, we present the
3.6 A˚ crystal structure ofMarburg virusGP in complex
with a cross-reactive antibody fromahuman survivor,
anda lower resolution structureof theantibodybound
to Ebola virus GP. The antibody, MR78, recognizes
a GP1 epitope conserved across the filovirus fam-
ily, which likely represents the binding site of their
NPC1 receptor. Indeed, MR78 blocks binding of
the essential NPC1 domain C. These structures and
additional small-angle X-ray scattering of mucin-con-
taining MARV and EBOV GPs suggest why such
antibodies were not previously elicited in studies
of Ebola virus, and provide critical templates for
development of immunotherapeutics and inhibitors
of entry.
INTRODUCTION
The filovirus family includes Marburg virus and five ebolaviruses
(Ebola, Sudan, Reston, Bundibugyo, and Taı¨ Forest viruses),
most of which cause highly lethal hemorrhagic fever andmultiple
outbreaks among humans. Among the filoviruses, Marburg virus
was the first to be identified when it sickened laboratory workers
in Europe in 1967 (Malherbe and Strickland-Cholmley, 1968; Sie-
gert et al., 1968). Marburg virus has since re-emerged multiple
times, with modern strains conferring greater lethality (90%)
(Geisbert et al., 2007; Towner et al., 2006). Sudan virus has
caused at least six outbreaks between 1976 and 2013 (Albarin˜o
et al., 2013; Bowen et al., 1977; Sanchez and Rollin, 2005; Shoe-
maker et al., 2012), Bundibugyo virus emerged in 2007 (Towner904 Cell 160, 904–912, February 26, 2015 ª2015 Elsevier Inc.et al., 2008; Wamala et al., 2010) and again in 2012 (Albarin˜o
et al., 2013), and Reston virus was found to infect ranches of
swine being raised for human consumption in Asia in 2009 and
2011 (Barrette et al., 2009; Pan et al., 2014; Sayama et al.,
2012). Ebola virus is typically found in Central Africa, but re-
emerged inWestern Africa in 2014 to cause an outbreak unprec-
edented in magnitude and geographic spread (WHO Ebola
Response Team, 2014). During this outbreak, an experimental
Ebola virus-specific monoclonal antibody (mAb) cocktail (Qiu
et al., 2014) was used compassionately in several patients. No
such treatment yet exists that could be used against Marburg
virus or the other four ebolaviruses.
Filoviruses express a single protein on their envelope sur-
face, a glycoprotein termed GP, which is responsible for
attachment to, and entry of, host cells (Sanchez et al., 1996).
GP forms a trimer on the viral surface. In the trimer, each mono-
mer is comprised of GP1 and GP2 subunits that are anchored
together by a GP1-GP2 disulfide bond (Volchkov et al., 1998).
GP1 contains a receptor-binding core topped by a glycan
cap and a heavily glycosylated mucin-like domain (Lee et al.,
2008), while GP2 contains two heptad repeats and a transmem-
brane domain. Filoviruses initially enter cells via macropinocyto-
sis (Aleksandrowicz et al., 2011; Nanbo et al., 2010; Saeed
et al., 2010; Mulherkar et al., 2011). Once in the endosome,
the viral surface GP is cleaved by host cathepsins. Cleavage re-
moves the mucin-like domains and glycan cap (Chandran et al.,
2005; Schornberg et al., 2006; Hood et al., 2010; Marzi et al.,
2012a; Brecher et al., 2012) and renders GP competent to bind
the Niemann Pick C1 (NPC1) receptor (Carette et al., 2011;
Coˆte´ et al., 2011). Interestingly, Ebola virus entry requires cleav-
age by cathepsin B (Chandran et al., 2005; Martinez et al., 2010;
Schornberg et al., 2006), while Marburg virus entry is indepen-
dent of cathepsin B (Gnirss et al., 2012; Misasi et al., 2012).
The reasons underlying these differences are unknown. After
enzymatic cleavage and receptor binding, the GP2 subunit
unwinds from its GP1 clamp and rearranges irreversibly into a
six-helix bundle (Malashkevich et al., 1999; Weissenhorn et al.,
1998a; Weissenhorn et al., 1998b) to drive fusion of virus and
host membranes.
Antibody therapies recently have demonstrated effective
post-exposure protection against filoviruses in animal models
(Dye et al., 2012; Marzi et al., 2012b; Olinger et al., 2012; Pettitt
et al., 2013; Qiu et al., 2012; Qiu et al., 2014). MAbs can be pro-
duced on large scale and offer more reproducible effects than
polyclonal sera from survivors. However, most mAbs available
only recognize Ebola virus. Very few are yet described against
Marburg virus, and no antibodies are yet described that cross-
react among the filoviruses. Indeed, Marburg and Ebola GP
are 72% different in protein sequence, and the filoviruses are
thought to be antigenically distinct. Further, there is no structure
available for the unique Marburg virus GP, by which we may
interpret differences in requirements for viral entry, or develop
immunotherapeutics or inhibitors of entry.
Here, we report the crystal structure of the trimeric, receptor-
competent form of Marburg virus GP in complex with a neutral-
izing antibody, termed MR78, that was identified in a recent
human survivor of Marburg virus infection (Flyak et al., 2015).
Atypically, MR78 cross-reacts to cleaved Ebola virus GP. An
additional structure of MR78 in complex with Ebola virus GP
illustrates the basis of the cross-reactivity: the antibody binds
a hydrophobic ‘‘trough’’ at the top of GP1, the sequence and
structure of which are conserved across the filoviruses. We pro-
pose that this trough is the binding site of the critical domain C of
the NPC1 receptor. Indeed, MR78 blocks binding of domain C
to Marburg GP. Further, the extended third complementarity-
determining region of the heavy chain (CDR H3) of MR78 mimics
the glycan cap that shields this site on Ebola virus prior to entry
and may mimic the receptor itself. These crystal structures plus
additional biophysical analysis of complete, mucin-containing
Ebola and Marburg GP ectodomains reveal that the receptor-
binding site is masked on the surface of Ebola virus but more
exposed on the surface of Marburg virus. These findings may
explain why a cross-reactive antibody such as MR78 has not
been identified in studies of Ebola virus.
RESULTS
Structure Determination
Trimeric GP ectodomains for Marburg virus (MARV; strain
Ravn) or Ebola virus (EBOV, also known as Ebola Zaire;
strain Mayinga) were expressed in Drosophila S2 cells, with
or without their mucin-like domains (GP and GPDmuc, respec-
tively). MARV and EBOV GPDmuc were further proteolyzed
by trypsin or thermolysin, respectively, to produce cleaved
GP (GPcl) resembling the version of GP competent for receptor
binding in the endosome (Figure S1A). Three hundred versions
of MARV GP were engineered and complexed with 22 different
mAbs in order to find a crystallizable combination. Hundreds
of crystals of the final MARV GPcl-MR78 combination were
grown and screened for X-ray diffraction: just one crystal
yielded suitable diffraction.
Diffraction to 3.6 A˚ resolution was obtained from a single crys-
tal of the MARV GPcl-Fab MR78 complex. The structure was
determined by molecular replacement using EBOV GP and
Fab KZ52 (Lee et al., 2008) as search models and was refined
to Rwork of 24.7 % and Rfree of 27.9 % (Table S1). Four GP-Fab
complexes are contained in the asymmetric unit: one completetrimer and one other monomer, which forms its biologically rele-
vant trimer around a crystallographic 3-fold axis.
Differences in GP Structure between EBOV and MARV
Although the overall organization is similar betweenMarburg and
Ebola GPs (1.8 A˚ rmsd among 212 Ca atoms) (Figures 1A and
1B), several structural differences exist that may explain their
differing requirements for cellular entry. The first difference is
that the intra-GP1 disulfide bond formed by C121 and C147 in
ebolavirus GP structures (Ebola [Lee et al., 2008] and Sudan
[Bale et al., 2012; Dias et al., 2011]) does not exist in MARV. In
MARV, the two cysteines are replaced instead with L105 and
H131 (Figure 1C and Figure S1B). As a result, the equivalent
polypeptides, which form the crest of the receptor-binding sub-
unit, differ in structure and flexibility. In the ebolaviruses, the
polypeptide bearing C147 (residues 145 to 150) turns inward, to-
ward the trimer center to disulfide bond to C121. In MARV, the
equivalent polypeptide (residues 129 to 134) turns outward into
solvent, away from the trimer center.
A second difference between MARV and the ebolaviruses lies
at the base of the cathepsin cleavage loop. In MARV, these res-
idues (172-180) form a clear alpha helix (a2), which packs against
the outside of the GP2 fusion loop, interacting with both the N-
and C-terminal strands of the fusion loop (Figure 1D). In ebolavi-
ruses, the equivalent residues predict to form a loop rather than a
helix and are disordered (Bale et al., 2012; Dias et al., 2011; Lee
et al., 2008). In MARV GP, the peptide connecting this a2 helix to
b14 in the glycan cap would necessarily and immediately cover
the both N- and C-terminal arms of the GP2 fusion loop, and if
uncleaved, would hinder the conformational changes of fusion.
Structural differences in a2 of MARV may prevent effective pro-
cessing by cathepsin B.
The third difference in the MARV GP structure lies at the N ter-
minus, in the base of the b sheet that forms the GP1 spool, about
which the metastable GP2 subunit is wound. In EBOV, the base
of the spool connects to the anchoring GP1-GP2 disulfide bond
by a short stretch of polypeptide that intimately interacts with
GP2. This short connecting polypeptide contains an N-linked
glycan at Asn40, and also contains residue Asp47, which renders
EBOV dependent on cathepsin B for entry (Misasi et al., 2012). In
EBOV entry, cathepsin B removes an additional and critical
1 kDa of mass from GP beyond that removed by cathepsin L,
but the site and consequences of that extra cleavage event are
not yet known. We propose that if cathepsin B cleaves this con-
necting loop, EBOV GP2 would be freed from the constraints of
the disulfide bond and better able to undergo the conformational
rearrangements of fusion. Our crystal structure reveals that
MARV, which is cathepsin B-independent, is structured differ-
ently from EBOV at the same site. In MARV, the base of the
GP1 spool is more mobile and is shifted toward the center of
the trimer, inside of the fusion loop. Further, unlike in ebolavi-
ruses (Dias et al., 2011; Bale et al., 2012), the polypeptide
connection to the MARV GP1-GP2 disulfide could not be visual-
ized and the N-linked glycan is absent. The nearest glycan is
instead attached to residue 171 on the MARV GP1 b sheet itself
(Figure 1E). These differences in sequence, glycosylation,
mobility, and conformation likely allow MARV to be cleaved by
other enzymes and render MARV cathepsin B-independent.Cell 160, 904–912, February 26, 2015 ª2015 Elsevier Inc. 905
Figure 1. Structure of Marburg Virus GP
(A) Crystal structure of MARV GPcl (GP1, purple and GP2, dark gray) superimposed with the equivalent structure of EBOV (PDB ID, 3CSY; GP1, blue; and GP2,
light gray). The glycan cap of EBOV GP is deleted for clarity. The yellow box outlines the MR78 epitope and putative receptor-binding site. The black box outlines
the interaction site of the MARV-specific helix a2 of GP1 (purple) with the fusion loop of GP2 (dark gray). The visible N-linked sugars on MARV and EBOV GPcl
crystal structures are shown as dot models. MARV GPcl bears glycans at positions N94 and N171, which are not glycosylated in EBOV. See also Figure S1.
(B) Top view of GP.
(C) MARV GP lacks the intra-GP1 disulfide bond of EBOV. C147 of EBOV (blue) is replaced by H131 in MARV (purple), and the corresponding polypeptide traces
outward from the trimer center. The orange box outlines the glycan attachment sites at the base of each GP.
(D) Residues 172–180 of MARV form an a helix (a2) that packs against both N- and C-terminal arms of the fusion loop. In ebolaviruses, the equivalent residues are
predict to form a loop rather than a helix and are disordered in crystal structures.
(E) At the base of GP, MARV bears a glycan attached to N171 while EBOV bears a glycan attached to N40 (drawn as an oval as it was not included in the EBOV
crystal structure).Overall Organization of the MARV or EBOV GPcl Bound
to Fab MR78
The crystal structure of MARVGPcl in complex with the Fab frag-
ment of MR78 indicates that MR78 binds the membrane-distal
head of GP1 (Figure 2A). We determined an additional, low-res-
olution structure of EBOV GPcl bound to both MR78 and KZ52.
The ternary EBOV complex, determined by molecular replace-
ment, demonstrates that theMR78 antibody recognizes a similar
site on both MARV and EBOV (Figures 2B, S2, and Table S1).
MR78 binds into a highly conserved hydrophobic trough re-
vealed at the top of the EBOV GP1 core, after removal of the
glycan cap by proteolytic cleavage in the endosome. Although
MARV and EBOV diverge significantly in sequence overall, resi-
dues contained in this site, the MR78 epitope, are 85% similar
between the viruses (Figures 3A and S1B).
Likely Receptor-Binding Site
The location and structural conservation of this site suggest that
it could be the binding site of the NPC1 receptor, used by all
known filoviruses (Carette et al., 2011; Coˆte´ et al., 2011; Miller
et al., 2012; Ng et al., 2014). Indeed, in ELISA, MR78 inhibits
binding of NPC1 domain C to MARV GP (Figure S3A). This906 Cell 160, 904–912, February 26, 2015 ª2015 Elsevier Inc.site, at the apex of cleaved GP1, resembles an ocean wave
morphology, with a lower trough beneath a rising crest. The
trough is hydrophobic and is formed by a1, b4 and the loop
that connects them (residues 63-74 in MARV). It is 22 A˚ wide
and 8 A˚ deep at F72. The crest is hydrophilic, includes charged
residues previously identified as essential for virus entry (Dube
et al., 2009; Manicassamy et al., 2005; Manicassamy et al.,
2007), and is formed by strands b7, b9 and their connecting
loops (residues 92–106 and 120–134 in MARV). The 120–134
loop contains H131, which replaces the cysteine and the intra-
GP1 disulfide bond of EBOV (Figure 3B).
Here, we show by ELISA that a Q128S and N129S double
mutant in MARV GP abrogates binding to NPC1 domain C (Fig-
ure S4A). Q128 and N129 are at the tip of the crest and could
make direct hydrophilic interaction with NPC1. The trough itself
is formed by hydrophobic side chains, such as F72 (equivalent to
F88 in EBOV). Also forming the trough are the main chains of hy-
drophilic residues; these polar side chains reach away from the
trough into the trimer to make key stabilizing contacts to GP2.
Two examples are R73 and K79, previously shown to be essen-
tial for MARV infectivity (Manicassamy et al., 2007). In the crystal
structure, R73makesmultiple hydrogen bonds to the fusion loop
Figure 2. MR78Binds BothMARV andEBOV
GPcl at the Apex of GP1
(A) 3.6 A˚ crystal structure of MARV GPcl in com-
plex with Fab MR78. Each GP1 is colored a
different shade of purple, GP2 is gray, and the
MR78 Fab is in yellow.
(B) 8 A˚ structure of EBOVGPcl in complexwith Fab
MR78, determined by molecular replacement and
rigid body refinement. Each EBOV GP1 is colored
a different shade of blue and GP2 is gray. See also
Figure S2. Fab MR78 (yellow) binds the apex of
GP1 of both viruses.of the neighboring protomer in the trimer (Figure S4B) and likely
plays a key role in maintaining the prefusion structure or trans-
mitting a conformational change to the fusion loop after receptor
binding. K79 interacts with themain chain of residues 574–577 of
GP2 (Figure S4C), residues that connect the separated helical
segments of the first heptad repeat. We propose that binding
of NPC1 domain C involves contact with the hydrophilic crest
and hydrophobic trough, and that binding in the trough may
transmit conformational changes to GP2 via R73 and K79 (equiv-
alent to R89 andK95 in EBOV). AlthoughMR78 binds bothMARV
and EBOVGPcl, it only outcompetes NPC1 domain C for binding
of MARV GPcl (Figure S3B). MR78 may have lower affinity for
EBOV GPcl than MARV GPcl or domain C may bind the GPs
slightly differently.
GP-MR78 Interactions
The interaction surface between the MR78 antibody and MARV
GP buries 976 A˚2 of molecular surface and is primarily hydropho-
bic. Contact is mediated by both the heavy and light chains, but
the primary region of interaction is the 17-residue CDR H3 (Fig-
ures 3C and S3CD), which penetrates the hydrophobic trough
in MARV GP1. In this interaction, F111.2 and Y112.2 of the
CDR H3 interact with P63, S67, W70, F72, I95 and I125 of
MARV GP (IMGT numbering, Figure 4A).
Notably, these interactions are similar to those made by the
Ebola virus glycan cap, which occupies this site prior to enzy-
matic cleavage in the endosome. In Ebola virus, the equivalent in-
teractions are made by F225 and Y232 of the EBOV glycan cap
interacting with P80, T83, W86, F88, L111 and V141 on EBOV
GP (Figure 4B). Similarity may even extend to the key domain CCell 160, 904–912,of the NPC1 receptor itself, as domain C
contains similar Phenylalanine and Tyro-
sine residues that are essential for bind-
ing GP (Ndundo and Chandran, personal
communication). Further, F72 in MARV,
which is equivalent to F88 in EBOV, inter-
acts with CDR H3 in the bottom of the
trough. Both F72 of MARV and F88 of
EBOVare critical for attachment and entry
(Martinez et al., 2013; Mpanju et al., 2006)
and may interact directly with essential
hydrophobic residues of domain C. The
binding mode of MR78 is reminiscent of
anti-influenza virus human mAbs in which
longCDRH3s similarly reach into the con-served receptor-binding site (Barbey-Martin et al., 2002; Bize-
bard et al., 1995; Hong et al., 2013; Lee et al., 2014; Schmidt
et al., 2013; Whittle et al., 2011; Xu et al., 2013). In many cases
those influenza mAbs also use Phe or Tyr aromatic residues to
interact with an aromatic residue in the viral receptor binding
domain, suggesting that the favorable energetics and inter-
molecular interactions of common aromatic molecules may
constitute a canonical mode of binding of antiviral antibodies to
recessed receptor-binding sites.
Although the MR78 epitope is largely conserved in sequence
and structure between MARV and EBOV, it differs in its exposure
at different stages of virus entry. MR78 binds MARV GP equally
well whether MARV GP is in its uncleaved, viral-surface form or
its cleaved, endosomal form. In contrast,MR78 does not bind un-
cleavedEBOVGP. It onlybinds theendosomal, cleaved form from
which the glycan cap has been removed. Together, these results
suggest that in EBOV, the glycan cap effectively blocks theMR78
epitope andputative receptor-binding site on the (uncleaved) viral
surface, but that in MARV, the epitope and at least part of the
receptor-binding site is fully exposed on the viral surface. Better
exposure of this sitemay explainwhy antibodies against the puta-
tive receptor-binding site were elicited by MARV infection (see
companionpaperbyFlyaket al., 2015), but seem tobemore rarely
elicited and have not yet been described against EBOV.
Differences in Mucin-Like Domains between MARV and
EBOV, and Possible Effect on Antibody Reactivity
In addition to a glycan cap, the GP spike on the viral surface in-
cludes three heavily glycosylated mucin-like domains that are
75 kDa each in mass and are predicted to have little secondaryFebruary 26, 2015 ª2015 Elsevier Inc. 907
Figure 3. MR78 Recognizes a Conserved Epitope at the Apex of Cleaved GP1
(A) Conservation of the MR78 epitope among filovirus GPs, mapped onto one monomer of MARV GPcl. Sequence alignment was performed in ebolavirus (Ebola,
Sudan, Reston, Taı¨ Forest, Bundibugyo), marburgvirus (Musoke, Angola, Popp, Ci67, DRC1999, Ravn), and cuevavirus (Lloviu) genuses. Residues identical
across the filoviruses are colored red; residues that possess strong similarity, magenta; weak similarity, pink; no similarity, gray.
(B) The apex of cleaved MARV GP1, where Fab MR78 binds, forms a wave crest-and-trough morphology (magenta). The hydrophilic crest and the hydrophobic
trough each contain residues previously shown to be critical for virus entry (Dube et al., 2009; Manicassamy et al., 2005; Manicassamy et al., 2007; Mpanju et al.,
2006). The diagonal black line indicates the base of the trough. See also Figure S4.
(C) Surface representation of the interface between onemonomer of MARV GPcl (bottom) and FabMR78 (top). CDR H1 is colored red; CDRH2, orange; CDRH3,
purple; CDR L1, blue; CDR L2, green; CDR L3, forest green. The footprint on MARV GPcl is colored according to the CDR that mediates the contact. GP residues
contacted by MR78 are indicated and colored according to the CDR that mediates the contact (CDR names in parentheses).structure. All mucin-containing GPs thus far have been refractory
to crystallization. In order to visualize the native glycoprotein ec-
todomain and position of themucin-like domain relative to the re-
ceptor-binding core, we turned to Small-Angle X-ray Scattering
(SAXS) in solution. SAXS data collected for mucin-containing
EBOV or MARV GP trimers indicate that the mucin-like domains
of both viruses are large and extend outward from the GP core.
The radius of gyration, RG, for mucin-deleted and mucin-con-
taining MARV GPs are 50 and 72 A˚, respectively, and maximum
dimension, Dmax, for mucin-deleted and mucin-containing GPs
are 160 and 250A˚, respectively, indicating that the mucin-like
domain of MARV widens the molecule up to 90 A˚ (Figures 5A
and S5). The mucin-like domains of MARV are a bit larger than
those of EBOV (67 A˚ RG and 225 A˚ Dmax for mucin-containing
EBOV GP), consistent with their greater volume determined by
SAXS (Figure S5C) and mass noted by SDS-PAGE (Figure S5D).
Themucin-like domains of EBOV appear to project more upward
(consistent with EM tomography [Tran et al., 2014]), while
those of MARV appear to project less upward, more equatorially,
and to cover the sides of the GP trimer (Figures 5A and 5B).
Although the mucin-like domains are likely flexible (see Porod-
Debey coefficient P in Figure S5C), an equatorial, rather than
upward projection is consistent with attachment points of the
mucin-like domain to both GP1 and GP2 in MARV. In EBOV,
a different position of the furin cleavage site results in all of
mucin-like domain being attached to GP1. The MARV GP2
portion of the mucin-like domain, residues 436–509, is attached
to residue 510 on the side of the MARV GP trimer, but is flexible
and disordered.908 Cell 160, 904–912, February 26, 2015 ª2015 Elsevier Inc.A differing position of the mucin-like domains between MARV
and EBOV would leave different surfaces exposed for immune
recognition. The equatorial projection of the MARV mucin-like
domain, for example, would leave the expected receptor-bind-
ing site at the top more accessible on MARV than EBOV, and
further supports the notion that antibodies against the expected
receptor-binding site would be more likely to be elicited using
marburgvirus antigens than ebolavirus antigens. The accompa-
nying paper (Flyak et al., 2015) and other immunization studies
(Qiu et al., 2011; Wilson et al., 2000) support this notion.
In contrast, on EBOV, the upward projection of the mucin-like
domains and the absence of mucin attached to EBOV GP2
would leave the EBOV base more exposed for antibody surveil-
lance, compared to that of MARV. Indeed, in the accompanying
paper by Flyak et al., none of the 18 neutralizing antibodies
raised against MARV appear to bind the base of the MARV GP,
while multiple neutralizing antibodies elicited by ebolaviruses
are known to bind, or thought to bind, to the base of ebolavirus
GP (Dias et al., 2011; Lee et al., 2008; Qiu et al., 2012; Murin
et al., 2014) (Figure 5C).
DISCUSSION
In summary, the crystal structures and accompanying experi-
ments indicate that MR78 binds a conserved site on the apex
of GP1 that is available on the surface of MARV GP, but masked
on EBOV GP prior to enzymatic cleavage. The epitope of MR78
likely overlaps with the receptor-binding site, and hydrophobic
contacts made by CDRH3 to the hydrophobic troughmaymimic
Figure 4. Similarity in Recognition of the Pu-
tative Receptor-Binding Site by MR78 and
the Ebola Virus Glycan Cap
(A) The CDR H3 of MR78 (yellow) reaches into the
hydrophobic trough of GP1 (purple). F111.2 and
Y112.2 of CDR H3 interact with P63, S67, W70,
F72, I95, and I125 of MARV GP.
(B) Similar residues of the EBOV glycan cap (light
blue) bind into this trough on the surface of EBOV
GP (blue), prior to enzymatic cleavage. Here, F225
and Y232 of the glycan cap interact with P80, T83,
W86, F88, L111, and V141 in the trough (PDB ID;
3CSY).those of the as-yet-unvisualizedNPC1domainC.MR78 does not
neutralize authentic EBOV, likely because its epitope is masked
on the EBOV surface by the mucin-like domain and glycan cap
on the virus surface. MR78 does, however, neutralize authentic
MARV (Flyak et al., 2015) and could be a valuable monoclonal
antibody therapeutic against this extremely lethal virus. Impor-
tantly, no mAb therapeutic yet exists against MARV, and few
mAbs are yet known against MARV from which such a therapeu-
tic could be developed. The crystal structure of MARV GP pre-
sented here, and the highly conserved MR78 epitope, provide
strategies for immunotherapy and templates for development
of potentially broad-spectrum inhibitors of filovirus entry.
EXPERIMENTAL PROCEDURES
Construction, Expression, and Purification of MARV/EBOV GP
DNA encoding the MARV GPDmuc ectodomain (residues 1–636 with a mucin
deletion of residues 257–425), point mutants of MARV GPDmuc and the
EBOV GPDmuc ectodomain (residues 1–637 with a mucin deletion of residues
314–462) were amplified by PCR using codon-optimized and whole-gene syn-
thesized MARV or EBOV GPs as templates. Four point mutations in MARV
GPDmuc, F438L,W439A, F445G, and F447N, on GP2, located around the furin
cleavage site were found to improve the efficiency of furin cleavage. GP con-
structs were cloned into a derivative of the expression vector pMT. This deriva-
tivevector contains thepuromycin resistant geneandaC-terminal double-strep
tag sequence. Expression plasmids were transfected using Effectin (QIAGEN)
into 80% confluent Drosophila Schneider S2 cells. The cells were first cultured
in complete Schneider’s medium supplemented with 10% (v/v) FCS (LONZA),
and were adapted to Insect Xpress medium by progressively modifying the
Schneider/Insect Xpress medium ratio with 6.0 mg/ml puromycin. Large-scale
expression of the MARV/EBOV GPDmuc was performed using stable S2 cell
lines in 2 l Erlenmeyer flask at 27.0C, induced with 0.5 mM CuSO4. Superna-
tants containing the expressed proteins were harvested 4 days after induction,
and mixed with the Strept-Tactin affinity column binding buffer (100 mM
Tris-HCl, 150 mM NaCl, 1 mM EDTA, 15 mg/ml Avidin [pH8.0]). The proteins
were purified via Strept-Tactin affinity, followed by Superdex 200GL 10/300
(GE Healthcare Life Sciences) size-exclusion chromatography (S200 SEC).Cell 160, 904–912,Preparation and Crystallization of GP-
Antibody Complexes
To mimic endosomal protease cleavage and pro-
duce MARV GPcl, MARV GPDmuc was incubated
with 0.01 mg trypsin at 37C for 1 hr in 20 mM
TBS [pH 8.0], 100 mM NaCl. The reaction was
stopped using 0.5 mM 4-(2-Aminoethyl) benzene-
sulfonyl fluoride hydrochloride (AEBSF), and the
protein was purified by S200 SEC. EBOV GPcl
was produced by incubating EBOV GPDmuc
with 0.02 mg thermolysin overnight at room tem-perature in 20 mM TBS [pH 7.5], 100 mM NaCl, 1 mM CaCl2, and purified by
S200 SEC. Hybridoma cells expressing the human MR78 antibody were
generated from peripheral blood mononuclear cells (PBMCs) from a donor,
who contracted MARV infection in the Python Cave in Queen Elizabeth Na-
tional Park, Uganda in 2008 (see Flyak et al., 2015). MR78 was expressed in
serum-free medium (Hybridoma-SFM, GIBCO), and culture supernatants
were centrifuged, sterile-filtered, and purified over HiTrap Protein G columns
(GE Healthcare Life Sciences). Fab fragments were generated by standard
papain digestion, with released Fc and undigested IgG removed by Protein
A chromatography, and remaining Fab fragments further purified by MonoQ
ion-exchange chromatography. For crystallization, purified MARV GPcl was
mixed with excess Fab MR78 for 2 days at 4C. Complexes were separated
from unbound Fab via S200 SEC. Crystals were grown by hanging-drop va-
por diffusion at 20C using 0.8 ml protein (13.0 mg ml1, in 20 mM Tris-HCl
[pH 8.0], 100 mM NaCl) and 0.8 ml of mother liquor (100 mM NaCl, 50 mM
MES [pH 6.5], 13 % PEG 4000, 0.5 % ethyl acetate). These crystals were cry-
oprotected with 25% glycerol plus mother liquor before flash cooling in liquid
nitrogen. One crystal diffracted to a resolution of 3.6 A˚. EBOV GPcl was com-
plexed with Fabs KZ52 and MR78 and crystallized using hanging-drop vapor
diffusion at 20C with 1.0 ml of protein (6 mg/ml, 150 mM NaCl, 10 mM Tris
[pH 7.5]) and 1.0 ml of mother liquor (100 mM NaAcetate [pH 4.6], 200 mM
NH4SO4, 10% PEG 3350, 2% PEG 400). The crystals were then cryopro-
tected by washing in 100 mM NaAcetate [pH 4.6], 200 mM NH4SO4, 12%
PEG 3350, 10% PEG 400, 10% ethylene glycol. Only diffraction to 8 A˚
was obtained, but this data permitted molecular replacement using Phaser
(McCoy et al., 2007) and EBOV GP and KZ52 (Lee et al., 2008) as search
models.
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Figure 5. MARV and EBOV Present Different Surfaces for Antibody Recognition
(A and B) Molecular envelopes of mucin-containing MARV and EBOV GP ectodomains determined by SAXS. Rendered Gaussian distributions of molecular
envelopes are illustrated in light gray, with ribbon models of the crystallized MARV GPcl and EBOV GPDmuc trimers to scale and overlaid for comparison. The
trimers are illustrated as ribbons. Note that the glycan cap was removed fromMARVGP used in crystallization in order to improve diffraction but was contained in
the complete MARV GP used for SAXS. The glycan cap did not inhibit diffraction of EBOV GP and is included in the EBOV GP crystal structure. MARV GPcl is
colored in purple (GP1) and gray (GP2). EBOV GPDmuc is colored blue (GP1), white blue (GP1 glycan cap), and gray (GP2). MARV GP is drawn in two possible
orientations because definitive placement of polypeptide is challenging at this resolution. In either orientation however, the mucin-like domains of MARV project
sideways, equatorially or downward from the core of GP. In MARV, the mucin-like domain is attached to both GP1 and GP2. By contrast, in EBOV, the mucin-like
domain is attached solely to GP1, there is no anchor at the base. Both these SAXS experiments and previous electron tomography (Tran et al., 2014) agree on the
upward projection of the mucin-like domains in EBOV. See also Figure S5.
(C) Differing positions of the mucin-like domains between MARV and EBOV may lead to elicitation of different types of antibodies. The lower position and GP2
anchor of the mucin-like domain of MARV may better mask the base of GP but expose its upper surfaces, allowing antibodies like mAb MR78 to be elicited. The
upward projection of the EBOV mucin-like domain and absence of any GP2 anchor, appear to better mask upper surfaces, but expose the base, allowing
antibodies such as KZ52 (Lee et al., 2008), 2G4, 4G7 (Murin et al., 2014), and 16F6 (directed against Sudan ebolavirus [Dias et al., 2011; Bale et al., 2012]) to be
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ABSTRACT  29 
 30 
Recent experiments suggest that some glycoprotein (GP) specific monoclonal antibodies (mAbs) can protect 31 
experimental animals against the filovirus Ebola virus (EBOV). There is a need for isolation of mAbs capable of 32 
neutralizing multiple filoviruses. Antibody neutralization assays for filoviruses frequently use surrogate systems 33 
such as the rhabdovirus vesicular stomatitis Indiana virus (VSV), lentiviruses or gammaretroviruses with their 34 
envelope proteins replaced with EBOV glycoprotein (GP) or pseudotyped with EBOV GP. It is optimal for both 35 
screening and in-depth characterization of newly identified neutralizing mAbs to generate recombinant 36 
filoviruses that express a reporter fluorescent protein in order to more easily monitor and quantify the infection. 37 
Our study showed that unlike neutralization-sensitive chimeric VSV, authentic  filoviruses are highly resistant to 38 
neutralization by mAbs. We used reverse genetics techniques to replace EBOV GP with its counterpart from 39 
the heterologous filoviruses Bundibugyo virus (BDBV), Sudan virus (SUDV), and even Marburg virus (MARV) 40 
and Lloviu virus (LLOV), which belong to the heterologous genera in the filovirus family. This work resulted in 41 
generation of multiple chimeric filoviruses, demonstrating the ability of filoviruses to tolerate swapping of the 42 
envelope protein. The sensitivity of chimeric filoviruses to neutralizing mAbs was similar to that of authentic 43 
biologically derived filoviruses with the same GP. Moreover, disabling the expression of the secreted GP (sGP) 44 
resulted in an increased susceptibility of an engineered virus to the BDBV52 mAb isolated from a BDBV 45 
survivor, suggesting a role for sGP in evasion of antibody neutralization in the context of a human filovirus 46 
infection.    47 
  48 
 3
IMPORTANCE  49 
 50 
The study demonstrated that chimeric rhabdoviruses in which G protein is replaced with filovirus GP, widely 51 
used as surrogate targets for characterization of filovirus neutralizing antibodies, do not accurately predict the 52 
ability of antibodies to neutralize authentic filoviruses, which appeared to be resistant to neutralization. 53 
However, a recombinant EBOV expressing a fluorescent protein tolerated swapping of GP with counterparts 54 
from heterologous filoviruses, allowing high-throughput screening of B cell lines to isolate mAbs of any filovirus 55 
specificity. Human mAb BDBV52, that was isolated from a survivor of BDBV infection, was capable of partially 56 
neutralizing a chimeric EBOV carrying BDBV GP in which expression of sGP was disabled. In contrast, the 57 
parental virus expressing sGP was resistant to the mAb. Thus, the ability of filoviruses to tolerate swapping of 58 
GP can be used for identification of neutralizing mAbs specific to any filovirus and for characterization of mAb 59 
specificity and mechanism of action. 60 
 61 
  62 
 4
INTRODUCTION 63 
 64 
The family Filoviridae is composed of the genus Ebolavirus, which includes Ebola (EBOV), Sudan (SUDV), Taï 65 
Forest (TAFV), Reston (RESTV), and Bundibugyo (BDBV) viruses, the genus Marburgvirus, which includes 66 
Marburg (MARV) and Ravn (RAVV) viruses, and the putative genus Cuevavirus, which includes Lloviu virus 67 
(LLOV) (1). All of these viruses, with the exception of TAFV, RESTV and LLOV, are known to cause disease 68 
outbreaks in humans with high case fatality (2, 3). The recent outbreak of EBOV disease in Western Africa (4) 69 
demonstrated that filoviruses can cause large epidemics. In addition, identification of the “new” filoviruses 70 
BDBV and LLOV was reported as recently as in 2007 or 2011, respectively (5, 6), suggesting the possibility of 71 
emergence or identification of previously unknown filoviruses. 72 
 73 
For decades, no treatment demonstrated protective efficacy against filoviruses in the non-human primate 74 
model, which is considered the best model of filovirus disease predictive for a similar effect in humans. 75 
However, recently developed treatments based on polyclonal (7) or monoclonal antibodies (mAbs) (8-10) have 76 
shown impressive levels of efficacy in non-human primates. Development of mAb-based treatments and 77 
understanding of mechanisms of antibody neutralization of RNA viruses can be greatly facilitated by 78 
development of reverse genetics systems, which allow recovery of recombinant viruses from DNA copies of 79 
their genomes or antigenomes. The advantages of such systems for work with polyclonal or monoclonal Abs 80 
include the possibility of introduction of mutations in genes encoding major protective antigens, such as the 81 
glycoprotein (GP), which is the sole envelope protein of filoviruses. GP is expressed as a precursor protein that 82 
is cleaved post-translationally to GP1 and GP2 subunits, and the mature integral membrane protein is present 83 
on the surface of viral particles as two disulfide-linked subunits (11, 12). The GP gene of ebolaviruses encodes 84 
two proteins: the full-length GP, which is a part of the viral particles and a type I transmembrane protein, and 85 
the secreted GP (sGP). It also encodes a much less abundant small soluble GP (ssGP). The GP gene does 86 
not have a continuous open reading frame, and thus the expression of full-length GP and ssGP result from 87 
transcriptional editing. In contrast, sGP does not require transcriptional editing, and has an identical N-terminal 88 
part of GP, but a unique C-terminal part (13-15). Unlike ebolaviruses, marburgvirus GP genes have a 89 
 5
continuous open reading frame that encodes full-length GP but not sGP (16, 17). Another advantage of 90 
reverse genetics techniques is the possibility to engineer viruses expressing green fluorescent protein (GFP) or 91 
another reporter protein to visualize infection. However, development of reverse genetics systems is very labor 92 
and time consuming and is not always successful. To date, such systems have been developed only for three 93 
filoviruses: EBOV, MARV and RESTV (reviewed in reference (18))), and are not available for the other 94 
filoviruses causing a severe disease, including SUDV, BDBV or RAVV. In the absence of reverse genetics 95 
systems and/or biosafety level 4 (BSL-4) facilities required for work with filoviruses, researchers use various 96 
surrogate systems for characterization of filovirus-specific mAbs or investigation of various steps of filovirus life 97 
cycle involving GP. These systems include chimeric vesicular stomatitis Indiana viruses (VSV) with the G 98 
protein replaced with filovirus GP (19-21), and pseudotyped gammaretroviruses (22, 23) and lentiviruses (24-99 
26), which have their respective envelope proteins replaced with a filovirus GP provided in trans. It is generally 100 
assumed that these surrogate systems can be used to accurately characterize neutralizing properties of 101 
filovirus polyclonal or monoclonal Abs.  102 
 103 
In the present study, we used the EBOV reverse genetics system to show that the virus can tolerate 104 
replacement of GP with its counterpart not only from heterologous ebolaviruses, but remarkably also from a 105 
more distantly related marburgvirus and cuevavirus. The generated chimeric viruses were used, in parallel, 106 
with chimeric VSVs, for characterization of filovirus-reactive mAbs isolated from human survivors of previous 107 
BDBV or MARV infection. We show here that filoviruses, including the chimeric filoviruses, are more resistant 108 
to neutralization by many mAbs, when compared to their chimeric VSV counterparts. These data suggest that 109 
chimeric VSVs may not be optimal for accurate quantification of neutralizing activity of filovirus antibodies. We 110 
also demonstrate the development of a high-throughput system suitable for functional screening and analysis 111 
of large panels of filovirus mAbs. Finally, we used the chimeric viruses to demonstrate that BDBV sGP serves 112 
as a decoy for a BDBV GP-specific antibody isolated from a BDBV survivor. 113 
 114 
 115 
 116 
 6
MATERIALS AND METHODS 117 
 118 
Construction of chimeric EBOV viruses and biological filovirus isolates used in the study. To construct 119 
the full-length genome cDNA of EBOV with its GP swapped with that of BDBV, SUDV or MARV, we used the 120 
plasmid carrying the genomic RNA of wild-type EBOV (pEBOwt) and its modified version with the 121 
transcriptional cassette encoding enhanced green fluorescent protein added between the NP and VP35 genes 122 
(pEBO-eGFP) (27), which were provided by Dr. Jonathan Towner and Dr. Stuart Nichol (CDC). First, the 123 
pEBOwtΔBamHI-SbfI,AscI-PspOMI plasmid subclone was generated from the pEBOwt construct by 124 
consecutive two-step removal of BamHI-SbfI and AscI-PspOMI fragments; after pEBOwt digestion with the 125 
each pair of restriction endonucleases, the residual vector part was treated with the Klenow fragment of DNA 126 
polymerase I and self-ligated. The resulting subclone was subjected to mutagenesis using the QuikChange 127 
site-directed mutagenesis kit (Stratagene, La Jolla, CA) for introduction of NheI and XhoI restriction 128 
endonuclease sites flanking the GP open reading frame (ORF). Additionally, the similar pEBOwtΔBamHI-129 
SbfI,AscI-PspOMI subclone was generated with BamHI restriction endonuclease site instead of XhoI 130 
downstream of the EBOV GP ectodomain encoding region corresponding to the genomic sequence of EBOV 131 
Ebola virus/H.sapiens-tc/COD/1976/Yambuku-Mayinga, nucleotides 6039-7987 (GenBank accession number 132 
NC_002549.1). For cloning of GP ORF of MARV, BDBV and SUDV, Vero-E6 cells were infected with Marburg 133 
virus/H.sapiens-tc/UGA/2007/Kitaka-200702854, Bundibugyo virus/H.sapiens-tc/UGA/200706291/Butalya-134 
811249, or Sudan virus/H.sapiens-tc/UGA/2000/Gulu-200011676, and subjected to RNA isolation following cell 135 
lysis in TRIzol reagent (LifeTechnologies, Carlsbad, CA). Total RNA was reverse-transcribed, and PCR 136 
fragments corresponding to GP ORFs of three different filovirus species were generated and cloned into 137 
pUC19 vector by SphI and XmaI sites. In order to perform subsequent cloning steps toward generation of full-138 
length clones, the following restriction endonuclease sites were knocked down by introduction of silent 139 
mutations: BamHI and XhoI in MARV GP ORF, ApaI and NheI in BDBV GP ORF, and ApaI, SacI and XhoI in 140 
SUDV GP ORF. To disable the expression of sGP, the GP gene transcriptional editing site was modified from 141 
AAAAAAA to AAGAAGAA (antigenome DNA sense) by site-directed mutagenesis, resulting in a plasmid 142 
designated pUC19-BDBV-GPΔsGP. Next, the resulting pUC19 clones were used to PCR amplify BDBV GP 143 
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ORF with the following primers: direct, 144 
ACAGTAGCTAGCAACACAATGGTTACATCAGGAATTCTACAATTGCCC, reverse, 145 
ACAGTACTCGAGAAAAATTAGAGTAGAAATTTGCAAATACACAGCAGTGC;  146 
SUDV GP was amplified with the primers: direct, ACAGTAGCTAGCAACACAATGGGGGGTCTTAGCCTACT, 147 
reverse, ACAGTACTCGAGAAAAATCAGCAAAGCAGCTTGCAAAC; 148 
MARV GP was amplified with the primers: direct, 149 
TCTAGCAGGCTAGCAACACAATGAGGACTACATGCTTCTT, reverse, 150 
TCTAGCAGCTCGAGAAAAACTATCCAATATATTTAGTAAAGATACGACAA; and MARV GP ectodomain was 151 
amplified with the primers: direct, TCTAGCAGGCTAGCAACACAATGAGGACTACATGCTTCTT, and reverse, 152 
AGTCACGTGGATCCAGTCGGATGTCCACCATTTACCACC (NheI, XhoI or BamHI restriction endonuclease 153 
sites are underlined, the start of GP ORF direct sequence and the end of GP ORF or GP ectodomain 154 
complementary sequences are italicized). The PCR products were used to replace EBOV GP ORF in 155 
pEBOwtΔBamHI-SbfI,AscI-PspOMI subclone with ORF for GP of BDBV, SUDV or MARV by NheI and XhoI 156 
sites, or for the replacement of EBOV GP ectodomain encoding region with that of MARV by NheI and BamHI 157 
sites, respectively. To generate the final full-length constructs, the ApaI-SacI fragments of the generated 158 
subclones were transferred to pEBO-eGFP plasmid for substitution of the existing EBOV GP ORF with an ORF 159 
encoding the GP of BDBV, SUDV, or MARV, or to replace the EBOV GP ectodomain with a MARV GP 160 
ectodomain. For the construction of EBOV full-length clone with its GP replaced by that of LLOV, we first 161 
changed editing site in LLOV GP ORF from 8A to 7A (antigenome DNA sense) by mutagenizing pBsII SK (+)-162 
LLOV GP plasmid (provided by Dr. Ayato Takada, reference (28)) to make it identical to the original LLOV 163 
sequence (6). Also, two existing KpnI restriction endonuclease sites in LLOV GP ORF were knocked down by 164 
introduction of silent mutations. The resulting LLOV GP ORF cDNA was PCR-amplified using the following 165 
primers: direct, TCTAGCAGGCTAGCAACACAATGGTGCCCACCTACCCGTA, and reverse, 166 
TCTAGCAGCTCGAGAAAAATCATCGTGTTATTCTGCACA (NheI or XhoI restriction endonuclease sites are 167 
underlined, the start of LLOV GP ORF direct sequence and the end of LLOV GP ORF complementary 168 
sequence are italicized), and cloned into pEBOwtΔBamHI-SbfI,AscI-PspOMI plasmid. The ApaI-KpnI fragment 169 
from the resulting subclone was transferred to the pEBO-eGFP full-length clone with one of its KpnI sites (in 170 
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polymerase L ORF, nucleotides 14292-14297 in EBOV genome) disabled by introduction of a silent mutation 171 
for substitution of the existing ORF of EBOV GP with an ORF encoding the GP of LLOV. The chimeric viruses 172 
Ebola virus/H.sapiens-rec/COD/1976/Yambuku-Mayinga-eGFP-BDBV_GP (hereafter referred as 173 
EBOV/BDBV-GP), its derivative Ebola virus/H.sapiens-rec/COD/1976/Yambuku-Mayinga-eGFP-174 
BDBV_GPdelta_sGP (referred as EBOV/BDBV-GPΔsGP) that is deficient in the production of sGP, Ebola 175 
virus/H.sapiens-rec/COD/1976/Yambuku-Mayinga-eGFP-SUDV_GP (referred as EBOV/SUDV-GP), Ebola 176 
virus/H.sapiens-rec/COD/1976/Yambuku-Mayinga-eGFP-MARV_GP (referred as EBOV/MARV-GP), Ebola 177 
virus/H.sapiens-rec/COD/1976/Yambuku-Mayinga-eGFP-MARV_GPed (referred as EBOV/MARV-GPed), and 178 
Ebola virus/H.sapiens-rec/COD/1976/Yambuku-Mayinga-eGFP-LLOV_GP (referred as EBOV/LLOV-GP) were 179 
rescued as previously described (29) and propagated by two passages in Vero-E6 cell culture monolayers. 180 
Genomic RNA of all recovered viruses was sequenced using Illumina HiSeq 1000 sequencing system as 181 
previously described (30) and the 3’ and 5’ termini were sequenced by RNA circularization as previously 182 
described (31). The sequences were deposited in GenBank, accession numbers KU174137-KU174142. Work 183 
with the filovirus full-length clones was performed in a laboratory approved by the NIH Recombinant DNA 184 
Advisory Committee. Generation of the chimeric viruses was approved by the UTMB Institutional Biosafety 185 
Committee. Recovery of the recombinant filoviruses and all work with filoviruses were performed in the BSL-4 186 
facility of the Galveston National Laboratory. The growth kinetics experiments on chimeric EBOV viruses were 187 
performed as previously described (29). BDBV and MARV were provided originally by the Special Pathogens 188 
Branch of the U.S. Centers for Disease Control and Prevention (CDC) and deposited at the World Reference 189 
Center of Emerging Viruses and Arboviruses (WRCEVA) housed at the Galveston National Laboratory, the 190 
University of Texas Medical Branch at Galveston. BDBV isolate 200706291 Uganda was isolated originally 191 
from the serum of a patient during the first recorded outbreak caused by this virus (5), and passaged three 192 
times in Vero-E6 cells. MARV isolate 200702854 Uganda was isolated originally from a subject designated 193 
“Patient A” during the outbreak in Uganda in 2007 (32, 33) and underwent four passages in Vero-E6 cells. 194 
 195 
Immunostaining of chimeric EBOV plaques. Vero-E6 cell culture monolayers were inoculated with dilutions 196 
of chimeric EBOV constructs, covered with 0.9% methylcellulose (Sigma-Aldrich, Saint Louis, MO), and 197 
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incubated at 37°C. At day 6 after infection, the overlay was removed, cells were fixed with formalin for 24 198 
hours, taken out of BSL-4, and blocked in 5% skim milk in phosphate buffered saline (PBS) containing 0.1% 199 
Tween-20 (Sigma-Aldrich) for one hour. Next, monolayers were incubated for 1 hour at 37°C with the selected 200 
mAbs (1 µg/ml) in solution, or with 1:1,000 dilution of rabbit polyclonal serum raised against EBOV isolate 201 
Mayinga or MARV isolate Musoke, and then washed three times with blocking solution. Thereafter, the 202 
respective goat anti-human or goat anti-rabbit IgG antibodies conjugated with horse radish peroxidase (KPL, 203 
Gaithersburg, MD) were added at 1:1,000 dilution in blocking buffer, and monolayers were incubated for one 204 
hour at 37°C and washed three times with PBS. Virus plaques were visualized by staining with the 4CN two-205 
component peroxidase substrate system (KPL, Gaithersburg, MD).   206 
 207 
Chimeric VSV with filovirus GP proteins. VSV/MARV-GP was constructed and recovered as previously 208 
described (34). VSV/BDBV-GP was provided by Dr. Thomas Geisbert (University of Texas Medical Branch at 209 
Galveston, Galveston, Texas), and VSV/EBOV-GP (35) was provided by Dr. Heinz Feldmann (Rocky Mountain 210 
Laboratories, National Institutes of Health, Hamilton, Montana).  211 
 212 
Plaque reduction assay. For plaque-based neutralization assays, 150 PFUs of filoviruses or chimeric VSVs 213 
were pre-incubated with varying concentrations of mAbs in 100 µl volume for 1 hour at 37°C in triplicate and 214 
placed on monolayers of Vero-E6 cells in 24-well plates. After adsorption of virus for 1 hour at 37°C, cells were 215 
overlaid with 1 ml of 0.9% methylcellulose in MEM medium containing 10% of fetal bovine serum (Quality 216 
Biologicals, Gaithersburg, MD) and 0.1% of gentamicin sulfate (Mediatech, Manassas, VA) and incubated at 217 
37°C. Chimeric VSV plaques were visualized by staining monolayers with 0.25% crystal violet solution in 218 
formalin on day 3, 4 or 5 after infection, and filovirus plaques were immunostained with rabbit anti-EBOV 219 
polyclonal serum on day 6 after infection as described above. Plaques were counted, and neutralization curves 220 
were plotted as percentages of reduction of plaque numbers as compared to mock-neutralized virus. 221 
 222 
High-throughput screening neutralization assay. Four hundred PFUs of recombinant EBOV expressing 223 
eGFP or EBOV/BDBV-GP were incubated with varying concentrations of mAbs in black polystyrene 96-well 224 
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plates with clear bottoms (Corning, NY) for 1 hour at 37°C in MEM medium containing 10% fetal bovine serum 225 
and 0.1% of gentamicin sulfate. Next, 4 x 104 Vero-E6 cells in the same medium were added to the virus-226 
antibody mixtures and incubated at 37°C for 4 days. The fluorescence intensity of infected cells at 488 nm 227 
wave length was measured in triplicate using the 2104 EnVision multilabel reader (PerkinElmer, Waltham, 228 
MA). The signal readout was normalized to virus control aliquots with no mAb added and presented as the 229 
percentage of neutralization.       230 
 231 
Binding of antibodies to the recombinant GPs of various filovirus species. Soluble forms of GP of BDBV, 232 
EBOV, SUDV, MARV or sGP of BDBV, EBOV, SUDV were coated overnight onto 384-well plates (Thermo 233 
Scientific Nunc, Waltham, MA) at 1 μg/ml in PBS. Plates were blocked with 25 µl of blocking solution/well for 234 
1 hour. Blocking solution consisted of 10 g powdered milk (Bio-Rad, Hercules, CA), 10 ml of goat serum 235 
(Gibco, Waltham, MA), 100 ml of 10x PBS, and 0.5 ml of Tween-20 mixed to a 1 l final volume with distilled 236 
water. Purified antibodies were applied to the plates at a concentration 10 μg/ml in blocking solution for 2 hr. 237 
The presence of antibodies bound to the GP and sGP proteins was determined using goat anti-human IgG 238 
alkaline phosphatase conjugate (Meridian Life Science, Memphis, TN) and p-nitrophenol phosphate substrate 239 
tablets (Sigma-Aldrich), with optical density read at 405 nm after 1 hour. 240 
 241 
 242 
 243 
RESULTS   244 
 245 
Filoviruses are resistant to antibody neutralization compared to chimeric VSVs. We used human Abs to 246 
compare their ability to neutralize filoviruses EBOV or MARV on the one hand or recombinant VSVs 247 
expressing the same filovirus GPs on the other hand (Fig. 1A). We first tested a recombinant form of the 248 
EBOV-specific antibody KZ52, isolated from a phage display library constructed from antibody genes from a 249 
human survivor of natural EBOV infection (36), which is protective in the guinea pig model of EBOV infection 250 
(37). The antibody appeared to neutralize authentic EBOV less efficiently than VSV/EBOV-GP. Next, 251 
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antibodies BDBV43 and BDBV52, isolated from a human survivor of BDBV infection (38) were tested. Again, 252 
authentic BDBV was less efficiently neutralized than VSV/BDBV-GP. Moreover, BDBV52 did not neutralize 253 
authentic BDBV at any concentration tested (up to 200 µg/ml), but effectively neutralized VSV/BDBV-GP. 254 
Analysis of neutralization by additional BDBV antibodies from the survivor suggested a similar pattern, i.e., less 255 
efficient neutralization of authentic as compared to VSV/BDBV-GP (data not shown). Analysis of the antibody 256 
MR201 that we isolated previously from a MARV survivor (34) also demonstrated a great difference between 257 
the neutralization of authentic MARV and VSV/MARV-GP. For example, 50 µg/ml of MR201 neutralized only 258 
7% of MARV, but as much as 94% of VSV/MARV-GP. Taken together, these data suggest that authentic 259 
filoviruses generally are more resistant to neutralization by mAbs compared to chimeric VSVs, which can, as a 260 
result of these findings, produce greatly exaggerated data on mAb neutralization.  261 
 262 
Replacement of the EBOV GP with its counterpart from heterologous ebolaviruses results in viable 263 
chimeric viruses. Infection of cells with the recombinant EBOV expressing eGFP from an added gene results 264 
in a bright eGFP fluorescence in infected cells starting at 36-48 hrs post-infection (27), which opens the 265 
possibility for use of this virus for development of a high-throughput screening of mAbs. As noted above, the 266 
genus Ebolavirus includes five virus species whose representatives EBOV, BDBV and SUDV cause a severe 267 
disease in humans. We therefore attempted to generate recombinant replication-competent EBOV-derived 268 
viruses in which the GP protein was exchanged with that of BDBV or SUDV. We replaced the ORF of EBOV 269 
GP in the EBOV full-length clone with that of BDBV or SUDV and used the plasmids in virus recovery 270 
experiments, as previously described (27, 29) (Fig. 2A,D). Indeed, the experiments resulted in recovery of 271 
viable chimeric viruses expressing eGFP: EBOV/BDBV-GP and EBOV/SUDV-GP (Fig. 3A); sequencing 272 
analysis revealed no adventitious mutations in the GP gene or elsewhere in the genome. We then compared 273 
the multi-step growth kinetics of the recombinant viruses (Fig. 3B). Contrary to our expectations, EBOV/BDBV-274 
GP replicated slightly faster than EBOV, and EBOV/SUDV-GP replicated much faster than EBOV (Fig. 3B). 275 
For example, on day 1 or 2, the respective titers of EBOV/SUDV-GP were greater than those of EBOV by 2.5 276 
or 1.3 log10, although the final viral titers of all viruses were comparable. These data suggest that EBOV can 277 
tolerate swapping of GP with its counterparts from heterologous ebolaviruses. 278 
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 279 
EBOV can tolerate swapping of the glycoprotein with that of MARV and LLOV. The two members of 280 
genus Marburgvirus, MARV and RAVV, have only partial antigenic relatedness (39), further suggesting the 281 
need for development of a single filovirus platform capable of expressing the GPs from individual 282 
marburgviruses for accurate characterization of antibodies. Filovirus GP is a type I transmembrane protein (16, 283 
17), which interacts with VP40 (40); its transmembrane domain affects conformation of the protein (41) and is 284 
required for incorporation in viral particles (42). Since the MARV GP cytoplasmic tail (amino acids RIFTKVIG) 285 
has no similarity to its EBOV GP counterpart (amino acids KFVF), and the transmembrane domains exhibit 286 
only a limited similarity (16, 43), the compatibility between MARV GP with EBOV particles was difficult to 287 
predict. We therefore initially attempted to replace the EBOV GP ectodomain only (which represents the GP 288 
lacking the cytoplasmic tail and the highly conserved transmembrane domain) with that of MARV (Fig. 2B,D). 289 
As a result, a fully viable virus designated EBOV/MARV-GPed was recovered (Fig. 3A), which replicated at a 290 
rate similar to that of EBOV (Fig. 3B). Since EBOV easily tolerated swapping of the GP ectodomain, we next 291 
attempted to replace the whole GP with that of MARV (Fig. 2B). This approach also resulted in recovery of a 292 
viable virus (Fig. 3A) that replicated at a level similar to that of EBOV (Fig. 3B), suggesting that the interaction 293 
of the GP cytoplasmic tail with VP40 (the matrix protein) may be not highly specific. We also attempted to 294 
replace the whole GP with its counterpart from cuevavirus LLOV, whose RNA was identified in a dead bat in 295 
Spain (6) but the virus was never isolated. This experiment resulted in recovery of a viable virus designated 296 
EBOV/LLOV-GP (Fig. 2A,C), whose replication was slightly reduced as compared to EBOV (Fig. 3B). Again, 297 
adventitious mutations were not detected in GP or elsewhere in the genome of EBOV/MARV-GP, 298 
EBOV/MARV-GPed and EBOV/LLOV-GP. Thus, EBOV can tolerate swapping GP with its counterparts not 299 
only from heterologous ebolaviruses, but also from more distantly related and distinct marburgvirus and 300 
cuevavirus.  301 
 302 
The generated chimeric filoviruses produce plaques, which can be stained by mAbs specific to their 303 
glycoproteins. We next tested the ability of mAbs isolated from filovirus survivors to bind to plaques formed by 304 
the constructed viruses. We tested the binding of mAbs BDBV43 or BDBV52 recently isolated from a survivor 305 
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of BDBV infection (A.I.F. et al., unpublished data) and MR78, MR235 or MR246 from a survivor of MARV 306 
infection (34) (Fig. 4A). The comparison was performed in parallel using rabbit hyperimmune serum against 307 
EBOV or MARV. We found that rabbit EBOV-specific immune serum was able to stain plaques not only for 308 
EBOV, but also for all constructs generated, including EBOV/MARV-GP and EBOV/MARV-GPed. This 309 
observation can be explained by the contribution of binding of antibodies in the immune serum that recognize 310 
internal EBOV proteins, such as NP and VP40. Interestingly, BDBV43 stained the three ebolavirus GP-based 311 
constructs with varying intensity and also EBOV/MARV-GP and EBOV/MARV-GPed, although with a low 312 
intensity, while BDBV52 stained EBOV/BDBV-GP and weakly EBOV/MARV-GP and EBOV/MARV-GPed, but 313 
not EBOV and EBOV/SUDV-GP. These data suggest the two BDBV mAbs interact with epitopes that are 314 
partially conserved across all or some members of the family Filoviridae. In contrast, MARV polyclonal 315 
antibodies stained plaques of EBOV/MARV-GP or EBOV/MARV-GPed but not the ebolavirus constructs. 316 
Again, similarly to polyclonal MARV antibodies, the three MARV mAbs stained only MARV, but not the 317 
ebolavirus GP-based constructs. The GP proteins of EBOV and MARV have considerable amino acid similarity 318 
(44), with several stretches of four or more identical amino acids located in the receptor-binding region of GP1 319 
and heptad repeats 1 and 2 in GP2 (based on comparison of EBOV isolate Mayinga and MARV isolate 320 
Uganda, Fig. 4B). In contrast, the mucin-like domains of EBOV and MARV have almost no sequence similarity. 321 
Therefore, the two BDBV mAbs react with conserved epitopes, while the two MARV-specific mAbs and the 322 
polyclonal MARV Abs are directed against more variable epitopes. These data demonstrate that chimeric 323 
filovirus constructs are useful in the characterization of antibodies specific for any filovirus species.  324 
 325 
Chimeric filoviruses are neutralized according to the GP ectodomain specificity of mAbs. To determine 326 
the binding specificities of the mAbs used in the study, we tested a panel of mAbs for their ability to bind a 327 
panel of recombinant filovirus GP or sGP proteins (Fig. 5A). All mAbs tested, with the exception of BDBV43, 328 
bound exclusively to full-length GP of the targeted filoviruses, and all of the mAbs except BDBV43 and 329 
BDBV52 did not detectably bind to sGP. In contrast, BDBV43 bound to both GP and sGP of all three 330 
ebolaviruses: EBOV, BDBV and SUDV, but not to MARV, while BDBV52 bound to both GP and sGP of BDBV 331 
only. We next tested the ability of selected mAbs to neutralize EBOV, BDBV, MARV, EBOV/MARV-GP or 332 
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EBOV/MARV-GPed (Fig. 5B). As expected, EBOV was neutralized effectively by mAb KZ52 and, to a lesser 333 
degree, by BDBV43, but not by BDBV41 or BDBV52. BDBV was neutralized by BDBV41 and BDBV43, but not 334 
by BDBV52, despite the fact that this mAb binds to BDBV GP. MARV and the chimeric viruses carrying MARV 335 
GP or its ectodomain were neutralized by MR78, but not the other mAbs. Thus, the GP ectodomain 336 
specificities of chimeric filoviruses determine the neutralization efficiencies of antibodies, which do not 337 
necessary correlate with the protein binding data. These data suggest that chimeric filoviruses are useful for 338 
highly specific antibody neutralization tests.  339 
 340 
Use of the chimeric filoviruses for a high-throughput screening (HTS) assay of mAbs. Neutralization 341 
tests of large panels of mAbs or multiple serum samples against multiple filovirus species by conventional 342 
plaque reduction assay, which must be performed in BSL-4 biocontainment, is laborious. We therefore tested 343 
the generated chimeric viruses as targets for a HTS neutralization assay in which eGFP fluorescence provided 344 
a measure of remaining infectivity and thus a measure of antibody neutralization. In preliminary experiments, 345 
we performed test neutralizations of varying doses of EBOV/BDBV-GP ranging from 4 to 4,000 PFUs with 346 
varying concentrations of mAb BDBV41. Following a one hour incubation, virus-antibody aliquots were mixed 347 
with varying amounts of Vero-E6 cells ranging from 2,500 to 40,000, and then added as a suspension to 348 
individual wells of 96-well plates. eGFP fluorescence was read on days 2, 3, 4, 5 and 6. As an example of our 349 
preliminary data, infection of 40,000 cells with 150 or 300 PFUs resulted in a two-fold difference in the signal 350 
on day 4 (Fig. 6A). In another example, residual infectivity in Vero-E6 cells was measured in a broad range of 351 
various concentrations of mAb BDBV41 mixed with EBOV/BDBV-GP in triple aliquots. Quantitation of eGFP 352 
signal on a fluorescence plate reader on day 4 post infection demonstrated that the level of eGFP signal was 353 
inversely proportional to the amount of mAb added (Fig. 6B). Interestingly, based on visual examination of 354 
plates, this antibody inhibited or prevented spread of the viral infection, but did not completely eliminate initial 355 
infectious foci even at the greatest concentration tested, 200 µg/ml (Fig. 6C). Based on the optimization 356 
experiments, we found that inoculation of 40,000 cells with 400 PFU (MOI of 0.01) of EBOV/BDBV-GP gave 357 
the greatest possible dynamic range of the signal at various antibody concentrations (data not shown). Next, 358 
we used the optimized assay conditions to determine neutralization potency of BDBV41 in comparison with the 359 
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classic plaque reduction assay with BDBV, VSV/BDBV-GP or EBOV/BDBV-GP (Fig. 6D). As in the case of 360 
KZ52, MR201 and BDBV43 (Fig. 1), VSV/BDBV-GP was more easily neutralized by BDBV41 in classic plaque 361 
reduction assays. Use of EBOV/BDBV-GP instead of BDBV for the plaque reduction assay resulted in a similar 362 
neutralization curve, and use of EBOV/BDBV-GP in a HTS assay also resulted in a neutralization curve similar 363 
to that generated by plaque reduction assays with BDBV or EBOV/BDBV-GP. Thus, chimeric filoviruses 364 
expressing eGFP can be used as a substitute for their natural counterparts in plaque reduction assays as well 365 
as being used in HTS assays to rapidly identify mAbs neutralizing individual filovirus species.  366 
 367 
The sGP protein prevents virus neutralization by BDBV52. We next tested the possibility that the 368 
generated chimeric viruses are useful for a qualitative characterization of mAbs. We previously demonstrated 369 
that the secreted G protein of respiratory syncytial virus, which, similarly to EBOV is a non-segmented negative 370 
strand virus, reduces the efficiency of virus neutralization by serving as a decoy for neutralizing antibodies (45). 371 
More recently, a similar immune evasion mechanism was demonstrated for EBOV sGP (26). However, these 372 
studies involved mouse polyclonal antibodies, and the BDBV sGP study involved a chimeric VSV expressing 373 
EBOV GP, and therefore, the importance of this mechanism for pathogenesis of human disease remained 374 
unknown. Data presented here show that BDBV52 bound to both BDBV sGP and GP (Fig. 5A). We 375 
hypothesized that sGP serves as a decoy for BDBV52 and antibodies with similar epitope specificities, thereby 376 
preventing their ability to effectively neutralize BDBV. To test the hypothesis, we modified the GP gene of 377 
EBOV/BDBV-GP cDNA to disable the expression of sGP by mutating the transcription-editing site from 378 
UUUUUUU to UUCUUCUU (negative-sense RNA strand). As a result, the modified GP gene had the 379 
continuous open reading frame encoding GP only. The resulting virus designated EBOV/BDBV-GPΔsGP was 380 
recovered and sequencing data confirmed the stability of the mutation and lack of any adventitious mutations 381 
in the genome (data not shown). sGP is not required for viral replication in cultured cells . To determine if 382 
disabling of expression of sGP makes the virus more sensitive to neutralization by BDBV52, we compared 383 
susceptibility of the two viruses to the antibody. We found that while EBOV/BDBV-GP was completely resistant 384 
to the antibody, EBOV/BDBV-GPΔsGP was partially neutralized at the highest antibody concentration tested, 385 
200 µg/ml (Fig. 7A), suggesting that BDBV52 binds part of sGP shared with GP (Fig. 7B). These data 386 
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demonstrate for the first time the ability of an ebolavirus to evade neutralization by a naturally-occurring human 387 
mAb isolated from a survivor. 388 
 389 
 390 
DISCUSSION   391 
 392 
The recent devastating outbreak of EBOV in Western Africa (4) demonstrated the pressing need in 393 
development of means of treatments and prophylaxes of infections caused by filoviruses. To date, the greatest 394 
progress has been achieved, which require detailed characterization of monoclonal or polyclonal Abs. Data 395 
presented in this study suggest that surrogate systems such as chimeric VSV expressing filovirus GP may 396 
produce misleading results and therefore appear to be suboptimal for reliable characterization of filovirus 397 
antibodies. The simultaneous circulation of multiple lineages of filoviruses in the same outbreak (46, 47) along 398 
with the emergence of “new” filoviruses (5, 6), and improved methods for isolation of mAbs from survivors (34, 399 
38, 48) along with the utility of their use in therapeutics strongly support the need for improved efficient means 400 
of rapid screening and characterization of large panels of mAbs. While a previous study demonstrated the 401 
possibility of generation of viable ebolaviruses with some genes replaced with counterparts from a 402 
heterologous ebolavirus (49), this study demonstrates that EBOV can easily tolerate exchange of GP not only 403 
from ebolaviruses, but also from more distantly related marburgvirus and cuevavirus. Each of the chimeric 404 
viruses easily tolerated and expressed eGFP from an added gene. Moreover, we show that chimeric filoviruses 405 
are useful for a HTS screening process to identify neutralizing mAbs. In addition, we show that binding to GP 406 
does not necessarily predict the ability of a mAb to neutralize a filovirus, the effect most likely related to a 407 
different conformation of GP in a free form and in a viral particle. Taken together, these results illustrate the 408 
practicality of a quick exchange of GP in EBOV with its counterpart from any circulating filovirus and the use of 409 
the resulting chimeric filoviruses for a rapid analysis of large panels of monoclonal or polyclonal Abs.  410 
 411 
The present study shows that filoviruses are more resistant to neutralization by mAbs than chimeric VSV with 412 
filovirus GP widely used for quantitative analysis of filovirus-specific mAbs. While the exact reason for this 413 
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phenomenon requires additional studies, we hypothesize that it may be related to a much greater length of 414 
filovirus particles, 1,028 nm for EBOV or 876 nm for MARV (50), as compared to 175 nm for VSV (51). The 415 
greater length of filovirus particles suggests a greater number of GP trimers per filovirus particle, which require 416 
a greater number of bound mAbs to abrogate infectivity, as compared to a chimeric VSV. However, this model 417 
cannot explain why for some antibodies, such as KZ52 and BDBV43, the difference between neutralization of a 418 
filovirus and the corresponding chimeric VSV is moderate, while for others, such as BDBV52 and MR201, the 419 
difference is dramatic (Fig. 1A). Most likely, other factors, such as epitope specificity of mAbs, also affect the 420 
observed difference. 421 
 422 
A recently published study demonstrated that sGP interferes with the antibody-mediated neutralization of 423 
EBOV GP-lentivirus pseudotype by antisera from sGP or GP immunized mice (26). The importance of this 424 
mechanism in the context of human filovirus infections remains unclear. In a separate study we isolated 425 
BDBV52, an antibody from a survivor, which binds both the recombinant GP and sGP, but does not neutralize 426 
EBOV/BDBV-GP (38). We hypothesized that this mAb can neutralize virus in the absence of sGP. To test the 427 
hypothesis, we generated the derivative of EBOV/BDBV-GP, which does not express sGP, EBOV/BDBV-428 
GPΔsGP. Indeed, this virus was partially neutralized by BDBV52. These data represent the first demonstration 429 
that ebolavirus survivors have mAbs that bind sGP, which do not neutralize the virus, but can partially 430 
neutralize the virus when sGP expression is disabled. Thus, expression of sGP might help the virus to evade 431 
effective antibody neutralization. Of note, a recent study demonstrated that disabling of the transcriptional 432 
editing site of the GP gene reduces EBOV virulence, but the expression of sGP per se did not affect it (52). We 433 
are unaware of any comparison of sGP expression by the various ebolaviruses; however, the identical GP 434 
transcription editing sites and the high levels of similarity of the polymerase (L) genes of EBOV, BDBV and 435 
SUDV (5, 41) suggest that the levels of expression of sGP by these viruses and by EBOV/BDBV-GP and 436 
EBOV/SUDV-GP are comparable.  437 
 438 
In summary, these data suggest that (i) chimeric VSV expressing filovirus GP may not provide an accurate 439 
prediction of the neutralizing capacity of antibodies, (ii) EBOV can easily tolerate exchange of GP from other 440 
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ebolaviruses or the heterologous marburgvirus or cuevavirus, (iii) swapping the GP genes and expression of a 441 
fluorescent protein from a recombinant filovirus allows for the rapid screening of large number of antibodies 442 
specific for virtually any filovirus, and (iv) sGP serves as a decoy, reducing the effectiveness of virus 443 
neutralization during filovirus human infections. 444 
 445 
 446 
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FIGURE LEGENDS 620 
 621 
Figure 1. Filoviruses are resistant to neutralization by mAbs. Percentage of neutralization of filoviruses 622 
EBOV, BDBV or MARV or the corresponding pseudotyped VSVs by human mAbs isolated from survivors. 623 
Asterisks indicate concentrations of mAbs which gave different (p < 0.05) percentages of neutralization for 624 
filoviruses versus pseudotyped VSVs.  625 
 626 
Figure 2.  Swapping of GP or their ectodomains with their counterparts from heterologous filoviruses 627 
result in viable chimeric filoviruses. A-C. Cloning strategy for generation of EBOV/BDBV-GP, EBOV/SUDV-628 
GP, or EBOV/MARV-GP (A), EBOV/MARV-GPed (B), and EBOV/LLOV-GP (C) full-length clones. D. 629 
Schematic representation of the recombinant eGFP-expressing filovirus constructs. 630 
 631 
Figure 3. Swapping of filovirus GP has only a minimal effect on the efficiency of viral replication. 632 
A. Fluorescent plaques of recombinant wild-type and chimeric filoviruses on day 3 after inoculation of Vero-E6 633 
cell culture monolayers. The micrographs were taken at 10x magnification. B. Growth kinetics of the EBOV 634 
chimeras in Vero-E6 cells inoculated at an MOI of 0.1 PFU/cell. The red curve corresponding to EBOV/BDBV-635 
GP is completely hidden under the blue curve representing EBOV/MARV-GP since these two viruses have 636 
similar growth kinetics. Asterisks or pound symbol show differences (p < 0.05) in viral titers of the chimeric 637 
viruses compared to EBOV on days 1 – 6.  638 
 639 
Figure 4. Plaques of chimeric filoviruses can be immunostained by mAbs specific to ectodomains of 640 
their GP proteins. A. Vero-E6 cell culture monolayers were inoculated with dilutions of the indicated viruses, 641 
covered with 0.9% methylcellulose, and incubated for six days. Viral plaques were immunostained as 642 
described in Materials and Methods. B. Top: the degree of difference between the amino acid sequences of 643 
BDBV, SUDV or MARV GP versus EBOV GP calculated as 1.00-H where H is position homogeneity (53). 644 
Bottom: parts of GP1 and GP2 are designated in colors as follows: SS, signal sequence, RBR, receptor-645 
binding region, GC, glycan cap, MD, mucin-like domain, IFL, internal fusion loop, HR1, heptad repeat 1, HR2, 646 
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heptad repeat 2, MPER, membrane-proximal external region, TM, transmembrane domain, CT, cytoplasmic 647 
tail (adapted from reference (54)). Note that the lengths of the proteins, as indicated in the plots, are greater 648 
than that of BDBV, SUDV, EBOV and MARV GP due to the gaps introduced in the alignments.  649 
 650 
Figure 5. Chimeric filoviruses are neutralized according to GP ectodomain specificity of antibodies. A. 651 
Binding of filovirus-specific human mAbs to recombinant GP or sGP of the indicated filovirus species. B. 652 
Percentages of neutralization of wild type or chimeric filoviruses by various concentrations of human mAbs. 653 
 654 
Figure 6. Use of chimeric filoviruses for high throughput screening (HTS) of mAbs. A. Comparison of the 655 
levels of fluorescence on day 4 after inoculation of cells with 150 or 300 PFU of EBOV/BDBV-GP. B. Levels of 656 
eGFP fluorescence in triplicate Vero-E6 cell suspensions inoculated with 400 PFU of EBOV/BDBV-GP pre-657 
treated with various concentrations of BDBV41. C. UV fluorescent microscopy of Vero-E6 cells inoculated with 658 
400 PFU of EBOV/BDBV-GP pre-treated with various concentrations of BDBV41; mAb concentrations and the 659 
levels of fluorescence for representative wells I – IV are indicated on Panel B. D. Comparison of the 660 
neutralizing activities of BDBV41 in plaque reduction assay with a biological isolate of BDBV, recombinant 661 
EBOV/BDBV-GP filovirus or pseudotyped VSV (VSV/BDBV-GP), and in HTS with EBOV/BDBV-GP chimera. 662 
 663 
Figure 7. The sGP protein reduces virus neutralization by mAb BDBV52. A. Percent neutralization of 664 
EBOV/BDBV-GP or EBOV/BDBV-GPΔsGP by BDBV52 or BDBV41. Disabling of sGP expression makes the 665 
virus partially susceptible to BDBV52. In contrast, both viruses are equally susceptible to BDBV41, suggesting 666 
that the increased susceptibility of EBOV/BDBV-GPΔsGP to BDBV52 is not a result of the altered properties of 667 
viral particles. B. Binding of BDBV52 to both GP and sGP. Parts of GP are designated in colors as in Fig. 4B. 668 
sGP shares with GP the N-terminal part, including SS, RBD, and most of GC, and also has the unique part 669 
(UP) at the C-terminus (13, 14). The most likely location of BDBV52 epitope identified in Flyak et al., 670 
unpublished, is indicated for both sGP and GP1,2. 671 
 672 
 673 
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In Brief
Natural Ebola virus infection causes the
induction of B cells that encode potent
neutralizing human antibodies, which
possess, in some cases, a surprising level
of cross-reactivity for multiple species of
filoviruses. The neutralizing antibody
repertoire recognizes diverse features on
the surface glycoprotein, but most of the
potent antibodies recognize the glycan
cap region.
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Recent studies have suggested that antibody-medi-
ated protection against the Ebolaviruses may be
achievable, but little is known about whether or not
antibodies can confer cross-reactive protection
against viruses belonging to diverse Ebolavirus
species, such as Ebola virus (EBOV), Sudan virus
(SUDV), and Bundibugyo virus (BDBV). We isolated
a large panel of human monoclonal antibodies
(mAbs) against BDBV glycoprotein (GP) using pe-
ripheral blood B cells from survivors of the 2007
BDBV outbreak in Uganda. We determined that a
large proportion of mAbs with potent neutralizing ac-
tivity against BDBV bind to the glycan cap and recog-
nize diverse epitopes within this major antigenic site.
We identified several glycan cap-specific mAbs that
neutralized multiple ebolaviruses, including SUDV,
and a cross-reactive mAb that completely protected
guinea pigs from the lethal challenge with heterolo-
gous EBOV. Our results provide a roadmap to
develop a single antibody-based treatment effective
against multiple Ebolavirus infections.
INTRODUCTION
The genus Ebolavirus, family Filoviridae, contains three viral spe-
cies that are known to cause large deadly disease outbreaks in
Africa: Zaire ebolavirus represented by Ebola virus (EBOV),
Sudan ebolavirus represented by Sudan virus (SUDV), and Bun-392 Cell 164, 392–405, January 28, 2016 ª2016 Elsevier Inc.dibugyo ebolavirus represented by Bundibugyo virus (BDBV).
The most recent EBOV outbreak has caused more than 28,000
cases and more than 11,000 deaths (according to the October
14, 2015, World Health Organization [WHO] Ebola Situation
Report). While there is no FDA-approved treatment for filovirus
infections, several experimental therapeutics against EBOV are
being investigated, including small interfering RNAs (Geisbert
et al., 2010; Thi et al., 2015), antisense oligonucleotides (Warren
et al., 2010, 2015), a nucleoside analog (Warren et al., 2014),
therapeutic vaccines (Feldmann et al., 2007; Geisbert et al.,
2008), and monoclonal antibody (mAb) cocktails (Olinger et al.,
2012; Qiu et al., 2012, 2014). Of these, preliminary treatment
studies suggest that the effect of the ZMapp mAb cocktail ex-
ceeded the efficacy and treatment window of other experimental
therapeutics described so far (Qiu et al., 2014).
The ZMapp cocktail is composed of three EBOV glycoprotein
(GP)-specific mAbs (designated c13C6, c2G4, and c4G7) that
were isolated initially from mice (Qiu et al., 2011; Wilson et al.,
2000), chimerized with human antibody-constant regions, and
then produced in Nicotiana benthamiana (Qiu et al., 2014). Sin-
gle-particle electron microscopy (EM) reconstructions of these
mAbs in complex with EBOV surface protein have revealed key
sites of vulnerability on the EBOV GP (Murin et al., 2014). One
such site lies within the GP base at the GP1/GP2 interface; two
of three mAbs from the ZMapp cocktail (c2G4 and c4G7) bind
to overlapping epitopes located in this region. The third mAb
from the ZMapp cocktail, c13C6, binds a second antigenic
site, which is located in the glycan cap region. GP base region-
specific mAbs c2G4 and c4G7 displayed high neutralization ac-
tivity in vitro (IC50 < 0.1 mg/ml), whereas the glycan cap-specific
mAb c13C6 weakly neutralized EBOV only in the presence of
complement (IC50 > 1.0 mg/ml) (Qiu et al., 2014). The lower
AB C
D
(legend on next page)
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in vitro neutralization activity of glycan cap-specific antibodies
may be due to the removal of the glycan cap by host proteases
(Chandran et al., 2005; Coˆte´ et al., 2011; Misasi et al., 2012) in-
side the endosome before GP engagement with the Niemann-
Pick C1 receptor (Carette et al., 2011; Coˆte´ et al., 2011).
The ability of mAbs to bind to conserved neutralizing epitopes
present on the surface of highly variable viral proteins has been
documented extensively for HIV (Burton et al., 2012), influenza
viruses (Pappas et al., 2014), dengue virus (Rouvinski et al.,
2015), paramyxoviruses (Corti et al., 2013), and alphaviruses
(Fox et al., 2015). Despite similar requirements for virus entry
into the cell (Misasi et al., 2012), GPs from BDBV, EBOV, and
SUDV strains differ by over 30% at the amino acid level (Towner
et al., 2008). This overall genetic divergence among species of
genus Ebolavirus has hampered the development of ebolavirus
cross-neutralizing Abs. The key components of multiple anti-
body cocktails developed over the last decade neutralize only
viruses of species Zaire ebolavirus. A weakly neutralizing mAb
c13C6 was shown to cross-react with SUDV GPs (Wilson
et al., 2000), but it is unknown whether this mAb can neutralize
SUDV. Recently, several studies have shown that cross-reactive
antibodies in serum can be elicited during natural infection in hu-
mans or vaccination of animals. The serum of individuals who
survived BDBV, EBOV, or SUDV infections contained ebolavirus
cross-reactive IgG, but not IgM (Macneil et al., 2011). Other
studies demonstrated that mice immunized with a vaccine
bearing the GP of EBOV generated cross-reactive polyclonal
mAbs to other ebolaviruses, such as BDBV and SUDV (Meyer
et al., 2015; Ou et al., 2012). Four broadly reactive non-neutral-
izing mAbs were isolated in mice after vaccinating animals with
recombinant vesicular stomatitis virus (rVSV) expressing EBOV
GP and then boosting initial immune response with the heterolo-
gous virus containing SUDV GP (Hernandez et al., 2015). The
epitopes recognized by such cross-reactive mAbs are unknown.
In this study, we isolated a large panel of BDBV-specific and
ebolavirus cross-reactive mAbs from B cells of survivors of
BDBV infection. The results show that a large proportion of
mAbs with potent neutralizing activity against BDBV bind to the
glycan cap and recognize diverse epitopes within this major anti-
genic site. We identified several glycan cap-specific mAbs that
neutralized multiple Ebolavirus species and a cross-reactive
mAb that completely protected guinea pigs from the lethal chal-
lenge with heterologous EBOV when used as monotherapy.
Several of these naturally occurring antibodies exhibit the most
potent protective capacity reported, and they possessed unprec-
edented cross-reactivity for multiple Ebolavirus species, including
SUDV, forwhichneutralizinghumanmAbshavenotbeenreported.Figure 1. Cross-Reactive B Cell Responses in Filovirus Immune Donor
(A–C) Supernatants from EBV-transformed PBMC samples isolated from survivo
Results for four BDBV survivors (A), one EBOV survivor (B), and oneMARV survivo
full-length extracellular domain of GP of the indicated virus species. Reactive s
species-specific cell lines are highlighted in black; and cross-reactive lines to two
shown that the amino acid sequence of GP differs between BDBV and EBOV by
(D) Percentages of lines secreting antibodies specific to BDBV, EBOV, or MARV G
or BDBV, EBOV, and MARV (designated BDBV/EBOV/MARV) are shown. Increas
indicated virus.
See also Figure S1.
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Isolation of Human mAbs
To generate human cell lines secreting human mAbs to BDBV,
we transformed peripheral blood B cells from seven survivors
of the 2007 Uganda BDBV outbreak with Epstein-Barr virus, as
described in the Experimental Procedures. To determine the
breadth of antibody response in survivors of ebolavirus infection,
we screened supernatants from EBV-transformed B cell lines for
binding to GPs from diverse representatives of filovirus species:
BDBV, EBOV, or Marburg virus (MARV) (Figures 1A and S1). We
also used the same GP panel to screen supernatants from trans-
formed B cell lines derived from a survivor of the 2014 EBOV
outbreak (Figure 1B) or from a donor who survived MARV infec-
tion (Figure 1C). We color coded GP-reactive supernatants
based on the cross-reactivity pattern as follows: species-spe-
cific cell lines are highlighted in black; and cross-reactive lines
to two or three species are shown in yellow or blue, respectively
(Figures 1A–1C and S1).
While approximately half of GP-specific B cell lines obtained
from BDBV survivors produced antibodies specific to BDBV
GP, 24%–50% of GP-reactive B cell culture supernatants also
cross-reacted with EBOV GP (Figures 1A and 1D). Similarly,
36% of GP-specific B cell lines obtained from the EBOV survivor
cross-reacted with the heterologous BDBV GP (Figures 1B and
1D). Despite the apparent presence of B cells encoding cross-
reactive antibodies in survivors of BDBV or EBOV infections to
GPs from heterologous Ebolavirus species, we detected a very
limited cross-reactivity with GPs from MARV, which belongs to
a different genus in the family Filoviridae (Figures 1A and 1D).
In line with this finding, 90% of GP-reactive B cell lines obtained
from the MARV survivor reacted with autologous GP, and only
2% of antigen-specific B cell lines produced Ebolavirus cross-
reactive Abs (Figures 1C and 1D). The limited cross-reactivity
of mAbs to GPs from Ebolavirus andMarburgvirus species likely
is due in part to low sequence conservation between GPs from
two genera (only 27% amino acid identity between BDBV and
MARV GP) as well as differences in epitope availability caused
by different positions of the mucin-like domains on the GP sur-
face of Ebolavirus and Marburgvirus (Flyak et al., 2015; Fusco
et al., 2015; Hashiguchi et al., 2015).
Binding and Neutralizing Activity of Human mAbs
We fused transformed cells from B cell lines producing BDBV
GP-reactive Abs with myeloma cells and generated 90 cloned
hybridomas secreting BDBV GP-reactive human mAbs. To
determine the breadth of mAb binding, we screened the mAbss
rs were screened in ELISA-binding assays using BDBV, EBOV, or MARV GPs.
r (C) are shown. Height of the bars indicates OD405 nm values in ELISA binding to
upernates are color coded based on the cross-reactivity pattern as follows:
or three species are shown in yellow or blue, respectively. Previous work has
over 34% and between BDBV and MARV by over 72%.
Ps or cross-reactive antibodies to BDBV and EBOV (designated BDBV/EBOV)
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Figure 2. Cross-Neutralizing Antibodies from Survivors of Natural BDBV Infection
(A) Heatmap showing the binding of BDBVmAbs to a panel of filovirus GPs. The EC50 value for eachGP-mAb combination is shown, with dark red, orange, yellow,
or white shading indicating high, intermediate, low, or no detectable binding, respectively. EC50 values greater than 10,000 ng/ml are indicated (>). NAb names are
highlighted in red.
(B) Heatmap showing the neutralization potency of BDBV GP-specific mAbs against BDBV. The IC50 value for each virus-mAb combination is shown. IC50 values
greater than 10,000 ng/ml are indicated (>). Neutralization assays were performed in triplicate.
(legend continued on next page)
Cell 164, 392–405, January 28, 2016 ª2016 Elsevier Inc. 395
in ELISA-binding assays using recombinant GPs from multiple
filoviruses: BDBV, EBOV, SUDV, or MARV GPs. While 33 Abs
recognized only the autologous BDBV GP (designated groups
1A and 1B), 20 Abs recognized both BDBV and EBOV GPs
(groups 2A and 2B), and 37 Abs recognized all three GPs from
BDBV, EBOV, and SUDV (groups 3A and 3B) (Figures 2A and
2C; Data S1). The relative proportions of antibodies that recog-
nize GPs from 1, 2, or 3 Ebolavirus species did not correlate fully
with the B cell line frequencies in the initial screen, which can be
explained by our prioritization on recovery of a high number of
cross-reactive mAbs. We were not able to isolate Abs that bind
to the heterologous MARV GP (Figures 2A and 2C; Data S1).
We further characterized the binding of species-specific or
cross-reactive mAbs to recombinant GPs by performing a bind-
ing assay with the recombinant form of GP that is secreted from
the cell to the extracellular space during natural infection (sGP,
secreted GP) (Sanchez et al., 1996; Volchkov et al., 1995). While
the Ebolavirus GP is a trimer, sGP forms dimers in which each
protomer shares only the amino-terminal 295 amino acids with
GP. The majority of mAbs recognized epitopes shared between
BDBVGP and BDBV sGP (designated groups 1A, 2A, or 3A) (Fig-
ures 2A and 2C). We also identified antibodies that bound to
BDBV GP, but failed to bind BDBV sGP in ELISA (designated
groups 1B, 2B, or 3B) (Figures 2A and 2C). Antibodies from
groups 1B, 2B, or 3B also bound the recombinant GP form
that lacks highly glycosylated mucin-like domains (BDBV
GPDmuc), suggesting that mAbs from these three groups target
epitopes outside of mucin-like domains (Figure S2).
To evaluate the inhibitory activity of isolated mAbs, we tested
mAbs in a BDBV neutralization assay. Of the 90 BDBV GP-reac-
tive mAbs, 31 had half-maximal inhibitory concentration (IC50)
values <10 mg/ml, and we defined these as neutralizing anti-
bodies (nAbs) (Figures 2B, where nAb names are highlighted in
red, and S3). Several nAbs displayed an extremely high neutral-
izing potency, with IC50 values below 1 ng/ml (Figure 2B). Also,
18 of 31 nAbs bound only to BDBV GP in ELISA, six nAbs recog-
nized BDBV and EBOV GPs, and the remaining seven nAbs
bound to GPs from representatives of three Ebolavirus species,
BDBV, EBOV, and SUDV. These results suggested that cross-
reactive mAbs in our panel might possess neutralizing activity
to multiple ebolaviruses. To test this hypothesis, we screened
BDBV425 (a group 2A nAb) in an EBOV neutralization assay as
the nAb with the lowest half-maximal effective concentration
(EC50) value to the heterologous EBOV GP, and we determined
that BDBV425 neutralized the heterologous EBOV. Encouraged
by this result, we tested nAbs from groups 3A and 3B in EBOV or
SUDV neutralization assays to determine whether cross-reactive
nAbs can neutralize three Ebolavirus species. We found two
cross-reactive nAbs from group 3A (BDBV43 and BDBV324)
that neutralized all three ebolaviruses BDBV, EBOV, and SUDV
(Figure 2D, BDBV43). The remaining five nAbs from groups 3A
and 3B neutralized BDBV and EBOV, but failed to neutralize(C) Binding of representative mAbs from six distinct binding groups to the filoviru
(D) Neutralization activity of representative neutralizing mAbs from three bindin
experiment, performed in triplicate.
See also Table S1, Data S1, and Figures S2 and S3.
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variable domain sequences for 26 nAbs revealed that all
BDBV-specific and cross-reactive nAbs were encoded by
unique Ab genes (Table S1).
Major Antigenic Sites Recognized by Human mAbs
To determine whether Abs from distinct binding groups targeted
different antigenic regions on the BDBV GP surface, we per-
formed a quantitative competition-binding assay using a real-
time biosensor. We tested four BDBV nAbs from binding group
1A, five nAbs from binding group 1B, four nAbs from group 3A,
and three nAbs from group 3B in a tandem blocking assay, in
which BDBV GP was attached to the biosensor. We also tested
five non-neutralizing antibodies from group 1A to determine
whether non-neutralizing antibodies target a unique epitope on
GP surface. Non-neutralizing and neutralizing mAbs from group
1A and nAbs from group 3A blocked binding of each other to the
GP antigen and segregated into a single competition-binding
group (Figure 3). These results suggest that mAbs from groups
1A and 3A target a single antigenic region that contains epitopes
shared between GP and sGP (Figure 2A). The nAbs from group
3B that did not recognize sGP in ELISA (Figure 2A) segregated
into a separate competition-binding group. Group 1B antibodies
were interesting in that two nAbs in this group competed for
binding with group 3B nAbs, while three nAbs from the group
competed for binding with antibodies from group 3A (Figure 3).
These findings suggested that there are at least two major
antigenic regions recognized by human BDBV nAbs, based on
competition-binding studies. The first major antigenic region
contains epitopes that both sGP and GP share (recognized by
mAbs from groups 1A and 3A) as well as epitopes that are
present only on the GP surface (recognized by three mAbs
from group 1B). The second major antigenic region contains
only epitopes that are present on the GP surface, but not sGP
(recognized by two mAbs from group 1B and three mAbs from
group 3B).
Diverse Patterns of Molecular Recognition Defined by
Negative-Stain EM
To determine the location of the two major antigenic regions
targeted by human BDBV nAbs, we performed negative-stain
single-particle EM studies using antibodies from groups 1A
and 1B. The EM class averages and reconstructions showed
clearly that the two major antigenic regions, defined in competi-
tion-binding experiments, corresponded to two distinct sites on
the GP surface: the glycan cap and the GP base.
Comparison of the structures of glycan cap-directed mAbs
from group 1A with those in group 1B revealed that the anti-
bodies have partially overlapping epitopes, but approach the
glycan cap at distinct angles (Figures 4A, 4B, and S4). We fitted
a previously determined atomic resolution structure of SUDV
GPDmuc (Bale et al., 2012), which reveals more residues of thes GPs is shown.
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Figure 3. BDBV-Neutralizing Antibodies Target at Least Two Distinct Antigenic Regions of the GP Surface
Data from competition-binding assays using non-neutralizing mAbs from binding group 1A (white background) and neutralizing mAbs from binding groups 1A,
1B, 3A, or 3B (pink background). Numbers indicate the percentage binding of secondmAb in the presence of the first mAb compared to binding of un-competed
second mAb. MAbs were judged to compete for the same site if maximum binding of the second mAb was reduced to <30% of its un-competed binding (black
boxes with white numbers). The mAbs were considered non-competing if maximum binding of the second mAb was >70% of its un-competed binding (white
boxes with red numbers). Gray boxes with black numbers indicate an intermediate phenotype (competition resulted in between 30% and 70% of un-competed
binding). Blue, purple, and green dashed lines indicate what appear to be major competition groups; the blue and purple groups overlap substantially, but not
completely.glycan cap region than the equivalent EBOV structure, into the
envelope of GP from the EM reconstructions, andwe determined
the regions targeted by each mAb (Figures 4D and 4E).
BDBV335, which binds GP and sGP equally well, mainly targets
a region between residues 274 and 282. This region appears well
defined in the BDBV335 EM map, indicated by the large lobe on
the outside of the glycan cap that closely resembles that region
in the GP crystal structure. When viewed along the 3-fold axis of
GP, BDBV41 binds to the right of BDBV335, further up on the
glycan cap, close to a loop that extends from residue 266 to277. Consistent with this position, we passaged a chimeric
VSV in which the G protein was replaced with BDBV GP as a
sole surface protein (VSV/BDBV-GP) in the presence of mAb
BDBV41 to generate a neutralization escape mutant virus that
was completely resistant to the antibody and that possessed
two amino acid substitutions, G271R and T272S (Figure S5).
The mutation at the 272 position likely explains why BDBV41 is
a group 1 antibody, i.e., only recognizes BDBV (with T272), but
not EBOV or SUDV (which have the alternate residue K272).
BDBV41 also may make contacts with a loop that extendsCell 164, 392–405, January 28, 2016 ª2016 Elsevier Inc. 397
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Figure 4. BDBV-Neutralizing Antibodies Bind to the Glycan Cap or Base Region of GP
(A) Shown are negative-stain EM reference-free 2D class averages of group 1A antibodies that bind both the glycan cap of GP and sGP, and group 1B antibodies
that bind the glycan cap of GP, but not sGP. BDBV GP or GPDmuc was used to generate complexes.
(B) 3D reconstructions of glycan cap binders from groups 1A and 1B reveal that these antibodies bind the glycan cap at overlapping but distinct epitopes. Top
(left) and side (right) views of the complexes are shown.
(C) Reference-free 2D class averages of group 1B antibodies (left) reveal that these antibodies bind an epitope below the base of GP that is flexible. In the middle
image, GP is colored yellow and each Fab is colored green. The righthand panel illustrates a superimposition of crystal structures of SUDV GPDmuc (PDB: 3VE0)
and Fabs (PDB: 3CSY) to demonstrate how Fabs may bind to GP.
(D) The composite model delineates the epitopes of the glycan cap mAbs in group 1A or 1B. Side (above) and top (below) views are shown.
(E) Docking a crystal structure of SUDV GPDmuc (PDB: 3VE0) (Bale et al., 2012), which contains a more complete model of the glycan cap region targeted by
group 1A/B mAbs, reveals how group 1A/B mAbs target a broad region in the GP1 centered on the glycan cap, near the beginning of the mucin-like domains.
Group 1BmAbs that target the base likely bind to a loop near the membrane proximal external region (MPER) that is flexible and has not yet been resolved at high
resolution. TM, transmembrane region; CT, cytoplasmic tail.
See also Figure S4.toward the mucin-like domains, from residue 309 to 312 or
further in regions that were unresolved in the GP crystal struc-
ture. BDBV432 binds to the left of BDBV335, at the top of a helix
loop at residues 259–266, and likely makes extensive contacts
with a loop from residues around 302–312. Despite a lack of
binding to sGP, BDBV432, as well as BDBV353, binds in the
glycan cap region, suggesting that these mAbs make contacts
with residues that are exclusive to GP.
The other antibodies in group 1B bind to an epitope at the base
of GP. These antibodies, including BDBV255 and BDBV259,
bind further down on GP than has been observed previously398 Cell 164, 392–405, January 28, 2016 ª2016 Elsevier Inc.with murine mAbs, possibly contacting residues within GP2
that are part of the membrane proximal external region (MPER)
(Figures 4C–4E). These antibodies were refractory to a recon-
struction by EM due to predominant side views of the particles
and also apparent flexibility. The class averages, however,
clearly show that these antibodies bind an epitope that extends
down below the base of GP. Three Fabs can be seen in some of
the class averages, indicating that despite the apparent small
size of this region, three antibodies can be accommodated on
one GP trimer. Although the Fabs adopt various positions in
each class average, there is not a continuous range of flexibility
A B D
C
Figure 5. Epitope Mapping of Group 3A mAbs Using Saturation Mutagenesis and Negative-Stain EM
(A and B) Epitope residues for three nAbs from group 3A (BDBV270, BDBV289, and BDBV324) were identified as those for which mutation to alanine specifically
reduced binding of these antibodies. GP residueW275was common to all three nAbs, while L273was specific for BDBV324 and Y241was specific for BDBV289.
The mutated residues are shown in space-filling forms on a ribbon diagram of the EBOV GP structure, based on PDB: 3CSY.
(C) Binding values for nAbs and previously isolated mAbs KZ52, 2G4, and 4G7 to library clones with mutations at residues L273, W275, and Y241. The Ab
reactivities against each mutant EBOV GP clone were calculated relative to reactivity with wild-type EBOV GP.
(D) BDBV289 (brown) binds at the top of the viral GP near the glycan cap region. Complexes are of BDBV antibody Fab fragments bound to BDBV GPDTM with
side view (top panel) or top view (bottom panel). A representative Fab crystal structure is fit in the Fab density for each reconstruction (from PDB: 3CSY). A
monomer of the GP trimer crystal structure (PDB: 3CSY) is also fit in the GP density, with white corresponding to GP1 and black to GP2. Two critical residues for
binding by BDBV289 (W275 and Y241, determined using saturation mutagenesis) are highlighted in green.
See also Figure S5.since the Fabs themselves are well resolved. These antibodies
may require the full MPER and transmembrane (TM) regions,
as well as a membrane, in order to bind stably. These features
are all lacking in the current recombinant protein used here, a
soluble form of the extracellular domain of GP. While the GP2 re-
gion is well conserved across the filoviruses, these BDBV-spe-
cific mAbs likely bind non-conserved regions in GP2 proximal
to the TM region.
Epitope Mapping of Group 3A mAbs Using Saturation
Mutagenesis and Negative-Stain EM
As the group 3A (cross-reactive) nAbs competed for binding with
group 1A (BDBV-specific) nAbs (Figure 3), we hypothesized that
some structural features of the glycan cap are conserved among
GPs frommultiple Ebolavirus species. We sought to identify crit-
ical amino acids that defined epitopes for three group 3 nAbs(BDBV270, BDBV289, and BDBV324) using a comprehensive
EBOV GP alanine-scanning mutation library (Davidson et al.,
2015). Epitope mapping identified critical residues for binding
by each nAb as follows: W275 for BDBV270, W275 and Y241
for BDBV289, and W275 and L273 for BDBV324. Residues for
which mutation reduced binding of three nAbs from group 3A
were visualized on the surface of the high-resolution structure
of EBOV GP (PDB: 3CSY). This finding suggests that each of
these antibodies recognizes overlapping epitopes in the GP
glycan cap (Figures 5A and 5B). The previously describedmurine
nAbs 2G4 and 4G7 and the human nAb KZ52 were shown previ-
ously to bind the base region of the GP (Lee et al., 2008; Murin
et al., 2014), and mutations of the W275 or L273 residue did
not reduce the binding of these nAbs (Figure 5C). We passaged
VSV/BDBV-GP in the presence of BDBV223 or BDBV289 in an
attempt to generate escape mutant viruses, but could not detectCell 164, 392–405, January 28, 2016 ª2016 Elsevier Inc. 399
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Figure 6. Survival and Clinical Signs of EBOV-Inoculated Mice Treated with BDBV mAbs
Groups of five mice in each group were injected with individual mAbs by the i.p. route 1 day after EBOV challenge, using 100 mg mAb per treatment. Animals
treated with dengue virus-specific human mAb 2D22 served as controls.
(A) Kaplan-Meier survival curves are shown.
(B) Body weight is shown.
(C) Illness score is shown.neutralization-resistant viruses. An isolate passaged in the pres-
ence of BDBV223 with a R574H polymorphism in heptad repeat
1 (HR1) region was identified, and for BDBV289 an isolate with an
I584M polymorphism in the HR1 region alone or in combination
with an E149K substitution in the receptor-binding domain was
identified. However, none of these mutations was associated
with the ability of those viruses to resist neutralization by the cor-
responding mAb.
We further characterized BDBV289 by single-particle EM
studies of antibody in complex with GP. BDBV289 binds the
glycan cap region of GP, centered on the residues W275 and
Y241 (Figures 5D and S4). The angle of approach resembles
that of the mAb 1H3 from the antibody cocktail ZMab, although
1H3 is specific to EBOV and is weakly neutralizing (Murin et al.,
2014; Qiu et al., 2011). Further, BDBV289 also binds sGP, which
shares the first 295 amino acids of GP1 with GP, including the
glycan cap region (Sanchez et al., 1996; Volchkov et al., 1995).
Therefore, despite previous hypotheses that propose that sGP
is an immune decoy and that cleavage of the glycan cap prevents
neutralizing antibodies from binding this region (Mohan et al.,
2012; Murin et al., 2014), we have now identified several anti-
bodies that challenge these ideas. Interestingly, BDBV289 tar-
gets an overlapping epitope with antibodies that we identified
to be specific toBDBVand that do not bind sGP (Figure 4). There-400 Cell 164, 392–405, January 28, 2016 ª2016 Elsevier Inc.fore, the glycan cap region is a major antigenic site that contains
epitopes with subtle features that influence sGP and GP binding,
neutralization, and species cross-reactivity of targeting mAbs.
Therapeutic Efficacy of Human mAbs in Small Animal
Models of EBOV Infection
To determine the therapeutic activity of cross-neutralizing Abs,
we tested several antibodies inmice.We focused on cross-reac-
tive antibodies, and we studied the heterologous effect of BDBV
survivor mAbs against EBOV challenge. We selected two nAbs
from groups 3A (BDBV289) and 3B (BDBV223) that bound non-
overlapping antigenic regions in the competition-binding exper-
iments (Figure 3). The 7-week-old BALB/c mice received 100 mg
antibody by the intraperitoneal (i.p.) route 1 or 3 days after inoc-
ulation with 1,000 plaque-forming units (PFUs) of mouse-adapt-
ed EBOV, strain Mayinga (Bray et al., 1998). BDBV223 and
BDBV289 reduced disease and protected mice from death
when delivered 1 day after challenge with EBOV (Figure 6). We
did not observe a therapeutic effect in the mice receiving the an-
tibodies 3 days after the challenge.
Finally, we set out to test in vivo efficacy of the cross-reactive
nAbs BDBV289 and BDBV223 using a guinea pigmodel of EBOV
infection. The 5- to 6-week-old guinea pigs, strain Hartley, were
injected with 5mg antibody by the i.p. route once (day 1) or twice
(days 1 and 3) after inoculation with 1,000 PFU of guinea pig-
adapted EBOV, strain Mayinga. BDBV223 provided marginal
protection, as only one of five animals survived the lethal
challenge (Figure 7). Surprisingly, a glycan cap-specific nAb,
BDBV289, fully protected guinea pigs when delivered twice after
the virus challenge. The protective efficiency of BDBV289 with a
single treatment against a heterologous EBOV (Figure 7, three of
five animals survived) was higher than the protective efficiency
of the equivalent glycan-cap-specific mAb c13C6, a component
of the ZMapp cocktail (one of six animals survived) (Qiu et al.,
2014). To determine whether a combination of two mAbs that
target two neutralizing epitopes on the EBOV GP surface confer
better protection than treatment with a single mAb alone, we
tested the combination of BDBV223 and BDBV289 in guinea
pigs. The combination of two antibodies provided complete pro-
tection against a heterologous EBOVwith only a single treatment
(Figure 7). We isolated viral RNA from blood of representative
animals that were treated with mAbs BDBV223 or BDBV289
but died, and then sequenced the genes encoding the GP
(Table S2). Several polymorphisms were detected, but none
appeared to be directly related to the epitope specificity of the
mAb used for treatment.
DISCUSSION
This study reveals that natural BDBV infection in humans triggers
the development of ebolavirus cross-reactive antibodies that
target epitopes on the GP surface that are conserved in diverse
species of genus Ebolavirus. During these studies, we isolated
90 human mAbs from humans following BDBV infection and
found 57 cross-reactive mAbs that recognized heterologous
EBOV GPs. Remarkably, some of the isolated cross-reactive
mAbs not only bound but also neutralized multiple Ebolavirus
species. The majority of cross-reactive mAbs neutralized
BDBV and EBOV, but we also isolated two antibodies that dis-
played potent neutralizing activity against representatives of
three Ebolavirus species, BDBV, EBOV, and SUDV. We tested
two cross-neutralizing mAbs in mice and guinea pigs and
showed that they protected animals from lethal challenge with
a heterologous species of EBOV. These data suggest that
cross-neutralizing mAbs can be used to develop a universal
treatment against multiple ebolaviruses, and they imply that
highly immunogenic vaccines with proper presentation of GP
from one species could induce some measure of cross-protec-
tion against viruses of the other species. The ability of these
mAbs to bind and neutralize a broad range of Ebolavirus species
also suggests that such antibodiesmight offer protection against
emerging filoviruses in the future.
Our study highlights the neutralization and protective po-
tencies of human glycan cap-specific antibodies. It has been
suggested previously that glycan cap-binding mAbs may not
neutralize well because cathepsins remove this region during
viral entry (Murin et al., 2014). However, several of the BDBV
glycan cap-specific mAbs isolated here exhibit very potent
neutralizing activity, and they recognize diverse epitopes
within this major antigenic site. Furthermore, a single glycan
cap-specific nAb, BDBV289, provided complete protection in
EBOV-challenged guinea pigs. The mechanism used by glycancap-binding mAbs to neutralize the virus in vitro is unclear. The
glycan cap-specific antibodies described here bind to sites
distant from the putative cathepsin cleavage site (located at res-
idue 190), so they are unlikely to interfere with GP cleavage.
While the amino acid sequence of the GP1 region is generally
less well conserved than that of GP2 in viruses of diverse filovirus
species, the five neutralizing glycan cap mAbs studied with EM
imaging here target conserved residues, indicating that these re-
gions may be important to the viral life cycle. Therefore, these
mAbs may block some yet undefined function of the glycan cap.
Several antibody-based treatments provided a complete spe-
cies-specific protection from EBOV in a non-human primate
model of infection (Qiu et al., 2014). However, antibody-based
therapeutics against other members of the Ebolavirus genus,
such and BDBV and SUDV, are not yet available. While one strat-
egy would be to develop separate antibody treatments for each
filovirus infection, an alternative strategy would be to have a uni-
versal treatment effective against diverse Ebolavirus species.
The development of universal antibody treatments for ebolavi-
ruses seems inevitable, given recent progress in the identifica-
tion of broad and potent neutralizing antibodies against viruses
that exhibit more antigenic diversity than the filoviruses such
as HIV (Burton et al., 2012), influenza viruses (Pappas et al.,
2014), dengue virus (Rouvinski et al., 2015), alphaviruses (Fox
et al., 2015), and paramyxoviruses (Corti et al., 2013). Our results
provide a roadmap to develop a single antibody-based treat-
ment effective against multiple Ebolavirus infections. We pro-
pose that the principal components of such treatment should
include cross-neutralizing mAbs that target conserved elements
of the non-overlapping major neutralizing antigenic sites on the
GP surface.
EXPERIMENTAL PROCEDURES
Donors
De-identified peripheral blood mononuclear cells (PBMCs) from seven survi-
vors of the 2007 BDBV outbreak in Uganda (Towner et al., 2008) were obtained
from a repository at Makerere University (Kampala, Uganda) managed in
collaboration with the U.S. Military HIV Research Program MHRP, which is
part of the Walter Reed Army Institute of Research. PBMCs were obtained af-
ter informed consent from a U.S. survivor of EBOV infection who was infected
while delivering health care in Liberia during the 2014 Ebola virus outbreak with
Makona virus. Cells from the EBOV survivor were obtained about 11 weeks af-
ter infection and about 7 weeks after discharge from hospital, following several
negative PCR tests for presence of virus. PBMCs were obtained from a U.S.
survivor of MARV infection who developed the disease in early 2008 following
exposure to fruit bats in the Python Cave in Queen Elizabeth National Park,
Uganda. This donor’s clinical course was documented previously (Centers
for Disease Control and Prevention, 2009), and we have reported previously
on isolation of human antibodies from this donor (Flyak et al., 2015). Peripheral
blood from the donor was obtained in 2012, 4 years after the illness, following
informed consent. The studies were approved by the Vanderbilt University
Institutional Review Board.
Viruses
BDBV strain 200706291 Uganda was isolated originally from the serum of
a patient during the first recorded outbreak caused by this virus (Towner
et al., 2008) and passaged three times in Vero E6 cells. The virus was provided
originally by the Special Pathogens Branch of the U.S. Centers for Disease
Control and Prevention (CDC) and deposited at the World Reference
Center of Emerging Viruses and Arboviruses (WRCEVA), housed at the
University of Texas Medical Branch (UTMB). The chimeric EBOV/BDBV-GP,Cell 164, 392–405, January 28, 2016 ª2016 Elsevier Inc. 401
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Figure 7. Survival and Clinical Signs of EBOV-Inoculated Guinea Pigs Treated with BDBV mAbs
(A and B) Groups of five guinea pigs per group were injected with individual mAbs by the i.p. route 1 day or 1 and 3 days after EBOV challenge, using 5 mg of
individual mAb (A) or 5mg of the combination of twomAbs per treatment (B), as indicated. Animals treatedwith dengue virus-specific humanmAb 2D22 served as
controls. The survival curves are based on morning and evening observations. Mortality in the morning is shown in whole day numbers, in the evening in half-day
values. The body weight and illness scores are shown with one value per day. See also Table S2.
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EBOV/MARV-GP, and EBOV/SUDV-GP constructs expressing EGFP were
obtained by replacing the gene encoding EBOV GP with that of BDBV,
MARV, or SUDV, respectively (P.A. Ilinykh, unpublished data) and passaged
two times in Vero E6 cells. Additional details are reported in the Supplemental
Experimental Procedures.
Generation of Human Hybridomas Secreting mAbs
Human hybridomas were generated as described previously (Flyak et al.,
2015). In brief, previously cryopreserved samples were transformed with
Epstein-Barr virus, CpG, and additional supplements. After 7 days, cells
from each well of the 384-well culture plates were expanded into four
96-well culture plates using cell culture medium containing irradiated heter-
ologous human PBMCs (recovered from blood unit leukofiltration filters,
Nashville Red Cross) and incubated for an additional 4 days. Plates were
screened for BDBV GP antigen-specific antibody-secreting cell lines using
ELISAs. Cells from wells with supernates reacting with antigen in an ELISA
were fused with HMMA2.5 myeloma cells using an established electrofusion
technique (Yu et al., 2008).
Human mAb and Fab Production and Purification
After fusion, hybridoma cell lines were cloned by single-cell fluorescence-
activated cell sorting and expanded in post-fusion medium as previously
described (Flyak et al., 2015). HiTrap Protein G or HiTrap MabSelectSure col-
umns were used to purify antibodies from filtered supernates. Fab fragments
were generated by papain digestion, as described previously (Flyak et al.,
2015).
Expression and Purification of Filovirus GPs
BDBV GP ectodomain (BDBV GP, residues 1–637) or the sGP dimer (BDBV
sGP, residues 1–316) was used to screen supernatants of transformed B cells.
Recombinant GPs were engineered with a C-terminal double strep tag and
cloned into a modified pMTpuro vector for expression in Drosophila S2 cells.
Briefly, plasmids were transfected into S2 cells using Effectene reagent
(QIAGEN) followed by stable cell selection with 6 mg/ml puromycin. S2 cells
first were cultured in Schneider’s medium supplemented with 10% (v/v) fetal
calf serum (FCS, Lonza), and later they were adapted to Insect Xpressmedium
for large-scale expression in 2-l shaker flasks. Stable cells were induced with
0.5 mM CuSO4 and harvested after 4 to 5 days at 27
C. Tangential flow filtra-
tion then was used to buffer exchange the supernatants into 100 mM Tris-HCl,
150 mM NaCl, 1 mM EDTA, and 15 mg/ml avidin (pH 8.0), and target proteins
were purified using Streptactin Superflow affinity (QIAGEN). GP ectodomains
were purified further with S200 size exclusion chromatography (SEC); sGPwas
purified with S75 SEC. Recombinant ectodomains for EBOV, SUDV, or MARV
were designed and expressed similarly.
Screening and EC50 ELISA-Binding Analysis
Soluble forms of the full-length extracellular domain of BDBV, EBOV, SUDV, or
MARV GPs or the sGP form of BDBV GP were coated overnight onto 384-well
plates at 1 mg/ml. For screening ELISA, 10 ml supernate from a well of a tissue-
culture plate was transferred to each well of a 384-well ELISA plate. For EC50-
binding analysis by ELISA, purified antibodies were applied to the plates at a
concentration range of 30 mg/ml to 170 ng/ml, using 3-fold serial dilutions.
The presence of antibodies bound to the GP was determined using goat
anti-human IgG alkaline phosphatase conjugate and p-nitrophenol phosphate
substrate tablets, with optical density read at 405 nm after 120 min. A non-
linear regression analysis was performed on the resulting curves using Prism
version 5 (GraphPad) to calculate EC50 values. The Circos software package
was used for data visualization (Krzywinski et al., 2009).
EBOV and MARV Neutralization Experiments
Isolated mAbs were screened initially in a high-throughput neutralization
assay using EBOV/BDBV-GP with or without 5% guinea pig complement
(MP Biomedicals) (P.A. Ilinykh, unpublished data). The mAbs that exhibited
neutralizing activity also were screened for neutralization of EGFP-expressing
EBOV (Towner et al., 2005). Several mAbs were tested for neutralization
of EBOV/SUDV-GP and EBOV/MARV-GP by the same approach. Additional
information is given in the Supplemental Experimental Procedures.Biolayer Interferometry Competition-Binding Assay
Competition binding studies using biolayer interferometry and biotinylated
BDBV GP (EZ-link Micro NHS-PEG4-Biotinylation Kit, Thermo Scientific
21955) (5 mg/ml) were performed on an Octet RED biosensor (ForteBio), as
described previously (Flyak et al., 2015). In brief, the antigen was immobilized
onto streptavidin-coated biosensor tips. After a brief washing step, biosensor
tips were immersed first into the wells containing first antibody at a concentra-
tion of 100 mg/ml and then into the wells containing a secondmAb at a concen-
tration of 100 mg/ml. The percentage binding of the second mAb in the pres-
ence of the first mAb was determined by comparing the maximal signal of
the second mAb applied after the first mAb complex to the maximal signal
of the second mAb alone.
Sequence Analysis of Antibody Variable Region Genes
Antibody variable gene sequence analysis was performed as previously
described (Flyak et al., 2015). Heavy-chain antibody variable region se-
quences were analyzed using the IMGT/V-Quest program (Brochet et al.,
2008; Giudicelli et al., 2011).
EM and Sample Preparation
Fabs were added in 10 M excess to BDBV GPdMuc and subsequently purified
and stained as previously described (Murin et al., 2014).
Image Processing of Protein Complexes
Particles were automatically picked using DoG Picker (Voss et al., 2009) and
particle stacks were generated using Appion (Lander et al., 2009). Subse-
quently, reference-free two-dimensional (2D) class averages were generated
using iterative multi-reference alignment (MRA)/multivariate statistical analysis
(MSA) (van Heel et al., 1996). Non-GP complexes and those with a clear lack of
full saturation by Fab were removed to generate a final stack for reconstruc-
tions. In some cases, orientation bias or flexibility of Fabs prevented conver-
gence of an acceptable model, although examination of class averages
allowed a general assignment of the epitope. Final stack class averages
were used to generate initial models using EMAN2 common lines (Tang
et al., 2007). A model matching its reference projections was further refined
using the entire raw particle stack with EMAN2, as described previously (Murin
et al., 2014). For the BDBV41 reconstruction, the EMAN2 reconstruction
lacked important features that were present in the class averages, indicating
that perhaps some particles lacked full Fab saturation. To circumvent this
problem, we utilized the Relion package, which allows three-dimensional
(3D) classification to remove particles that may only contain two Fabs, signif-
icantly improving the quality of the final EM map (Scheres, 2012). Modeling
fitting and EM figures were generated using UCSF Chimera (Pettersen et al.,
2004).
Epitope Mapping Using an EBOV GP Alanine-Scan Mutation Library
Comprehensive high-throughput alanine scanning (shotgun mutagenesis) was
carried out on an expression construct for EBOV GP (Yambuku-Mayinga
variant GP; UniProt: Q05320) (Davidson et al., 2015). Additional details are re-
ported in the Supplemental Experimental Procedures.
In Vivo Testing
The animal protocols for testing of mAbs in mice and guinea pigs were
approved by the Institutional Animal Care and Use Committee of the UTMB.
The 7-week-old BALB/c mice (Charles River Laboratories) were placed in
the ABSL-4 facility of the Galveston National Laboratory. Groups of mice at
five animals per group were injected with 1,000 PFU of the mouse-adapted
EBOV by the i.p. route. Then 24 or 72 hr later, animals were injected with indi-
vidual mAbs by the i.p. route using 100 mg per treatment. Animals treated with
the antibody specific to dengue virus 2D22 served as controls. Animals were
weighed and monitored daily over the 2-week period after challenge. Once
animals were symptomatic, they were examined no less than twice per day.
The disease was scored using the following parameters: dyspnea (possible
scores 0–5), recumbency (0–9), unresponsiveness (0–5), and bleeding/hemor-
rhage (0–5). To test the protective efficacy of mAbs in guinea pigs, five- to six-
week-old animals (strain Hartley) were placed in the ABSL-4 facility of the Gal-
veston National Laboratory. Groups of five animals per group were injectedCell 164, 392–405, January 28, 2016 ª2016 Elsevier Inc. 403
with 1,000 PFU of guinea pig-adapted EBOV by the i.p. route. Then 24 or 24
and 72 hr later, animals were injected with individual mAbs (5 mg per treat-
ment) or a cocktail of two mAbs (2.5 mg of each mAb per treatment). Animals
were weighed and monitored daily for 28 days. After animals became symp-
tomatic, they were examined no less than twice per day. The disease was
scored using the following parameters: appearance (possible scores 0–3),
body condition (0–3), natural behavior (0–3), and provoked behavior (0–3).
ACCESSION NUMBERS
The accession numbers for the EM reconstructions reported in this paper are
Electron Microscopy Data Bank: EMD-6527 through EMD-6532.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, two tables, and a data file and can be found with this article online
at http://dx.doi.org/10.1016/j.cell.2015.12.022.
AUTHOR CONTRIBUTIONS
A.I.F., A.B., and J.E.C. conceived the study. A.I.F., X.S., C.D.M., M.L.F., H.L.T.,
J.A.D., R.L., N. Kose, N. Kuzmina, P.A.I., H.K., L.B., G.S., C.K., C.B., and
T.G.K. performed experiments. A.I.F., X.S., P.A.I., N. Kose, N. Kuzmina,
A.B., E.D., B.J.D., J.C.S., E.O.S., A.B.W., A.B., and J.E.C. analyzed data.
A.I.F., P.A.I., A.B., and J.E.C. wrote the paper.
ACKNOWLEDGMENTS
This project received support from the Defense Threat Reduction Agency
(grant HDTRA1-13-1-0034 to J.E.C. and A.B.), U.S. NIH grant U19 AI109711
(to J.E.C. and A.B.), U19 AI109762 (to E.O.S. and A.B.W.), NIH contract
HHSN272201400058C (to B.J.D.), and R01 AI067927 (to E.O.S.). E.O.S. is
an Investigator in the Pathogenesis of Infectious Disease of the Burroughs
Wellcome Fund. The project was supported by NCRR Grant UL1
RR024975-01 and is now at the National Center for Advancing Translational
Sciences, Grant 2 UL1 TR000445-06. The content is solely the responsibility
of the authors and does not necessarily represent the official views of the
NIH.We thank the donors and Cheryl Stewart and Jill Janssen in the Vanderbilt
Clinical Trials Center for help in sample acquisition in the United States. We
thank Monica Millard and Hannah Kibuuka of the Makerere University Walter
Reed Project (MUWRP) in Kampala, Uganda, who provided repository sam-
ples from the Long-term Bundibugyo Ebola virus survivors study done in
collaboration with U.S. Army Medical Research Institute of Infectious Dis-
eases. We thank Frances Smith-House at Vanderbilt and Kathleen Pommert
at Scripps for excellent technical support. L.B. was a summer undergraduate
research fellow at the Vanderbilt Vaccine Center, and J.A.D. was a summer un-
dergraduate research fellow at The Scripps Research Institute. We thank An-
drew McNeal and Rachel Fong for assistance with epitope mapping. We also
thank Dr. Alexander Freiberg (UTMB) for providing the guinea-pig-adapted
EBOV strain. Flow cytometry experiments were performed in the VMC Flow
Cytometry Shared Resource, supported by NIH grants P30 CA68485 and
DK058404. The EM work was conducted at The Scripps Research Institute
electron microscopy facility. C.D.M. is supported by a National Science Foun-
dation Graduate Research Fellowship.
Received: August 8, 2015
Revised: October 17, 2015
Accepted: December 3, 2015
Published: January 21, 2016
REFERENCES
Bale, S., Dias, J.M., Fusco, M.L., Hashiguchi, T., Wong, A.C., Liu, T., Keuhne,
A.I., Li, S., Woods, V.L., Jr., Chandran, K., et al. (2012). Structural basis for dif-
ferential neutralization of ebolaviruses. Viruses 4, 447–470.404 Cell 164, 392–405, January 28, 2016 ª2016 Elsevier Inc.Bray, M., Davis, K., Geisbert, T., Schmaljohn, C., and Huggins, J. (1998). A
mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic
fever. J. Infect. Dis. 178, 651–661.
Brochet, X., Lefranc,M.P., andGiudicelli, V. (2008). IMGT/V-QUEST: the highly
customized and integrated system for IG and TR standardized V-J and V-D-J
sequence analysis. Nucleic Acids Res. 36, W503–508.
Burton, D.R., Poignard, P., Stanfield, R.L., and Wilson, I.A. (2012). Broadly
neutralizing antibodies present new prospects to counter highly antigenically
diverse viruses. Science 337, 183–186.
Carette, J.E., Raaben, M., Wong, A.C., Herbert, A.S., Obernosterer, G.,
Mulherkar, N., Kuehne, A.I., Kranzusch, P.J., Griffin, A.M., Ruthel, G., et al.
(2011). Ebola virus entry requires the cholesterol transporter Niemann-Pick
C1. Nature 477, 340–343.
Centers for Disease Control and Prevention (CDC) (2009). Imported case of
Marburg hemorrhagic fever - Colorado, 2008. MMWR Morb. Mortal. Wkly.
Rep. 58, 1377–1381.
Chandran, K., Sullivan, N.J., Felbor, U., Whelan, S.P., and Cunningham, J.M.
(2005). Endosomal proteolysis of the Ebola virus glycoprotein is necessary for
infection. Science 308, 1643–1645.
Corti, D., Bianchi, S., Vanzetta, F., Minola, A., Perez, L., Agatic, G., Guarino, B.,
Silacci, C., Marcandalli, J., Marsland, B.J., et al. (2013). Cross-neutralization of
four paramyxoviruses by a humanmonoclonal antibody. Nature 501, 439–443.
Coˆte´, M., Misasi, J., Ren, T., Bruchez, A., Lee, K., Filone, C.M., Hensley, L., Li,
Q., Ory, D., Chandran, K., and Cunningham, J. (2011). Small molecule inhibi-
tors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature
477, 344–348.
Davidson, E., Bryan, C., Fong, R.H., Barnes, T., Pfaff, J.M., Mabila, M., Rucker,
J.B., and Doranz, B.J. (2015). Mechanism of binding to Ebola virus glycopro-
tein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J. Virol 89,
10982–10992.
Feldmann, H., Jones, S.M., Daddario-DiCaprio, K.M., Geisbert, J.B., Stro¨her,
U., Grolla, A., Bray, M., Fritz, E.A., Fernando, L., Feldmann, F., et al. (2007).
Effective post-exposure treatment of Ebola infection. PLoS Pathog. 3, e2.
Flyak, A.I., Ilinykh, P.A., Murin, C.D., Garron, T., Shen, X., Fusco, M.L.,
Hashiguchi, T., Bornholdt, Z.A., Slaughter, J.C., Sapparapu, G., et al. (2015).
Mechanism of human antibody-mediated neutralization of Marburg virus.
Cell 160, 893–903.
Fox, J.M., Long, F., Edeling, M.A., Lin, H., van Duijl-Richter, M.K., Fong, R.H.,
Kahle, K.M., Smit, J.M., Jin, J., Simmons, G., et al. (2015). Broadly Neutralizing
Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Cell
163, 1095–1107.
Fusco, M.L., Hashiguchi, T., Cassan, R., Biggins, J.E., Murin, C.D., Warfield,
K.L., Li, S., Holtsberg, F.W., Shulenin, S., Vu, H., et al. (2015). Protective
mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered
Marburg Virus GPs. PLoS Pathog. 11, e1005016.
Geisbert, T.W., Daddario-DiCaprio, K.M., Williams, K.J., Geisbert, J.B., Leung,
A., Feldmann, F., Hensley, L.E., Feldmann, H., and Jones, S.M. (2008). Recom-
binant vesicular stomatitis virus vector mediates postexposure protection
against Sudan Ebola hemorrhagic fever in nonhuman primates. J. Virol. 82,
5664–5668.
Geisbert, T.W., Bausch, D.G., and Feldmann, H. (2010). Prospects for immu-
nisation against Marburg and Ebola viruses. Rev. Med. Virol. 20, 344–357.
Giudicelli, V., Brochet, X., and Lefranc, M.P. (2011). IMGT/V-QUEST: IMGT
standardized analysis of the immunoglobulin (IG) and T cell receptor (TR)
nucleotide sequences. Cold Spring Harb. Protoc. 2011, 695–715.
Hashiguchi, T., Fusco, M.L., Bornholdt, Z.A., Lee, J.E., Flyak, A.I., Matsuoka,
R., Kohda, D., Yanagi, Y., Hammel, M., Crowe, J.E., Jr., and Saphire, E.O.
(2015). Structural basis for Marburg virus neutralization by a cross-reactive
human antibody. Cell 160, 904–912.
Hernandez, H., Marceau, C., Halliday, H., Callison, J., Borisevich, V., Escaffre,
O., Creech, J., Feldmann, H., and Rockx, B. (2015). Development and Charac-
terization of Broadly Cross-reactive Monoclonal Antibodies Against All Known
Ebolavirus Species. J. Infect. Dis. 212 (Suppl 2 ), S410–S413.
Krzywinski, M., Schein, J., Birol, I., Connors, J., Gascoyne, R., Horsman, D.,
Jones, S.J., and Marra, M.A. (2009). Circos: an information aesthetic for
comparative genomics. Genome Res. 19, 1639–1645.
Lander, G.C., Stagg, S.M., Voss, N.R., Cheng, A., Fellmann, D., Pulokas, J.,
Yoshioka, C., Irving, C., Mulder, A., Lau, P.W., et al. (2009). Appion:
an integrated, database-driven pipeline to facilitate EM image processing.
J. Struct. Biol. 166, 95–102.
Lee, J.E., Fusco, M.L., Hessell, A.J., Oswald, W.B., Burton, D.R., and Saphire,
E.O. (2008). Structure of the Ebola virus glycoprotein bound to an antibody
from a human survivor. Nature 454, 177–182.
Macneil, A., Reed, Z., and Rollin, P.E. (2011). Serologic cross-reactivity
of human IgM and IgG antibodies to five species of Ebola virus. PLoS Negl.
Trop. Dis. 5, e1175.
Meyer, M., Garron, T., Lubaki, N.M., Mire, C.E., Fenton, K.A., Klages, C., Olin-
ger, G.G., Geisbert, T.W., Collins, P.L., and Bukreyev, A. (2015). Aerosolized
Ebola vaccine protects primates and elicits lung-resident T cell responses.
J. Clin. Invest. 125, 3241–3255.
Misasi, J., Chandran, K., Yang, J.Y., Considine, B., Filone, C.M., Coˆte´, M.,
Sullivan, N., Fabozzi, G., Hensley, L., and Cunningham, J. (2012). Filoviruses
require endosomal cysteine proteases for entry but exhibit distinct protease
preferences. J. Virol. 86, 3284–3292.
Mohan, G.S., Li, W., Ye, L., Compans, R.W., and Yang, C. (2012). Antigenic
subversion: a novel mechanism of host immune evasion by Ebola virus.
PLoS Pathog. 8, e1003065.
Murin, C.D., Fusco, M.L., Bornholdt, Z.A., Qiu, X., Olinger, G.G., Zeitlin, L.,
Kobinger, G.P., Ward, A.B., and Saphire, E.O. (2014). Structures of protective
antibodies reveal sites of vulnerability on Ebola virus. Proc. Natl. Acad. Sci.
USA 111, 17182–17187.
Olinger, G.G., Jr., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B.,
Hiatt, E., Hume, S.D., Johnson, A.K., Morton, J., et al. (2012). Delayed
treatment of Ebola virus infection with plant-derived monoclonal antibodies
provides protection in rhesus macaques. Proc. Natl. Acad. Sci. USA 109,
18030–18035.
Ou, W., Delisle, J., Jacques, J., Shih, J., Price, G., Kuhn, J.H., Wang, V.,
Verthelyi, D., Kaplan, G., and Wilson, C.A. (2012). Induction of ebolavirus
cross-species immunity using retrovirus-like particles bearing the Ebola virus
glycoprotein lacking the mucin-like domain. Virol. J. 9, 32.
Pappas, L., Foglierini, M., Piccoli, L., Kallewaard, N.L., Turrini, F., Silacci, C.,
Fernandez-Rodriguez, B., Agatic, G., Giacchetto-Sasselli, I., Pellicciotta, G.,
et al. (2014). Rapid development of broadly influenza neutralizing antibodies
through redundant mutations. Nature 516, 418–422.
Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M.,
Meng, E.C., and Ferrin, T.E. (2004). UCSF Chimera–a visualization system
for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612.
Qiu, X., Alimonti, J.B., Melito, P.L., Fernando, L., Stro¨her, U., and Jones, S.M.
(2011). Characterization of Zaire ebolavirus glycoprotein-specific monoclonal
antibodies. Clin. Immunol. 141, 218–227.
Qiu, X., Audet, J., Wong, G., Pillet, S., Bello, A., Cabral, T., Strong, J.E., Plum-
mer, F., Corbett, C.R., Alimonti, J.B., and Kobinger, G.P. (2012). Successful
treatment of ebola virus-infected cynomolgus macaques with monoclonal an-
tibodies. Sci. Transl. Med. 4, 138ra81.
Qiu, X., Wong, G., Audet, J., Bello, A., Fernando, L., Alimonti, J.B., Fausther-
Bovendo, H., Wei, H., Aviles, J., Hiatt, E., et al. (2014). Reversion of advanced
Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47–53.Rouvinski, A., Guardado-Calvo, P., Barba-Spaeth, G., Duquerroy, S., Vaney,
M.C., Kikuti, C.M., Navarro Sanchez, M.E., Dejnirattisai, W., Wongwiwat, W.,
Haouz, A., et al. (2015). Recognition determinants of broadly neutralizing
human antibodies against dengue viruses. Nature 520, 109–113.
Sanchez, A., Trappier, S.G., Mahy, B.W., Peters, C.J., and Nichol, S.T. (1996).
The virion glycoproteins of Ebola viruses are encoded in two reading frames
and are expressed through transcriptional editing. Proc. Natl. Acad. Sci.
USA 93, 3602–3607.
Scheres, S.H. (2012). RELION: implementation of a Bayesian approach to
cryo-EM structure determination. J. Struct. Biol. 180, 519–530.
Tang, G., Peng, L., Baldwin, P.R., Mann, D.S., Jiang, W., Rees, I., and Ludtke,
S.J. (2007). EMAN2: an extensible image processing suite for electron micro-
scopy. J. Struct. Biol. 157, 38–46.
Thi, E.P., Mire, C.E., Lee, A.C., Geisbert, J.B., Zhou, J.Z., Agans, K.N., Snead,
N.M., Deer, D.J., Barnard, T.R., Fenton, K.A., et al. (2015). Lipid nanoparticle
siRNA treatment of Ebola-virus-Makona-infected nonhuman primates. Nature
521, 362–365.
Towner, J.S., Paragas, J., Dover, J.E., Gupta, M., Goldsmith, C.S., Huggins,
J.W., and Nichol, S.T. (2005). Generation of eGFP expressing recombinant
Zaire ebolavirus for analysis of early pathogenesis events and high-throughput
antiviral drug screening. Virology 332, 20–27.
Towner, J.S., Sealy, T.K., Khristova, M.L., Albarin˜o, C.G., Conlan, S., Reeder,
S.A., Quan, P.L., Lipkin, W.I., Downing, R., Tappero, J.W., et al. (2008). Newly
discovered ebola virus associatedwith hemorrhagic fever outbreak in Uganda.
PLoS Pathog. 4, e1000212.
van Heel, M., Harauz, G., Orlova, E.V., Schmidt, R., and Schatz, M. (1996).
A new generation of the IMAGIC image processing system. J. Struct. Biol.
116, 17–24.
Volchkov, V.E., Becker, S., Volchkova, V.A., Ternovoj, V.A., Kotov, A.N., Nete-
sov, S.V., and Klenk, H.D. (1995). GP mRNA of Ebola virus is edited by the
Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology
214, 421–430.
Voss, N.R., Yoshioka, C.K., Radermacher, M., Potter, C.S., and Carragher, B.
(2009). DoG Picker and TiltPicker: software tools to facilitate particle selection
in single particle electron microscopy. J. Struct. Biol. 166, 205–213.
Warren, T.K., Warfield, K.L., Wells, J., Swenson, D.L., Donner, K.S., Van Ton-
geren, S.A., Garza, N.L., Dong, L., Mourich, D.V., Crumley, S., et al. (2010).
Advanced antisense therapies for postexposure protection against lethal filo-
virus infections. Nat. Med. 16, 991–994.
Warren, T.K., Wells, J., Panchal, R.G., Stuthman, K.S., Garza, N.L., Van Ton-
geren, S.A., Dong, L., Retterer, C.J., Eaton, B.P., Pegoraro, G., et al. (2014).
Protection against filovirus diseases by a novel broad-spectrum nucleoside
analogue BCX4430. Nature 508, 402–405.
Warren, T.K., Whitehouse, C.A., Wells, J., Welch, L., Heald, A.E., Charleston,
J.S., Sazani, P., Reid, S.P., Iversen, P.L., and Bavari, S. (2015). A single phos-
phorodiamidate morpholino oligomer targeting VP24 protects rhesus mon-
keys against lethal Ebola virus infection. MBio 6, e02344-14.
Wilson, J.A., Hevey, M., Bakken, R., Guest, S., Bray, M., Schmaljohn, A.L., and
Hart, M.K. (2000). Epitopes involved in antibody-mediated protection from
Ebola virus. Science 287, 1664–1666.
Yu, X., McGraw, P.A., House, F.S., and Crowe, J.E., Jr. (2008). An optimized
electrofusion-based protocol for generating virus-specific human monoclonal
antibodies. J. Immunol. Methods 336, 142–151.Cell 164, 392–405, January 28, 2016 ª2016 Elsevier Inc. 405
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ABSTRACT The filovirus surface glycoprotein (GP) mediates viral entry into host cells. Following viral internalization into en-
dosomes, GP is cleaved by host cysteine proteases to expose a receptor-binding site (RBS) that is otherwise hidden from immune
surveillance. Here, we present the crystal structure of proteolytically cleaved Ebola virus GP to a resolution of 3.3 Å.We use this
structure in conjunction with functional analysis of a large panel of pseudotyped viruses bearing mutant GP proteins to map the
Ebola virus GP endosomal RBS at molecular resolution. Our studies indicate that binding of GP to its endosomal receptor
Niemann-Pick C1 occurs in two distinct stages: the initial electrostatic interactions are followed by specific interactions with a
hydrophobic trough that is exposed on the endosomally cleaved GP1 subunit. Finally, we demonstrate that monoclonal antibod-
ies targeting the filovirus RBS neutralize all known filovirus GPs, making this conserved pocket a promising target for the devel-
opment of panfilovirus therapeutics.
IMPORTANCE Ebola virus uses its glycoprotein (GP) to enter new host cells. During entry, GPmust be cleaved by human en-
zymes in order for receptor binding to occur. Here, we provide the crystal structure of the cleaved form of Ebola virus GP.We
demonstrate that cleavage exposes a site at the top of GP and that this site binds the critical domain C of the receptor, termed
Niemann-Pick C1 (NPC1). We performmutagenesis to find parts of the site essential for binding NPC1 andmap distinct roles
for an upper, charged crest and lower, hydrophobic trough in cleaved GP.We find that this 3-dimensional site is conserved
across the filovirus family and that antibody directed against this site is able to bind cleaved GP from every filovirus tested and
neutralize viruses bearing those GPs.
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Ebola virus (EBOV) and Marburg virus (MARV) are bothmembers of the Filoviridae family of enveloped negative-
strand RNA viruses and are the causative agents of a highly lethal
disease for which no approved vaccines or treatments are cur-
rently available (1, 2). Due to their virulence and biothreat poten-
tial, filoviruses are classified as category A pathogens. The ongoing
EBOV epidemic inWest Africa is the longest andmost widespread
filovirus outbreak on record (3).
Like all filoviruses, EBOV displays a single virus-encoded pro-
tein, the viral glycoprotein (GP), on the surface of the virion.
EBOV GP is a 676-residue class I membrane fusion glycoprotein.
However, EBOVGP differs from canonical class I fusion proteins,
such as those of human immunodeficiency virus and influenza A
virus, in that the architecture of its fusion loop more closely re-
sembles those of class II and III glycoproteins (4, 5). EBOV GP is
synthesized as a precursor polypeptide, GP0, which assembles into
trimers in the endoplasmic reticulum. Each GP0 subunit is then
posttranslationally cleaved by the Golgi endoprotease furin to
yield disulfide-linked GP1 (55 kDa) and GP2 (20 kDa) sub-
units. The final GP assembly, which is an 450 kDa trimer of
GP1,2 heterodimers, is then displayed on the surface of mature
EBOV virions (4, 5). GP1 contains the receptor-binding site and
regulates the triggering of the membrane fusion machinery in the
GP2 subunit (6).
The GP1 structure can be divided into three subdomains: the
mucin domain, glycan cap, and GP1 core. The outer mucin do-
main (GP1 residues 313 to 464), is predicted to be loosely struc-
tured and heavily glycosylated, incorporating five N-linked gly-
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cans and 12 to 17 predicted O-linked glycans (5). Interior to the
mucin-like domain is the glycan cap (GP1 residues 227 to 313),
which sits atop the GP1 core. The glycan cap is more ordered than
the mucin-like domain and contains four N-linked glycosylation
sites. Neither the mucin nor the glycan cap domain is essential for
viral entry. Indeed, removal of these domains enhances infection
by viruses pseudotyped with EBOVGP (7–9). Therefore, it is cur-
rently hypothesized that a primary function of the mucin domain
and glycan cap is to shield the GP1 core from immune surveillance
(4, 5, 10, 11).
EBOV virions are internalized into cells via a macro-
pinocytosis-like mechanism and undergo trafficking to late endo-
somes (12–15). There, host endosomal cysteine proteases, includ-
ing cathepsins L (CatL) and B (CatB), cleave GP1 to remove the
mucin and glycan cap domains. Cleavage generates a fusion-
competent GP trimer (GPCL) comprising the 19-kDa GP1 core
domain and GP2 (8, 9, 16). Cleavage of GP1,2 to GPCL is a prereq-
uisite for viral recognition of the host endosomal receptor
Niemann-Pick C1 (NPC1) (10, 17–20), strongly suggesting that
the receptor-binding site in theGP1 core structure is unmasked by
the cleavage of GP1 in late endosomes. Thus, GPCL represents the
structure of EBOV GP in a conformation that is competent for
receptor binding.
In order to observe possible structural changes in GPCL and
to illustrate definitively which surfaces and residues are un-
veiled upon endosomal proteolysis, we determined the crystal
structure of the EBOV GPCL trimer at a resolution of 3.3 Å, in
complex with the neutralizing human antibody Fab KZ52 (21).
We found that the main feature exposed upon priming of
EBOV GP is a wave-like morphology at the top of GPCL, with a
polar/basic crest rising above a large, recessed, hydrophobic
trough, previously occupied by the glycan cap prior to priming
by host cathepsins. Extensive structure-directed mutagenesis
of EBOV GPCL revealed that the basic character of the polar
crest is crucial to the EBOV-receptor interaction, likely because
it confers an initial electrostatic attraction between GPCL and
the second luminal domain of NPC1, domain C. We also find
that the trough makes specific hydrophobic contacts that are
essential to high-affinity GPCL-NPC1 domain C binding. Fi-
nally, we demonstrate that host-programmed unmasking of
the NPC1-binding site in EBOVGP creates a broadly conserved
target for neutralization by monoclonal antibodies (MAbs) re-
cently isolated from a human survivor of MARV infection (22).
Our results thus suggest a novel approach for developing engi-
neered MAbs with broad-spectrum activity against filoviruses.
RESULTS
The crystal structure of EBOVGPCL reveals the NPC1 receptor-
binding site that is unmasked upon endosomal cleavage. Puri-
fied EBOVGP1,2 ectodomains (expressed without mucin-like do-
mains; hereinafter referred to as GP) were treated with
thermolysin, which mimics host endosomal protease processing
of EBOV GP (8), in order to generate EBOV GPCL trimers for
crystallization. EBOV GPCL crystallizes in the space group H3
(R3:H) with four GPmonomers and four KZ52 Fabs in the asym-
metric unit (ASU). The ASU contains one full GP trimer and one
remainingGPmonomer, which itself forms a biologically relevant
trimer with two symmetry-related protomers about a crystallo-
graphic 3-fold axis. The overall changes to the tertiary structure
upon cleavage of GP are minimal, reflected in a root mean square
deviation (RMSD) of 0.419 Å compared to the structure of un-
cleaved EBOV GP (Fig. 1A) (4). This finding corroborates a pre-
viousmodel of EBOVGPCL which suggested only limited changes
in the GPCL structure upon thermolysin digestion (23). The struc-
ture of EBOV GPCL is more compact than that of EBOV GP and
exhibits more stable crystal packing, less disorder, and improved
resolution of X-ray diffraction over that of the previously deter-
mined uncleaved GP (4).
New regions of EBOV GP can now be visualized in the EBOV
GPCL structure. These include C-terminal residues of GP2, the
disulfide link between C53 of GP1 and C609 of GP2, and an intra-
GP2 disulfide bond between C601 and C610. As EBOV GP2 de-
scends from the base of the GP trimer structure, it forms a tightly
ordered loop structure that is stabilized by the intra-GP2 disulfide
bond between C601 and C610. This disulfide link turns the pep-
tide chain back toward the body of GPwhere it is anchored to GP1
by the C53-C609 inter-GP1,2 disulfide bond prior to turning
downward toward the transmembrane domain and viral mem-
brane (Fig. 1B).
Themost striking structural feature ofGPCL is the full exposure
of a charged hydrophilic crest and a large hydrophobic trough
structure in immediate proximity to the GP2 fusion loop. The
trough becomes exposed upon proteolytic excision of the glycan
cap from EBOV GP and is 13 Å wide, 23 Å long, and 10 Å deep
(Fig. 1C). Residues I113 and L111 form an exposed hydrophobic
face inside the trough, while residues V79, T83, W86, F88, L122,
V141, and I170 line the bottom of the trough.
Mutation of GP residues exposed after removal of the glycan
cap affects viral infectivity and binding to the filovirus receptor
NPC1. Previous work utilizing scanning mutagenesis of EBOV
GP identified multiple residues important for viral infectivity
(24–26). These studies were carried out prior to the availability
of a crystal structure of EBOV GP (4) or GPCL (this work) and
prior to identification of the endosomal receptor, NPC1 (17,
18). Here, we map these residues onto the crystal structure of
EBOV GPCL and determine whether mutations in EBOV GP
that reduce infectivity specifically correlate with defects in
GPCL-NPC1 binding. Previous work identified three lysines at
positions 114, 115, and 140 (16, 25) and hydrophobic residues
F88, L111, and L122 (25–27) for which mutation to alanine
diminishes infectivity (16, 25). These deficits in infectivity cor-
relate with reductions in NPC1 binding, as determined by co-
immunoprecipitation (28).
The crystal structure of EBOV GPCL illustrates that K114,
K115, and K140 lie along the crest and F88, L111, and L122 line
the trough of EBOV GPCL. These hydrophobic residues are
buried in uncleaved EBOV GP (4) but become solvent exposed
in the trough of EBOV GPCL. We systematically mutated resi-
dues that the GPCL crystal structure shows to be surface-
exposed after cleavage, in order to determine their importance
for NPC1 binding and viral infectivity and to define the GP1
receptor-binding site (RBS).
We pseudotyped vesicular stomatitis virus (VSV) particles
with 73 mutant GP proteins and tested them for viral incorpora-
tion of GP relative to the incorporation of the wild-type (WT)
protein, and for binding to the conformational antibody KZ52 (4,
21), which only recognizes properly folded GP (see Fig. S4 in the
supplemental material). The 68 VSV-GP mutants that met these
quality benchmarks were then evaluated for their capacity to rec-
ognize a purified, soluble form of human NPC1 domain C in an
Bornholdt et al.
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enzyme-linked immunosorbent assay (ELISA), as described pre-
viously (27, 29). We report that WT EBOV GPCL binds to NPC1
domain C with a 50% effective concentration (EC50) of0.5 nM,
consistent with a high-avidity binding interaction between these
proteins. In comparison, we find that mutants that demonstrate
reduced infectivity are also defective for binding to NPC1 domain
C (see Fig. S1 and S2 in the supplemental material). Furthermore,
a few single point mutations that cause drastic reductions (10-
fold) in the GPCL-NPC1 domain C-binding EC50 are located in or
around the hydrophobic trough and hydrophilic crest. Thesemu-
tants allow us to map those residues of EBOVGP1 that are critical
to NPC1 domain C onto the EBOV GPCL structure and to better
FIGURE 1 Crystal structure of ebolavirus GPCL. (A) The trimeric EBOV GPCL structure is shown, with GP1 colored teal, GP2 colored light blue, the
fusion loop colored orange, and disulfide bonds displayed as sticks and colored gold. The former position of the glycan cap, now absent in the GPCL
structure, is illustrated in semitransparent red and is derived from an alignment with the uncleaved EBOV GP structure (PDB code 3CSY). (B) Additional
residues at the C terminus of GP2 are now visible in this higher-resolution structure. These residues include C601-C608, contained within GP2, as well as
the C53-C609 disulfide bond that cross-links GP1 and GP2 together. (C) The structure of EBOV GPCL is displayed to the right, with the same coloring as
described for panel A. An enlarged illustration of the putative EBOV GP1 RBS is shown to the left, in two orientations. Residues forming the hydrophilic
crest and hydrophobic trough are labeled and colored green and purple, respectively. The disulfide bonds present around the crest and trough, C108-C135
and C121-C145, are colored gold.
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define the RBS (see Fig. S1 and S2). Interestingly, mutation to
alanine of two trough residues, F88 and L111, reduces viral infec-
tivity dramatically (by3 log10 units) but hasmoremodest effects
on GPCL-NPC1 binding (see Fig. S2A). The disparity between
strong reduction in infectivity butmodest effect onNPC1 binding
suggests that these residues may be important for steps in viral
entry post-NPC1 binding and prior to membrane fusion, such as
conformational changes or release of GP2.
The hydrophobic trough exposed on GP1 upon endosomal
cleavage is the primary binding site of NPC1 domainC.Weper-
formed further mutagenesis of the hydrophobic trough to better
define its precise role. Sincemost of the pointmutations to alanine
within the hydrophobic trough had only modest effects, we pos-
tulated that replacing them with bulkier methionine residues
would more completely occlude the trough and prevent GP-
NPC1 binding. We selected two trough residues, T83 and I113,
which did not inhibit NPC1 binding whenmutated to alanine, for
additionalmutagenesis tomethionine (Fig. 2A and B). To prevent
misfolding or disruption of the GP structure, we engineered com-
pensatorymutations with interacting residues of the glycan cap to
fit the larger methionine residues and prevent steric clashing. We
engineered the following mutants: I113M (trough)/F225A (cap),
T83M (trough)/F225VY232F (cap), and T83MI113M
(trough)/F225AY232F (cap) (Fig. 2C to E). For simplicity, since
the compensatory mutations are removed along with the glycan
cap upon proteolysis, we will only refer to these mutants by the
mutations remaining on EBOV GPCL: T83M, I113M, and
T83MI113M. All engineered VSV-GP mutants maintain high
levels of incorporation compared to the incorporation of WT GP
(see Fig. S2 in the supplemental material). As posited, the single
T83M and I113Mmutations, as well as the T83MI113M double
mutation, lead to defects in NPC1 domain C binding and pseudo-
virus infectivity by GPCL bearing them (Fig. 2A to C). We further
find that a single point mutation, L122A, located in the bottom of
the trough, abrogates both NPC1 domain C binding and pseu-
dotyped virus infectivity (Fig. 2E). The position of L122 suggests
that it has a structural role; the L122A mutation may destabilize
the local trough structure, preventing NPC1 binding and subse-
quent infectivity. Together, these findings provide evidence that
supports a direct correlation between NPC1 binding and infectiv-
ity and effectivelymaps theGPCL trough as a critical component of
the NPC1-binding site.
An overall basic charge on the GP1 crest is required for GP
binding to NPC1 domain C and viral infectivity. Experiments
performed prior to the identification of the filovirus endosomal
receptor NPC1 demonstrated that K114A, K115A, and K140A
mutations (now mapped to the GPCL crest) significantly reduce
viral infectivity (16, 25). Here, we investigated whether the ob-
served reductions in viral infectivity from these mutations corre-
late with defects in binding to NPC1 domain C. We show that
while the individualmutations K114A andK115Ahave onlymod-
est effects (see Fig. S1 and S2 in the supplemental material), the
double mutation (K114AK115A) dramatically inhibits GPCL-
NPC1 domain C binding and viral entry (Fig. 3A and B). In con-
trast, the K140A mutant showed no significant defect in viral in-
fectivity or NPC1 domain C binding (see Fig. S2). To test the
hypothesis that these crest residues participate in electrostatic in-
teractions with NPC1 during virus-receptor engagement, we en-
gineered and analyzed VSV-GPs in which these lysines were re-
placed with either basic or acidic residues. The K114RK115R
double mutant, which maintains the basic charge, remains fully
functional. In contrast, the K114EK115E double mutant, which
reverses charge, displays an even greater deficit in receptor-
binding function and entry activity than the neutral
K114AK115Amutant (Fig. 3A and B). To determine whether it
is the overall charge of the site or specific basic residues within the
site that are important, we mutated two glutamic acid residues in
proximity to positions 114 and 115 to alanine. The resulting qua-
druple mutant (K114AK115AE112AE120A), which is pre-
dicted to have WT-like electrostatics, exhibits receptor-binding
activity and infectivity at nearly WT levels (Fig. 3A and B). The
importance of a set of basic residues but lack of a specific require-
ment for any one of them individually suggest a need to maintain
an overall basic charge on the GPCL crest (Fig. 3C).
Neutralizing antibodies raised from a Marburg virus survi-
vor demonstrate potential panfilovirus neutralization activity.
The high degree of sequence and structural conservation in the
NPC1-binding site of filovirus glycoproteinsmakes it an attractive
target for the development of broadly neutralizing MAbs with
therapeutic potential (see Fig. S3 in the supplemental material).
Unfortunately, no such MAbs against ebolaviruses have been iso-
lated. Instead, most known neutralizing anti-ebolavirus MAbs
target a conformational epitope at the base of the GP1,2 trimer (4,
5, 30, 31). Recently, however, severalMAbs isolated fromahuman
survivor of MARV infection were found to recognize the hydro-
phobic GPCL trough and inhibit GP-NPC1 domainC binding (11,
22).Of significance, one anti-MARVMAb from that study,MR72,
cross-reacts with purified GP and GPCL of EBOV, while three
other MAbs, MR78, MR111, and MR191, cross-react only with
EBOV GPCL (22). MR72, MR78, MR111, and MR191 bind to
similar locations on MARV GP but approach from significantly
different angles (22). The third complementarity-determining re-
gion of the heavy chain variable region (CDRH3) of MR78 binds
into the expected MARV GP1 RBS (see Fig. S3) (11).
As the RBS is conserved in sequence and structure across
known filoviruses, we evaluated the capacity of MR72 and two
additional GPCL-reactive antibodies, MR78 and MR191 (22), to
recognize and neutralize VSV bearing GPCL from four ebolavi-
ruses (Sudan virus [SUDV], Bundibugyo virus [BDBV], Taï For-
est virus [TAFV], and Reston virus [RESTV]) and the cuevavirus
Lloviu virus (LLOV) (2, 32). Remarkably, we find that MR72 ef-
fectively neutralizes VSVs pseudotyped with GPCL derived from
all known filoviruses (Fig. 4A). In contrast, MR191 neutralizes
VSV bearing other filovirus GPs only weakly, and MR78 fails to
neutralize VSVs bearingGPCL derived from any species other than
MARV.We speculate that the steeper angle of approach ofMR191
to MARV GPCL compared to that of MR78 may enhance the
breadth of neutralization by improving access to the shared RBS
(Fig. 4A and S3). Of significance, we found that MR72 failed to
bindVSVs bearing uncleaved EBOVGP on the surface (see Fig. S3
in the supplemental material). This finding is in contrast to a
previous observation of MR72 binding to uncleaved soluble
EBOV GP ectodomain (see Fig. S3) (22). It is likely that there are
differences in the presentation of EBOV GP on the surface of
actual virions that prevent MR72 from binding and effectively
neutralizing either wild-type EBOV or VSV bearing uncleaved
EBOV GP.
The contrasting neutralization breadth properties of MR72
and MR78, despite their similar binding angles and shared
epitope, led us to explore our panel of GPCL mutations to identify
Bornholdt et al.
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FIGURE 2 Mutagenic occlusion of the EBOV GP1 receptor-binding site. (A) Alanine or methionine mutations were made to key residues in the RBS. The
affinities of wild-type and mutant GPCL for NPC1 domain C were analyzed via ELISA. Note that the L122A and T83MI113M mutations significantly reduce
binding to NPC1 domain C.Means SD (n 4) from a representative experiment are shown. (B) Graph displaying titers of VSV pseudoviruses harboring GP1
RBS mutations. Means SD (n 2–4) from a representative experiment are shown. (C) A semitransparent surface has been placed over the cartoon model of
theWTRBS on EBOVGP1 to display the RBS pocket (within the dashed oval outline). Residues T83 and I113 are illustrated as sticks (black). (D)Model of EBOV
RBS bearing the mutations T83M and I113M (red). The longer side chains of the introduced methionine residues fill the RBS pocket and likely prevent NPC1
domain C binding by occluding the NPC1 binding site. (E) The buried location of L122 (black) is displayed in the EBOV GP1 RBS. See also Fig. S1, S2, and S4
in the supplemental material.
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specific residues in the GP RBS that can affect MR78’s neutraliza-
tion of EBOVGPCL (see Fig. S2 in the supplemental material).We
find that a single pointmutation,V79A, allowsMR78 to neutralize
EBOVGPCL: althoughMR78 cannot neutralize VSVbearingwild-
type EBOV GPCL, it can neutralize V79A-bearing VSV-
EBOV GPCL (Fig. 4B). Position 79 in EBOV GP is equivalent to
position 63 in MARV. Structural alignment of EBOV GPCL with
MARV in the MARV GP-MR78 crystal structure (11) suggests
that the wild-type V79 may sterically clash with the light chain of
MR78. Replacement of valine with the smaller alanine residue
(V79A) may improve neutralization by relieving the steric clash
(Fig. 4B).
Furthermore, previous studies have shown that, unlike MR72,
MR78 fails to block NPC1 domain C binding to EBOVGPCL (11).
Therefore, we performed NPC1 domain C competitive-binding
assays to determine whetherMR78 neutralizes EBOVGPCL-V79A
by inhibiting GP-NPC1 binding. Curiously, even thoughMR78 is
now able to neutralize VSV bearing EBOVGPCL-V79A, it remains
unable to prevent binding of NPC1 domain C to EBOV GPCL or
EBOV GPCL-V79A (Fig. 4B). MR72, however, does block NPC1
binding to EBOV GPCL. Therefore, our data suggest that MAbs
MR72 and MR78 may neutralize by distinct mechanisms. MR72
effectively blocks GPCL-NPC1 binding for all filoviruses, whereas
MR78 does not block EBOV GPCL-NPC1 binding. We speculate
that MR78 neutralizes EBOV entry by inhibiting viral membrane
fusion downstream from virus receptor recognition.
In order to gauge the neutralization potentials of MR72 and
MR78 relative to those of other MAbs with demonstrated protec-
tive efficacy in vivo, we performed a comparative analysis with the
combinedMAbs of the EBOV-specific ZMapp cocktail: 2G4, 4G7,
and 13C6 (31, 33), as well as with KZ52, a known neutralizing
MAb from a human survivor (21). Our analysis demonstrates that
MR72 can neutralize pseudoviruses at 10-fold lower concentra-
tions of antibody than are required forKZ52 and theZMapp cock-
tail (Fig. 4C). Thus, MAbs such as MR72, which target the highly
conserved GP1 RBS, represent a novel avenue for both broad and
potent neutralization of filoviruses, if they can be delivered to the
endosomal compartments where GPCL is generated during entry.
DISCUSSION
In this study, we present the 3.3-Å crystal structure of thermolysin-
cleavedEBOVGP (GPCL), which is primed for interactionwith the
filovirus receptor, NPC1. Thermolysin has previously been dem-
onstrated to mimic host CatB and CatL proteolytic processing of
FIGURE 3 The basic electrostatic potential of the GP1 crest is vital to receptor binding. (A) ELISA analysis of binding of wild-type or mutant GPCL to NPC1
domain C. Replacement of positively charged K114 and K115 with neutral alanines or negatively charged glutamic acids reduces and abrogates NPC1 binding,
respectively. Concomitant mutation of neighboring E112 and E120 to neutral alanine residues restores affinity for NPC1 domain C. Means SD (n 4) from
a representative experiment are shown. (B) Growth titers of VSV pseudotyped with electrostatic mutants of EBOV GP correlate with the NPC1 domain C
affinities shown by the results in panel A: reduction in growth correlates with loss of positive charge. Means SD (n 2–4) from a representative experiment
are shown. (C) The electrostatic surface potential is calculated for each of themutant EBOVGPs using APBS in PyMol (The PyMOLMolecular Graphics System,
version 1.5.0.4. [Schrödinger, LLC], and APBS plugin for PyMol, M. G. Lerner and H. A. Carlson, University of Michigan, Ann Arbor, MI, 2006; 48). The view
is looking down onto the EBOVGP trimer. Mutants with an overall negative charge on the surface of GP1 demonstrate defects in both affinity for NPC1 domain
C and viral growth. See also Fig. S1, S2, and S4 in the supplemental material.
Bornholdt et al.
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EBOV GP, which occurs in the endosome and is required for
receptor binding and membrane fusion (8–10, 16). This high-
resolution structure of EBOVGPCL has now defined the intermo-
lecular disulfide bridge between C53 in GP1 and C609 in GP2, a
region previously unresolved for EBOV GP. The disulfide bridge
likely contributes to the inherent stability of ebolavirus GP despite
proteolytic processing. This stability is reflected in a high degree of
structural conservation between uncleaved EBOV GP (4) and
FIGURE 4 Monoclonal antibodies targeting the conserved GP1 RBS demonstrate panfilovirus neutralization activity. (A) VSV pseudotyped with GPs from different
species of filovirus (as indicated in the key to the right) were preprimed with thermolysin to expose the GP1 RBS and then analyzed for reduction in relative infectivity
following treatmentwithMR72orMR78. (B)The graph to the left shows a comparative analysis of the neutralizationofVSV-EBOVGPCL andVSV-EBOVGPCL-V79A
by MR72 and MR78. The graph to the right displays the results of competitive binding assays detecting NPC1 domain C binding in the presence of increasing
concentrations of MR72 or MR78 for EBOV GPCL and EBOVGPCL-V79A. The key for both graphs is on the far right. (C) Graph showing the results of comparative
infectivity assays of nonprimed VSV pseudotyped with EBOV GP treated with MAbs from the ZMapp cocktail (2G4, 4G7, and 13C6) (33) or the neutralizing EBOV
antibodyKZ52 (21).MR72 neutralizes primed EBOVGPCL pseudovirions at10-fold lower concentrations than are required for ZMapp orKZ52 to neutralize EBOV
GP pseudovirions. See also Fig. S3 in the supplemental material. Means SD (n 24) from a representative experiment are shown in each panel.
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GPCL; the aligned structures have anRMSDof 0.419Å. The crystal
structure of EBOV GPCL presented here also illustrates how pro-
teolytic priming removes the glycan cap of EBOV GP1 to expose
the binding site for the filovirus receptor NPC1. The GPCL crystal
structure suggests that the glycan cap may act as a final layer of
defense, shielding the critical and conserved NPC1 domain C
binding site fromhost immune surveillance prior to cellular entry.
We show that this RBS has a crest-and-trough morphology and
exists at the apex of the GPCL trimer.
The crest is lined with hydrophilic basic residues, while the
trough is recessed and entirely hydrophobic. Mutagenic analysis
of EBOV GPCL demonstrates that the crest is involved in nonspe-
cific electrostatic interactions with NPC1, requiring an overall ba-
sic charge to facilitate binding of NPC1 domain C. Mutations in
EBOV GP (such as K114EK115E) that reverse the electrostatic
charge on the GPCL crest consistently abrogate receptor binding
and reduce infectivity. In contrast, the GPCL trough is involved in
more specific hydrophobic interactions with NPC1 domain C.
Structure-based mutants with mutations designed to obstruct the
structure of the trough (such as T83MI113M) diminish the af-
finity of GP for NPC1 domain C and severely restrict the infectiv-
ity of VSV pseudotypes bearing these mutations. Based on the
crystal structure and results ofmutagenesis reported here, we pro-
pose that the NPC1 receptor binds GP in a two-stage process.
First, GPCL recruits the NPC1 domain C receptor through non-
specific electrostatic interactions between NPC1 and the basic
crest region on GPCL. Without this interaction, there is no detect-
able GP-receptor binding. Next, specific hydrophobic interac-
tions are initiated between theGP1 RBS trough andNPC1 domain
C. The specificity of these interactions likely explains the differen-
tial effects of individual mutations in the trough (Fig. 3 and 4),
whereas the effects of mutations in the crest were determined by
charge, not specific amino acid position.
We also further analyzed two mutants with a mutation in the
hydrophobic trough, F88A or L111A, which have been described
previously as unable to support infection (25, 26). These twomu-
tants are outliers in our analysis. Their infectivities are reduced by
more than three log10 infectious units relative to that ofWTEBOV
GP, despite only modest defects in binding of NPC1 domain C.
We postulate that these mutants are defective at a step down-
stream from NPC1 binding. They will provide useful tools to fur-
ther decipher precisely howGPCL-NPC1 binding facilitates fusion
triggering and membrane fusion.
Recent work has identified multiple neutralizing MAbs from a
patient who survived MARV infection. The MAbs from those
studies were found to bind to the apex of MARV GP1 (11, 22)—
the site we have confirmed here to be the filovirus GP1 receptor-
binding site. Since ebolavirus, marburgvirus, and cuevavirus GP
proteins all use the NPC1 protein as a receptor, it is not unex-
pected that the structure of the GP1 RBS would be highly con-
served across all filoviruses (10, 17–19, 32). Thus, we hypothesized
that the MAbs identified by Flyak et al. (22), shown to target the
RBS trough on MARV GP1 (11), should be broadly neutralizing.
However, unlike the GP proteins of marburgviruses, those of the
ebolaviruses and cuevavirus maintain a glycan cap structure that
effectively shields the GP1 RBS from immune surveillance. There-
fore, by proteolytically priming filovirus GPs on the surface of
VSV particles (such as VSV-EBOVGPCL), we were able to analyze
the neutralization potential of MAbs targeting the otherwise-
occluded filovirus RBS. Analysis of GPCL-bearing VSVs would tell
us if it was worthwhile to target such antibodies to the endosome
as future therapeutics.
Of the panel of neutralizing MAbs from an MARV survivor
described by Flyak et al. (22), only one, MR72, demonstrates sig-
nificant cross-reactivity to uncleaved EBOV GP. Three other
MAbs, MR78, MR111, and MR191, only react with EBOV GPCL.
We focused our analysis on the EBOV GP-reactive MR72 and the
EBOV GPCL-reactive MR78 and MR191, which approach GP
from different angles. Here, we show that MR72 effectively neu-
tralizes VSV pseudovirions bearing GPCL from EBOV, SUDV,
BDBV, TAFV, RESTV, or LLOV. MR191 neutralizes the EBOV,
BDBV, TAFV, and LLOV VSV-GPCL virions weakly (and RESTV
and SUDV GPCL not at all), with infectivity never reduced below
50% (see Fig. S3 in the supplemental material). In contrast, MR78
can only neutralize MARV GPCL. It cannot neutralize EBOV
GPCL-bearing VSVs, even though it is able to bind them.
The crystal structures of MARV GPCL and EBOV GPCL bound
to MR78 suggest that MR78 binds the same site in both viruses.
However, the resolution of the EBOV GPCL-MR78 complex was
too low to identify subtle differences imposed by sequence devia-
tions fromMARV GP that might explain why MR78 fails to neu-
tralize EBOV GPCL (11). Hence, we used a panel of VSV-EBOV
GP RBS mutants to understand which sequence variations could
prevent MR78-mediated neutralization of EBOV GPCL. Surpris-
ingly, the introduction of a single point mutation (V79A) within
the EBOV RBS allows MR78 to neutralize VSV-EBOV GPCL-
V79A.Of significance, BDBV, TAFV, andRESTVGPs also encode
valine at this position, while SUDV and LLOVGPs encode isoleu-
cine and leucine, respectively. The larger Val, Ile, and Leu aliphatic
residues encoded by the ebolaviruses and cuevavirus may prevent
MR78 from neutralizing their GPCL-bearing particles (Fig. 4A; see
also Fig. S3 in the supplemental material). We note that, unlike
MR78, MR191 exhibits no improvement in neutralization of
VSV-EBOV GPCL-V79A (see Fig. S3 in the supplemental mate-
rial). How MR72 but not MR78 is able to overcome divergent
amino acids at position 79 to broadly neutralize filovirus GPCL is
the subject of continued structural and biochemical study.
Remarkably, enhanced neutralization of EBOVGPCL-V79A by
MR78 was not accompanied by a commensurate increase in its
capacity to block NPC1 binding of this GP (Fig. 4). This apparent
uncoupling of neutralization and receptor blockage raises the pos-
sibility that MR78 may act as an allosteric inhibitor, preventing
membrane fusion by binding to GP1 subunits in the trimer that
are not occupied by NPC1 domain C in the endosome. There, it
may inhibit events that occur after receptor binding in order to
trigger GP-mediated membrane fusion. Mutations like L111A,
which eliminate infectivity without affecting receptor binding,
may target these same post-receptor-binding steps.
Recent events, including the unprecedented EBOV epidemic
in West Africa (3, 34), coinciding with human cases of MARV
emerging in central Africa (35) and the emergence of BDBV (36)
and re-emergence of SUDV (37) in this decade, highlight the ur-
gent need for broad-spectrum antifilovirus therapeutics (38).
Here, we demonstrate that the highly conserved binding site for
the essential intracellular receptor NPC1 provides an attractive
and underexplored target for broadly protective antibodies or
small-molecule therapeutics. However, one crucial challenge to
the development of such antibodies as therapeutics is an evolved
feature of the filovirus entry mechanism—the unavailability of its
NPC1-binding site to extracellular antibodies. The success of this
Bornholdt et al.
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antiviral strategy therefore requires novel protein engineering ap-
proaches to deliver GPCL-specificMAbs to late endosomes and/or
lysosomes, where theNPC1-binding site is unmasked by host pro-
teases.
MATERIALS AND METHODS
Expression and purification of GPCL-KZ52 complex for crystallization.
Ebola virus GP (lacking the mucin domain [residues 312 to 462]) was
produced by stable expression inDrosophila melanogaster S2 cells. Briefly,
Effectene (Qiagen) was used to transfect S2 cells with a modified pMT-
puro vector plasmid containing the GP gene of interest, followed by stable
selection of transfected cells with 6g/ml puromycin. Cells were cultured
at 27°C in complete Schneider’smedium for selection and then adapted to
Insect Xpress medium (Lonza) for large-scale expression in 2-liter Erlen-
meyer flasks. Secreted GP ectodomain expression was induced with
0.5 mM CuSO4, and supernatant harvested after 4 days. Ebola virus GP
was engineered with a double Strep-tag at the C terminus to facilitate
purification using Strep-Tactin resin (2-1201-010) (Qiagen) and then fur-
ther purified by Superdex 200 size exclusion chromatography (SEC) in
10 mM Tris-buffered saline (Tris-HCl, pH 7.5, 150 mM NaCl [TBS]).
EBOV GPCL was produced by incubation of 1 mg GP with 0.02 mg ther-
molysin overnight at room temperature in TBS containing 1 mM CaCl2
and purified by using Superdex 200 SEC. Trimeric EBOV GPCL was then
complexedwith aKZ52 Fab fragment prior to crystallization as previously
described (4).
Crystallization, data collection, and structure determinations. The
purified EBOVGPCL-KZ52 Fab complex was concentrated to 3.5mg/ml
in TBS. The crystal drops consisted of a 1:1 ratio of protein/well solu-
tion. The well solution consisted of 25% polyethylene glycol mono-
methyl ether 550 (PEG MME 550), 10% 2-propanol, 5% ethylene gly-
col, 100 mM sodium acetate, pH 4.7, and 100 mM calcium chloride.
Crystals grew over the course of a month and were flash frozen directly
out of the crystal drop into liquid nitrogen for data collection. Data
were collected remotely at the Argonne National Laboratory, Ad-
vanced Photon Source (APS), from the GM/CA beamline 23-ID-D.
The structure was determined using molecular replacement with
PHASER (39), within the CCP4 suite (40), using amodified EBOVGP-
KZ52 complex model (PDB code 3CSY) with all the residues corre-
sponding to the glycan cap removed (4). Refinement of the EBOV GPCL
crystal structurewas done through iterative cycles ofmodel building using
COOT, followed by refinement with Refmac5 and PHENIX (41–43).
Translation/libration/screw (TLS)motion was applied during refinement
with the TLS Motion Determination (TLSMD) server used to determine
the TLS structure partitions (44, 45). Five percent of the data was set aside
prior to refinement for the Rfree calculations for each data set (46). The
statistics and stereochemistry of the crystal structure were checked using
the MolProbity server until ranking at least at the 95th percentile (see
Fig. S2A in the supplemental material) (47). All of the structural figures
were rendered using PyMOL (PyMOL Molecular Graphics System, ver-
sion 1.5.0.4; Schrödinger, LLC).
Cells and viruses. African grivet monkey kidney (Vero) cells were
maintained at 37°C and 5% CO2 in high-glucose Dulbecco’s modified
Eagle medium (DMEM; Invitrogen Corp., Carlsbad, CA) supplemented
with 10% fetal calf serum. Replication-incompetent vesicular stomatitis
virus (VSV) (serotype Indiana) pseudotyped viruses were generated as
previously described (49). The wild type (VSV-WT GP) encodes en-
hanced green fluorescence protein (eGFP) in place of the VSV-G gene to
allow scoring of infection and bears the EBOV GPmuc gene (Mayinga
isolate, GenBank accession number AF086833) but lacks the mucin-like
domain (residues 309 to 489 [muc]) (6). Point mutants and multiple
mutants were generated by subcloning GP fragments containing the mu-
tation(s) to replace EBOV GPmuc. Cleaved VSV-GPCL particles were
generated by incubating VSV-GP pseudotypes with thermolysin (250g/
ml) for 1 h at 37°C. The reaction was stopped by adding phosphoramidon
(1 mM) and incubating on ice for 5 min.
Normalization of GP for ELISA.Normalization of GPCL amounts to
be used in the binding experiments was done by ELISA, as illustrated in
Fig. S4 in the supplemental material. Briefly, high-binding 96-well ELISA
plates (Corning) were coated with serial dilutions of GPCL in phosphate-
buffered saline (PBS), and allowed to bind at 37°C for 1 h. The plates were
blockedwith PBS containing 3%bovine serum albumin (PBSA), followed
by incubation with the anti-GP monoclonal antibody KZ52 (2 g/ml in
PBS) (21) and a horseradish-conjugated anti-human secondary antibody
(Santa Cruz Biotechnology), which was detected by ultra-TMB (3,3=,5,5=-
tetramethylbenzidine) substrate (Thermo Scientific). Absorbance read-
ings were subjected to a nonlinear regression analysis (GraphPad Prism
software) to generate binding curves and calculate an EC50 value. Addi-
tionally, the virions were normalized for GP incorporation by comparing
the amount of GP to the amount of the VSV matrix protein (M). Equal
amounts of purified virions were resolved on SDS-PAGE and blotted for
the VSV matrix protein using a mouse anti-VSV M antibody (23H12).
Quantification was done using a LI-COR IR dye-conjugated anti-mouse
Alexa Fluor 680 secondary antibody (Invitrogen) on theOdyssey Imaging
Station and Image Studio 2.1 software (LI-COR Biosciences), and the
results were normalized to the WT control. Virus particles that had less
than 25% incorporation of mutant GP compared to the incorporation of
WTGPor thatwere highly sensitive to proteolysis were excluded fromour
analysis.
GP-NPC1 domain C capture ELISA. Binding of GP to NPC1 do-
main C was performed as previously described (10, 32). Briefly, high-
binding 96-well ELISA plates (Corning) were coated with the anti-GP
monoclonal antibody KZ52 (2 g/ml in PBS) (21). Following a block-
ing step, either uncleaved or in vitro-cleaved GPCL pseudotypes were
captured on the plate. Unbound GP was washed off, and serial dilu-
tions of Flag-tagged purified soluble human NPC1 domain C (0 to
40 g/ml) were added. Bound NPC1 domain C was detected by a
horseradish-conjugated anti-Flag antibody (Sigma-Aldrich), using
ultra-TMB substrate (Thermo Scientific). EC50s were calculated from
binding curves generated by nonlinear regression analysis using
GraphPad Prism software. Binding ELISAs were done in duplicate in at
least two independent experiments. All incubation steps were done at
37°C for 1 h or at 4°C overnight.
Pseudovirus neutralization assays. Serial dilutions of MAbs and of a
no-antibody control were mixed with either cleaved or uncleaved
VSV-GP particles and allowed to bind for 1 h at room temperature.
Monolayers of Vero cells were inoculatedwith the antibody-virusmixture
in duplicate and incubated at 37°C in 5% CO2. Infection was scored 12 to
16 h postinfection by enumeration of eGFP-positive cells under a fluores-
cencemicroscope. The ZMapp cocktailMAbs 2G4, 4G7, and 13C6, as well
as MAb KZ52, prepared as previously described (33), were generously
provided byMapp Biopharmaceutical. MAbsMR78 andMR72 were pre-
pared as previously described (22).
Protein structure accession number. Coordinates and structure fac-
tors have been deposited into the Protein Data Bank under accession
number 5HJ3.
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